CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 15 June 2022Janssen Research & Development*
Clinical Protocol
A Phase 1b -2, Open -Label Study of JNJ -68284528, a Chimeric Antigen Receptor T cell
(CAR -T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory 
Multiple Myeloma
CARTITUDE -1
Protocol 68284528MMY2001; Phase 1b-2
AMENDMENT 5
JNJ-68284528
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen -Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout
the prot ocol to represent these various legal entities; the sponsor is identified on the Contact Information
page that accompanies the protocol.
This study  will be conducted under US Food & Drug Administration I
ND regulations (21 CFR 
Part 312).
EudraCT NUMBER:         2018 -000121 -32
Status: Approved
Date: 15June 2022
Prepared by: Janssen Research & Development
EDMS number: EDMS- ERI-155210182, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be d isclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These res trictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: 15 June 2022TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 5
LIST OF IN -TEXT T ABLES A ND FIGURES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 31
TIME AND EVENTS SCHE DULE .............................................................................................................. 33
ABBREVIA TIONS ...................................................................................................................................... 43
1. INTRODUCTION ................................................................................................................................ 45
1.1. Multiple Myeloma ........................................................................................................................... 45
1.2. BCMA ............................................................................................................................................. 45
1.3. CAR -T Therapy .............................................................................................................................. 45
1.4. JNJ-68284528 ................................................................................................................................ 46
1.5. Summary  of Clinical Studies .......................................................................................................... 47
1.6. Overall Rationale for the Study ...................................................................................................... 50
1.7. Potential Safety Risks and Mitigation Strategies ........................................................................... 50
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESES .......................................................................... 52
2.1. Objectives and Endpoints .............................................................................................................. 52
2.2. Hypotheses .................................................................................................................................... 54
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .54
3.1. Overview of Study Design .............................................................................................................. 54
3.2. Rationale of Dose and Administration Schedule Selection ............................................................ 57
3.3. Dose De -escalation ........................................................................................................................ 58
3.4. Dose Escalation ............................................................................................................................. 59
3.5. Safety Evaluat ion Team ................................................................................................................. 59
4. SUBJECT POPUL ATION.................................................................................................................. 60
4.1. Inclusion Criteria ............................................................................................................................ 60
4.2. Exclusion Criteria ........................................................................................................................... 63
5. INTERVENTION A LLOCAT ION A ND BLINDING ............................................................................ 66
6. DOSA GE, A DMINISTRA TION, A ND GUIDA NCE ............................................................................ 66
6.1. Study Treatment Administration ..................................................................................................... 66
6.1.1. Criteria for Apheresis .................................................................................................................. 67
6.1.2. Criteria for Conditioning Regimen (Cy clophosphamide and Fludarabine) Dosing ..................... 68
6.1.3. Evaluation Prior to Administration of JNJ -68284528 .................................................................. 69
6.1.4. JNJ-68284528 Administration .................................................................................................... 70
6.2. Pre-infusion Supportive Therapy ................................................................................................... 71
6.3. Management Guidelines for Potential Risks .................................................................................. 71
6.3.1. Management of Cytokine Release Syndrome ............................................................................ 71
6.3.2. Neurologic Toxicities ................................................................................................................... 74
6.3.2.1. CAR -T Cell -related Neurotoxicity (Immune Effector Cell -Associated Neurotoxicity 
Syndrome [ICANS]) ................................................................................................................. 74
6.3.2.2. Other Neurotoxicities ............................................................................................................... 76
6.3.3. Tumor Lysis Syndrome ............................................................................................................... 77
6.3.4. Cytopenia .................................................................................................................................... 78
6.3.5. Hypogammaglobulinemia ........................................................................................................... 78
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 15 June 20226.3.6. Infections .................................................................................................................................... 78
6.3.7. Hypersensitivity Reactions .......................................................................................................... 79
6.3.8. Second Primary  Malignancy ....................................................................................................... 79
7. INTERVENTION COMPLIA NCE ....................................................................................................... 79
8. PRESTUDY A ND CONCOMITA NT THERA PY................................................................................ 79
8.1. Permitted Medications .................................................................................................................... 80
8.2. Prohibited Therapies ...................................................................................................................... 80
8.3. Subsequent Anticancer Therapy .................................................................................................... 81
9. STUDY EVA LUATIONS .................................................................................................................... 81
9.1. Study Procedures ........................................................................................................................... 81
9.1.1. Overview ..................................................................................................................................... 81
9.1.2. Screening Phase ........................................................................................................................ 82
9.1.3. Apheresis .................................................................................................................................... 82
9.1.4. Cyclophosphamide and Fludarabine Conditioning Regimen ..................................................... 82
9.1.5. JNJ-68284528 Administration .................................................................................................... 82
9.1.6. Post- treatment Phase ................................................................................................................. 82
9.1.6.1. Post- infusion Period ................................................................................................................ 83
9.1.6.2. Post- treatment Period .............................................................................................................. 83
9.1.6.3. Long- term Follow -up................................................................................................................ 83
9.2. Safety Evaluations ......................................................................................................................... 84
9.3. Pharmacokinetics and Immunogenicity ......................................................................................... 88
9.3.1. Evaluations ................................................................................................................................ .88
9.3.2. Analytical Procedures ................................................................................................................. 88
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 89
9.3.4. Immunogenicity Assessment/Antibodies to JNJ -68284528 ....................................................... 89
9.4. Biom arker Evaluations ................................................................................................................... 89
9.4.1. Pharmacodynamic/Predictive Markers ....................................................................................... 90
9.4.2. Minimal Residual Disease .......................................................................................................... 91
9.5. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 91
9.6. Efficacy  Evaluations ....................................................................................................................... 91
9.6.1. Myeloma Protein Measurements in Serum and Ur ine................................................................ 92
9.6.2. Serum Calcium Corrected for Albumin ....................................................................................... 92
9.6.3. Bone Marrow Examination .......................................................................................................... 92
9.6.4. Skeletal Survey ........................................................................................................................... 93
9.6.5. Documentation of Extramedullar y Plasm acytomas .................................................................... 93
9.7. Sample Collection and Handling .................................................................................................... 94
9.8. Patient- reported Outcome Assessments (Phase 2 Only) .............................................................. 94
9.9. Qualitative Interviews (Phase 2 Only) ............................................................................................ 95
9.10. Medical Resource Utilization .......................................................................................................... 96
10. SUBJECT COMPLETION/DISCONTINUA TION OF STUDY TREA TMENT/ WITHDRA WAL 
FROM THE STUDY ........................................................................................................................... 96
10.1. Completion ..................................................................................................................................... 96
10.2. Discontinuation of Study Treatment ............................................................................................... 96
10.3. Withdrawal from the Study ............................................................................................................. 97
10.4. Withdrawal from the Use of Research Samples ............................................................................ 97
11. STATISTICA L METHODS ................................................................................................................. 97
11.1. Subject Information ........................................................................................................................ 98
11.2. Sample Size Determination ........................................................................................................... 98
11.3. Efficacy  Analyses ........................................................................................................................... 99
11.4. Safety Analyses ........................................................................................................................... 100
11.5. Pharmacokinetic Analy ses........................................................................................................... 101
11.6. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ 101
11.7. Immunogenicity Analyses ............................................................................................................ 101
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved ,  Date: 15 June 202211.8. Patient- reported Outcome Assessments (Phase 2 Only) ............................................................ 102
11.9. Medical Resource Utilization ........................................................................................................ 102
12. ADVERSE EVENT REPORT ING.................................................................................................... 102
12.1. Definitions .................................................................................................................................... 102
12.1.1. Adverse Event Definitions and Classifications ......................................................................... 102
12.1.2. Attribution Definitions ................................................................................................................ 103
12.1.3. Severity Criteria ........................................................................................................................ 104
12.2. Special Reporting Situations ........................................................................................................ 105
12.3. Procedures ................................................................................................................................... 105
12.3.1. All Adverse Events .................................................................................................................... 105
12.3.2. Serious Adverse Events ........................................................................................................... 106
12.3.3. Adverse Events of Special Interest ........................................................................................... 107
12.3.4. Pregnancy ................................................................................................................................ .108
12.4. Contacting Sponsor Regarding Safety ......................................................................................... 108
13. PRODUCT QUA LITY COMP LAINT HA NDLING ............................................................................ 108
13.1. Procedures ................................................................................................................................... 109
13.2. Contacting Sponsor Regarding Product Qu ality.......................................................................... 109
14. STUDY TREA TMENT INFORM ATION........................................................................................... 109
14.1. Physical Description of Study Treatment ..................................................................................... 109
14.2. Packaging .................................................................................................................................... 109
14.3. Labelin g........................................................................................................................................ 109
14.4. Preparation, Handling, and Storage ............................................................................................. 109
14.5. Drug Accounta bility...................................................................................................................... 110
15. STUDY -SPECIFIC M ATERIALS..................................................................................................... 110
16. ETHICA L ASPECTS ....................................................................................................................... 111
16.1. Study-specific Design Considerations ......................................................................................... 111
16.2. Regulatory Ethics Compliance ..................................................................................................... 112
16.2.1. Investigator Responsibilities ..................................................................................................... 112
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................. 112
16.2.3. Informed Consent ..................................................................................................................... 113
16.2.4. Privacy of Personal Data .......................................................................................................... 114
16.2.5. Long- term Retention of Samples for Additional Future Research ............................................ 115
16.2.6. Countr y Selection ..................................................................................................................... 115
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 115
17.1. Protocol Amendments .................................................................................................................. 115
17.2. Regulatory Documentation .......................................................................................................... 116
17.2.1. Regulatory Approval/Notification .............................................................................................. 116
17.2.2. Required Prestudy Documentation ........................................................................................... 116
17.3. Subject Identif ication, Enrollment, and Screening Logs .............................................................. 117
17.4. Source Documentation ................................................................................................................. 117
17.5. Case Report Form Completion .................................................................................................... 118
17.6. Data Quality Assurance/Quality Control ...................................................................................... 118
17.7. Record Retention ......................................................................................................................... 119
17.8. Monitoring .................................................................................................................................... 119
17.9. Study Com pletion/Termination ..................................................................................................... 120
17.9.1. Study Com pletion/End of Study ................................................................................................ 120
17.9.2. Study Termination ..................................................................................................................... 120
17.10. On-site Audits ............................................................................................................................... 120
17.11. Use of Information and Publication .............................................................................................. 121
REFERENCES .......................................................................................................................................... 123
INVESTIGA TOR A GREEME NT............................................................................................................... 164
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved ,  Date: 15 June 2022LIST OF A TTACHMENTS
Attachment 1: Criteria for Response to Multiple Myeloma Treatment ............................................. 125
Attachment 2: Deleted ..................................................................................................................... 127
Attachment 3: International Myeloma Working Group Diagnostic Criteria ...................................... 128
Attachment 4: Prior Cancer Therapy for Multiple Myeloma and Refractory Myeloma 
Definiti on................................................................................................................... 129
Attachment 5: Eastern Cooperative Oncology Group Performance Status Grade ......................... 130
Attachment 6: Form ulas for Estimating Glomerular Filtration Rate ................................................. 131
Attachment 7: Serum Calcium Corrected for Albumin ..................................................................... 132
Attachment 8: Hepatitis B Virus Screening ...................................................................................... 133
Attachment 9: Time and Events Schedules for Retreatment with JNJ -68284528 .......................... 134
Attachment 10: Patient Reported Outcomes (PRO) Measures ......................................................... 144
Attachment 11: Cytokine Release Syndrome ASBMT Consensus Grading Sy stem ........................ 153
Attachment 12: Immune Effector Cell -associated Encephalopathy (ICE) Tool ................................ .154
Attachment 13: Immune Effector Cell -associated Neurotoxicity Syndrome (ICANS) ASBMT 
Consensus Grading Systema,b................................................................................. 155
Attachment 14: Anticipated Adverse Events ...................................................................................... 156
Attachment 15: Handwriting Adverse Event Toxicity Grading Criteria .............................................. 157
Attachment 16: Anti -microbial Prophylaxis Recommendations ......................................................... 158
Attachment 17: COVID -19 Guidance on Study Conduct and Vaccine Timing .................................. 159
Attachment 18: Adverse Event Reporting Guidance for Study 68284528MMY2001 ........................ 163
LIST OF IN -TEXT TA BLES A ND FIGURES 
TABLES
Table 1: Time and Events Schedule for Study Procedures/ Assessments ............................................ 33
Table 2: Time and Events Schedule for Pharmacokinetic and Biomarker Sampling ............................. 40
Table 3: Potentia l Risks and Mitigation Strategies ................................................................................. 51
Table 4: Summary  of CRS Grade by Weight-adjusted Total CAR -positive T Cell Dose (Legend -
2 Study )..................................................................................................................................... 58
Table 5: Dose Limiting Toxicity Criteria .................................................................................................. 58
Table 6: JNJ-68284528 Administration ................................................................................................... 70
Table 7: Pre-infusion Medications .......................................................................................................... 71
Table 8: Guidelines for the Management of Cy tokine Release Syndrome ............................................. 73
Table 9: Guidelines for the Management of CAR -T Cell -related Neurotoxicity (eg, ICANS) ................. 75
Table 10: Guidelines for the Management of Raised ICP / Cerebral Edemaa.......................................... 76
Table 11: Sample Size Scenarios in Phase 1b ......................................................................................... 98
Table 12: Time and Events Schedule for Study Procedures/ Assessments at Retreatment with 
JNJ-68284528 ......................................................................................................................... 134
Table 13: Time and Events Schedule for Pharmacokinetic and Biomarker Sampling for 
Retreatment ............................................................................................................................ 140
FIGURES
Figure 1: LCAR -B38M Coding Region ..................................................................................................... 46
Figure 2:Schematic Overview of the Study Flow Chart .......................................................................... 56
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Status: Approved ,  Date: 15 June 2022PROTOCOL A MENDMENTS
Protocol Version Date
Original Protocol 11 Apr il2018
Amendment 1 20August 2018
Amendment 2 11March 2019
Amendment 3 30July 2019
Amendment 4 20March 2020
Amendment 5 15June 2022
Amendments below are listed beginning with the most recent amendment.
Amendment 5 (15June 2022)
The overall reason for the amendment: The reason for the amendment is to inform investigators that patients 
receiving cilta -cel are possibly at a higher risk of severe/fatal outcomes from COVID -19 infection compared with 
patients who are receiving standard of care therapy, and to provide addit ional guidance for COVID -19 prevention 
and mitigation. Additional guidance for HLH and additional clarifications were also incorporated .
Applicable Section(s) Description of Change(s)
Rationale: To present all of the guidance on COVID -19 prevention, outcomes, and mitigations in the same 
document.
Attachment 17 : 
COVID -19 Guidance 
on Study Conduct 
and Vaccine TimingIntegrated the COVID -19 guidance, which was provided as a separate document, into 
the protocol as Attachment 17 .
Rationale: To clarify the timing for COVID -19 vaccination for cilta- cel recipients , consistent with current 
recommendations across the cilta -cel program .
Attachment 17 : 
COVID -19 Guidance 
on Study Conduct 
and Vaccine TimingAdded guidance on COVID- 19 vaccine timing for cilta- cel recipients.
Rationale: To provide additional prevention and mitigation guidance for COVID- 19 infections in patients treated 
with cilta -cel.
1.7. Potential Safety 
Risks and Mitigation 
Strategies (Table 3)
6.3.6 .Infections
Attachment 17: 
COVID -19 Guidance 
on Study Conduct 
and Vaccine TimingAdded guidance on measures to prevent and mitigate COVID -19 infection, including the 
importance of vaccines and other preventative measures, the use of prophylaxis therapy 
(eg, Evusheld, if available), and the u se of antiviral therapy (eg, Paxlovid, if available) 
for COVID -19 infection.
Rationale: To expand the reporting timeframe for COVID -19 infections.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Time and Events 
Schedule (Table 1)
9.2.Safety 
Evaluations
12.3.1 .All Adverse 
Events
Attachment 9: Time 
and Events Schedules 
for Retreatment with 
JNJ-68284528 (Table 
12)Added text to indicate that events of COVID -19 infection will be reported during the 
first-year post -infusion of cilta -cel.
Rationale: To expand the reporting timeframe for COVID -19 medications.
Time and Events 
Schedule (Table 1)
8.Prestudy and 
Concomitant Therapy
Attachment 17: 
COVID -19 Guidance 
on Study Conduct 
and Vaccine Timing
Attachment 9: Time 
and Events Schedules 
for Retreatment with 
JNJ-68284528 (Table 
12)Specified that medications for the prevention and treatment of COVID- 19, including 
vaccinations against COVID -19, w ill be reported until 1 year after cilta -cel infusion.
Rationale: To increase aw areness and provide additional guidance about the risk of HLH , consistent with health 
authority feedback .
1.7. Potential Safety 
Risks and Mitigation 
Strategies (Table 3)
6.3.1 .Management of 
Cytokine Release 
SyndromeAdded language regarding features of HLH that may put subjects at high risk of 
bleeding and included additional measures to be taken if HLH is suspected.
Rationale: For clarity.
12.3.3. Adverse 
Events of Special 
InterestRemoved stated that “Grade 1 or 2 adverse events of special interest would not qualify 
for expedited reporting unless they meet serious adverse event criteria.”
Rationale: To ensure movement and neurocognitive toxicities (ie, parkinsonism) arecommunicated in an 
expedited fashion, consistent with health authority advice.
12.3.3. Adverse 
Events of Special 
InterestAdded clarification of the requirement for expedited reporting (within 24 hours) of any 
grade movement and neurocognitive toxicity (ie, parkinsonism).
Rationale: To help ensure adverse events are collected and reported as required .
Attachment 18: 
Adverse Event 
Reporting Guidance
for Study 
68284528MMY2001Attachment was added to summarize requirements for adverse event and expedited 
adverse event reporting.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Rationale: To be consistent with current recommendations for RCL assessment across the cilta -cel program.
Time and Events 
Schedule (Table 2)
Attachment 9: Time 
and Events Schedules 
for Retreatment with 
JNJ-68284528 (Table 
13)Clarified the timing (Study Day in addition to Month) of RCL assessment.
Time and Events 
Schedule (Table 2)
9.1.6.3. Long -term 
Follow -up
9.4. Biomarker 
Evaluations
Attachment 9: Time 
and Events Schedules 
for Retreatment with 
JNJ-68284528 (Table 
13)Added that, if post -treatment assays are negative for RCL during the first year, 
collection of follow -up samples may be discontinued, and yearly review of medical 
history will be sufficient for the patient. If any post -treatment samples are positive, 
further analysis of the RCL, and more extensive patient follow -up should be undertaken.
Rationale: Request for clarity regarding COVID -19 antibody reporting, including timeframe .
9.2. Safety 
EvaluationsAdded a request to provide COVID- 19 antibody titers, if available, post cilta- cel 
infusion for up to 1 year.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Status: Approved ,  Date: 15 June 2022Amendment 4 (20March 2020 )
The overall reason for the amendment: The overall reason for the amendment is to add other neurotoxicities as 
a safety risk and implement additional monitoring and risk minimization measures for JNJ -68284528.
Applicable Section(s) Description of Change(s)
Rationale: Safety information was update dto include other neurotoxicities.
Time and Events 
Schedules (Table 1 
and Table 12); 3.1 
Overvie w of Study 
DesignCollection of a handwriting sample and frequency of testing was added to the study 
procedures.
Updated footnote “q” (Table 1) and “n” (Table 12) to include handwriting sample.
Time and Events 
Schedules (Table 1 
and Table 12)Extended ICE neurologic test to be performed at least daily until ICANS is resolved .
For adverse events, added: Report new neurologic adverse events or exacerbat ion of 
existing neurologic adverse events up to 12 m onths after JNJ -68284528 infusion.
1.5 Summary of 
Clinical StudiesAdded asummary of data for Study 68284528MMY2001 and a description of 6cases of 
other neurotoxicities. Added updated information on Legend -2 study and Study 
68284528MMY2002.
1.7 Potential Safety 
Risks and Mitigation 
Strateg ies; Table 3Added other neurotoxicities to Table 3 (Potential Risks and Mitigation Strategies )as a 
subsection of neurologic toxicit ies(changed from neurological adverse events ).
Added specific information to CRS rather than just cross reference to Section 6.3.1.
Also updated guidance for cytopenias, infections, and hypogammaglobulinemia
2.1 Objectives and 
EndpointsAdded exploratory objective and endpoints to characterize potential early predictive 
markers for neurotoxicity .
6.1.4. JNJ -68284528 
AdministrationAdded the following: Hospitalization is required for Grade 2, 3, or 4 CAR -T cell -related 
neurotoxicity (eg, ICANS ) temporally associated with CRS. Hospitalization for neurotoxicity 
that is not temporarily associated with CRS, or any other neurologic adverse events, is at the 
discretion of the investigator.
6.3.2 Neurological 
Adverse EventsDivided section into overall neurologi c adverse events with sub -sections of CAR -T 
cell-related neurotoxicity (ICANS) (Section 6. 3.2.1 ) and other neurotoxicities (Section 
6.3.2.2 )
Added that subjects should be monitored for neurotoxicity for 1 year post JNJ -68284528 
infusion.
6.3.2.1 CAR -T Ce ll-
related Neurotoxicity 
(Immune Effector 
Cell-Associated 
Neurotoxicity 
Syndrome [ICANS])Added “Consider performing neuroimaging (eg, MRI)…”
Clarified that hospitalization is required for Grade 2, 3, or 4 CAR -T cell -related 
neurotoxicity temporally associated with CRS.
Added recommendation to rule out alternative etiologies at first sign of neurotoxicity.
6.3.2.2 Other 
NeurotoxicitiesNew  section with guidance to monitor for other neurotoxicities
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
9.2 Safety 
EvaluationsAdded the following:
Added handwriting assessments to safety measures
Added neurological adverse events to adverse events that are exception to 100 day 
reporting. New  neurological adverse events or exacerbation of existing neurological 
adverse events will be reported during the first year post JNJ -68284528 dose.
Added grading criteria to be used for neurotoxicity and changes in handwriting
For subjects w ith prior pert inent neurologic disease (eg, stroke, encephalitis) consider 
baseline MRI of the brain and an EEG.
Added a section describing the assessment for qualitative changes in handw riting.
12.3.1. All Adverse 
EventsAdded neurological adverse events to the exce ptions from reporting until 100 days after 
the last administration of study treatment.
Added “new neurological adverse events or exacerbation of existing neurologic adverse 
events” will be reported during the first year post -dosing JNJ -68284528.
Attachment 15
Handw riting Adverse 
Event Toxicity 
Grading CriteriaTable added for qualitative grading of handw riting sample.
Rationale: Change made to allow  for flexibility in assessments .
Time and Events 
Schedules (Table 1 
and Table 12)Added footnote “s” (Table 1) and “p”(Table 1 2): Local laboratory assessments may be 
used under specified circumstances (See Section 9.6)
9.6. Efficacy 
EvaluationsAdded provision for local laboratory data collection
Rationale: Revised text in the protocol for clarity.
Time and Events 
Schedules (Table 1 and 
Table 12)Revised as conmeds for adverse events are collected beyond Day 100: Continuous 
from the time of signing of ICF until at least 100 days after last administration of 
any study treatment . Concomitant usage for the treatment of adverse events after 100 
days should be reported.
Time and Events 
Schedules (Table 2 and 
Table 13)Clarified timing of sample collection for MRD
1.7Potential Safety Risks 
and Mitigation Strategies; 
Table 3Added guidance to CRS to “Notify the sponsor if subject is experiencing Grade 2 or 
higher CRS”.
Added guidance for neurologic adverse events to “Notify the sponsor if subject is 
experiencing any grade ICANS”.
Added guidance for neurologic adverse events to “Notify the sponsor if subject is 
experiencing any grade ICANS”.
6.3.4. Cytopenia Added language for parvovirus B19 testing in subjects w ith prolonged neutropenia
6.3.5. 
HypogammaglobulinemiaAdded language for IVIG prophylaxis
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
9.4. Biomarker 
EvaluationsAdded language for c ollection of tumor sample for subjects with SPM, 
plasmacytoma sample, and cerebral spinal fluid sample.
Added that if a subject dies and an autopsy is p erformed, specimens may be 
requested by the sponsor for analysis , as allowed by local regulations .
8. Prestudy and 
Concomitant TherapyAdded that all medications must be recorded “…until at least 100 days after 
infusion of JNJ -68284528
Added: After 100 days, only adverse events that are considered related to study 
drug need to be reported until the end of the study . This includes concomitant 
therapy and any medication used to treat or support adverse events or serious 
adverse events (within or beyond 100 days after infusion) .
8.1 Permitted 
MedicationsAdded that chemotherapy agents used to treat CAR -T cel l-related toxicities are 
permitted upon consultation with the sponsor.
8.2 Prohibited Therapies Removed exception for therapy to treat CAR -T cell -related toxicity from prohibited 
therapies. Added: ‘or protocol -specific therapies which may be used in conju nction 
with JNJ -68284528.
9.4.2. Minimal Residual 
DiseaseAdded guidance for in the event that a fresh bone marrow aspirate is not collected at 
baseline.
12.3.1. All Adverse 
EventsAdded “After 100 days, only adverse events that are considered related to study drug 
need to be reported until the end of the study.”
Revised as follows: “ Serious adverse events, including those spontaneously reported 
to the investigator within 100 days after the last administration of any study 
treatment must be reported usin g the Serious Adverse Event Form. ”
Clarified that all deaths not related to disease progression should be reported to the 
sponsor following expedited procedures.
12.3.3 Adverse Events of 
Special InterestAdded other neurotoxicities.
Added events that must be reported to the sponsor using the serious adverse event 
form within 24 hours of awareness.
14.5 Drug Accountability Added clarification that information in this section relates to study treatment that is 
supplied to investigational sites from the study sponsor.
6.3.6 Infections Deleted: Consider periodic monitoring for CMV with PCR testing. If PCR is 
positive based on local threshold, clinical judgment and institutional guidelines 
should be follow ed to decide about initiation of CMV treatment.  
Rationale: Updated information based on current clinical data.
1.7 Potential Safety Risks 
and Mitigation StrategiesRemoved statement “Clinical experience with JNJ -68284528 and LCAR -B38M 
CAR -T cells is limited” as to date almost 100 subjects have received an infusion of 
JNJ-68284528 .
Added: Longer follow -up and treatment of additional subjects, particularly subjects 
who have received fewer prior therapies than subjects in the Legend -2 and 
68284528 MMY2001 studies, may reveal additional risks.
Rationale: Flexibility added to bridging therapy language .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 12
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
3.1. Overview  of 
Study DesignRevised following guidance:
Additional cycles of bridging therapy m ay be considered based on subject’s clinical 
status and timing of availability of CAR -T product.  Investigator must contact the 
sponsor for approval.
Bridging therapy is now permitted for subjects receiving retreatment , with sponsor 
approval
Time and Events 
Schedule (Table 12)Since bridging therapy is now permitted for subjects receiving retreatment, added that 
echocardiogram or MUGA scan should be repeated after completion of bridging therapy 
if it includes agents with known cardiotoxicity
Rationale: Grading column added to CRS and ICANS management tables to reflect adoption of ASBMT criteria 
across study protocols.
6.3.1Management of 
Cytokine Release 
Syndrome ; Table 8
6.3.2.1 CAR -T Cell -
related Neurotoxicity 
(ICANS) ; Table 9Added column for CRS grade.
Added column for ICANS grade.
Added to row  1 (ICE score 7 -9) dexamethasone can be considered for Grade 1 ICANS.
Rationale: Added recommendations for extended anti -microbial usage .
6.3.6. Infections Added: Extended use of anti -microbial therapies for at least 6 month (or longer as per 
institutional guidelines) or consistent with post ASCT consensus guidelines after CAR -T 
dosing are recommended (see Attachment 16) .
Attachment 16 Table w ith anti -microbial prophylaxis recommendations
Rationale: Corrected an error.
9.3.3. 
Pharm acokinetic 
ParametersDeleted ‘for each dose level’ from the following statement as all subjects w ill be 
summarized in 1 group: Pharmacokinetic parameters will be estimated for individuals, 
and descriptive statistics will be calculated for each dose level . 
9.10 Medical 
Resource UtilizationAdded “ Health economics data such as medical resource utilization data associated 
with medical encounters….”
Added “ Health economics data such as costs associated with the medical encounters will 
be collected separately from the eCRF .All health economic data w ill be used only in a 
de-identified manner.”
Rationale: References were updated.
References Added reference: MD Anderson Cancer Center. IEC Therapy Toxicity Assessment and 
Management. 2019. Appendix J. https://www.mdanderson.org/documents/for -
physicians/algorithms/clinical -management/clin -management -cytokine -release -web-
algorithm.pdf
Deleted reference: Legend Biotech. Clinical Safety and Efficacy Report. Legend -2 
study. LCAR -B38M -02 or [STUDY_ID_REMOVED].
Rationale: Minor errors w ere noted.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 13
Status: Approved ,  Date: 15 June 2022Amendment 3 30July 2019
The overall reason for the amendment: The overall reason for the amendm ent is to transition into the Phase 2 
portion of the study ,describe the role of the Independent Review Committee (IRC), add the Medical Resource 
Utilization (MRU) assessment, and to a dd clarity to targeted sections of the protocol.
Applicable Section(s) Description of Change(s)
Rationale: Updated the protocol title page with the name of the study
Title page Updated the title of the protocol to i nclude “ CARTITUDE -1”.
Rationale: Independent Review Committee added for evaluation of disease status
Synopsis; 2.2 Hypothesis
Synopsis; 2.1 Objectives 
and Endpoints
2.2 Hypotheses
3.1 Overview  of Study 
Design;
11.3 Efficacy AnalysesAdded language for the inclusion of an Independent Review Committee to evaluate 
disease status.
Clarification added to the study hypothesis: “Treatment with JNJ -68284528 w ill 
demonstrate acceptable safety and will have significant anti -myeloma activity (ie, 
the lower limit of two -sided 95% confidence interval [CI] for ORR, as assessed by 
the IRC, is greater than 30%) at the targeted recommended Phase 2 dose (RP2D) 
level in subjects w ith advanced relapsed or refractory multiple myeloma.”
Update to the Evaluations: “ Disease status will be evaluated by an Independent 
Review Committee (IRC) according to clinical judgement as guided by the 
IMWG consensus recommendations for multiple myeloma .
The second primary endpoint was updated as follows: ORR (at least a partial 
response [PR] or better) as defined by the International Myeloma Working Group 
(IMWG) resp onse criteria as assessed by the Independent Review Committee 
(IRC) .
The follow ing statement was amended to describe the role of the IRC: “Treatment 
with JNJ -68284528 w ill dem onstrate acceptable safety and will have significant anti -
myeloma activity (ie, the lower limit of two -sided 95% confidence interval [CI] for 
ORR, as assessed by the IRC ,  is greater than 30%) at the targeted recommended 
Phase 2 dose (RP2D) dose level in subjects w ith advanced relapsed or refractory 
multiple myeloma. ”The following statement was amended to describe the role of the 
IRC in regard to the evaluation of the primary efficacy analysis: “ Disease status will 
be evaluated according to the IMWG consensus recommendations for multiple 
myeloma treatment response cr iteria (Attachment 1)10, 11,31.For the prim ary 
efficacy analysis, the disease status evaluation for each subject will be assessed 
by an Independent Review Committee (IRC). Disease status will be evaluated 
according to clinical judgement guided by the IMW G consensus 
recommendations for multiple m yeloma treatm ent response criteria 
(Attachm ent 1.) 10, 11,31. The process and convention of the IRC will be detailed 
in a separate charter. Response will be determined using a validated computer 
algorithm. ”
The fo llowing statement was added: “For efficacy, assessment by the IRC will be 
used as prim ary.”
Rationale: Changes and corrections made for clarity
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
T&E Schedule 
(Table 1 and Table 12)For safety criteria, added a cross reference to Section 6.1.3 (Evaluation Prior to 
Administration of JNJ -68284528).
Added w indow  for Hematology assessment prior to apheresis.
Revised infectious disease assessment to allow for a w indow of testing prior to 
apheresis for flexibility.
Revised skeletal survey evaluation to “As clinically indicated to assess for document
disease progression or response ”.
Footnote “f” (Table 1) and footnote “e” (Table 12) updated to include: “ Serology 
results performed as standard of care within 28 days p rior to apheresis are 
acceptable .
T&E Schedule 
(Table 1)Corrected PGIS post -treatment footnote: ‘X a’ to ‘Xo’ .
Footnote “b” updated to include: “ For subjects who discontinue the study before Day 
100, including those who have not received an infusion of JNJ-68284528 , the 
Day 100 assessments should be performed prior to withdrawal if feasible.” 
6.1. Study Treatment 
AdministrationAdded subheading for exceptional release criteria.
Rationale: Window  added to PK sampling for consistency in collections
T&E Schedule 
(Table 2 and Table 13)Additional window of “same day as dose of JNJ -68284528 infusion ”for the PK 
CAR positive T cell cellular blood sample, the PK CAR transgene levels blood 
sample, and the soluble serum BCMA sample. 
T&E Schedule 
(Table 2)Clarification to footnote “a”; added “ post JNJ-68284528 infusion ”.
Rationale: Medical Resource Utilization (MRU) data collection is added to evaluate the total health care 
resources for JNJ-68284528 CAR -Tprocess 
T&E Schedule 
(Table 1 and Table 12 );
2.1 Objectives and 
Endpoints;
9.10 Medical Resource 
Utilization; 
11.9 Medical Resource 
Utilization; Added Medical Resource Utilization requirements .
Patient Reported Outcome heading updated to include Medical Resource 
Utilization .
Row  added t o Table 1 for Medical Resource Utilization visit schedule.  
Added footnote “r” to define MRU data collection until Day 180 (± 7 days).
Added an exploratory objective and endpoint .
Added requirements of medical resource utilization
Added method of statistical analysis for medical resource utilization data. 
Rationale: Added kanamycin to hypersensitivity reactions
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
1.7. Potential Safety 
Risks and Mitigation 
Strategies ;
6.3.7 Hypersensitivity 
ReactionsAdded kanamycin to list of potential hypersensitivity reactions .
Rationale: Clarification made to retreatment criteria to incorporate guidance for ongoing hematologic vs non -
hematologic toxicity
3.1 Overview  of Study 
DesignModified the eligibility criteria for retreatment to:
 Progressive disease (PD) after best response of minimal response (MR) or better. 
 No history of Grade 3 or higher toxicities reported
 No ongoing Grade 3 or higher hem atologic toxicity .
 No ongoing Grade 2 non-hematologic toxicity (with the e xception of nausea, 
vomiting, hair loss, and constipation) .
 At least 6 months betw een first JNJ -682845 28infusion and detection of PD.
Rationale: Revision smade for clarity
6.1.1 Criteria for 
Apheresis;Added 24 -hoursprior to apheresis window  for results of clinical laboratory values 
required for enrollment.  
6.1.1 Criteria for 
Apheresis; 6.1.2 Criteria 
for Conditioning 
(Cyclophosphamide and 
Fludarabine) DosingAdded antitumor therapy from exclusion criteria (from S ection 4.2) in addition to 
cross reference for clarity.
6.1.2 Criteria for 
Conditioning 
(Cyclophosphamide and 
Fludarabine) DosingClinical laboratory values required for enrollment (Section 4.1), with the following 
exception s: lymphocyte count of ≥0.3 x 109/L. Transfusion support is permitted to 
maintain a hem oglobin of 8.0 g/dL ( 5 mm ol/L) as needed, and platelets of ≥50 
x 109/L until 3 days before the hematology laboratory test, preceding 
lymphodepletion. and transfusion of platelets and administration of myeloid growth 
factor is permitted until 3 days before the hematology laboratory test preceding 
lymphodepletion. Myeloid growth factors are permitted up to 1 day prior to the start 
of the conditioning regimen. Pegylated myeloid growth factors (ie, pegfilgrastim) are 
prohibited.
9.2 Safety Evaluations In clinical laboratory test subsection, updated “Blood urea nitrogen” to “Blood urea 
nitrogen/ urea” for countries outside of US.
Rationale: Clarification made to inclusion criteria to better define a regimen. A regimen is a line of therapy
4.1 Inclusion criteria Modification of inclusion criteria 4.1, 5, and 6 to replace the term “regimen” with 
“line of therapy”.  
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Rationale: Contraception guidance revised in response to cyclophosphamide labeling.
4.1 Inclusion criteria
4.2 Exclusion criteriaInclusion criterion #10:  
The timeframe for which subjects must agree to practice a highly 
effective method of contraception has been updated from the time of 
signing the ICF until at least 100 days 1 year after receiving a JNJ-
68284528 infusion.
In addit ion to the highly effective method of contraception a man must 
also agree to use a barrier method of contraception from the time of 
signing the ICF until at least 100 days 1 year after receiving a JNJ-
68284528 infusion.
Wom en and men must agree not to dona te eggs (ova, oocytes) or sperm, 
respectively, during the study and for 100days 1 year after the last dose 
of study treatment. 
Exclusion criterion #20:  
Pregnant or breast -feeding, or planning to become pregnant while 
enrolled in this study or within 100 days 1 year after receiving study 
treatment.
Exclusion criterion #21: 
Plans to father a child while enrolled in this study or within 100 days 1 
year after receiving study treatment.
Rationale: Clarification to safety language for consistency
6.1.2 Criteria for 
Conditioning Regimen 
(Cyclophosphamide and 
Fludarabine) DosingTo be consistent with the revisions to Section 6.1.2., text updated from: “No 
evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection. 
Subjects on an ti-infective agents within 7 days prior to apheresis must receive 
approval to proceed from sponsor” to “ No signs of active infection. For subjects 
requiring syste mic anti -microbial treatm ent or with temperature ≥38.0 Celsius 
within 7 days prior to the firs t dose of conditioning regimen, the investigator 
must receive approval to proceed from  the sponsor .” 
Rationale: The use of a catheter is no longer applicable
6.1.2 Criteria for 
Conditioning 
(Cyclophosphamide and 
Fludarabine) DosingDeleted statement regarding construction of catheter.
Rationale: Modified guidance for dosing delays to ensure subject safety prior to JNJ-68284528 infusion
6.1.3 Evaluation Prior to 
Administration of JNJ -
68284528JNJ-68284528 Dosing Delays: 
Subjects will be evaluated for safety on the day of JNJ-68284528 infusion. If a 
significant health status change (eg, clinical deterioration, rapidly progressing 
disease, constipation) occurs following the start of the conditioning regimen (see 
Section 6.1.2), the investigator should contact the sponsor prior to dosing.
Infusion of JNJ-68284528 must be delayed if any of the follow ing events occur:
Uncontrolled Signs ofactive infection. Do not administer JNJ -68284528 to 
subjects with active infection. For subjects requiring system ic anti -
microbial treatm ent, or with tem perature ≥38.0 Celsius within 48 hours 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
before JNJ-68284528 infusion, investigator must consult with the 
sponsor prior to dosing.
Grade ≥3 non -hematologic toxiciti es of the cyclophosphamide and 
fludarabine conditioning regimen (except for Grade 3 nausea, vomiting, 
diarrhea, or constipation). Investigator must consult with the sponsor 
prior to dosing.
Rationale: Added language to allow  testing of tumor sampling in case of a report of second primary 
malignancies (SPM ).
6.3.8 Second Primary 
Malignancy; 9.1.6.3 
Long -term Follow -upAdded sentence “A tumor sample should be collected and DNA, RNA or protein 
analysis m ay be performed to investigate the presence of lentiviral elem ents”.  
Rationale: Qualification made to prohibited therapy 
8.2 Prohibited Therapies Pegylated myeloid growth factors (ie, pegfilgrastim) are prohibited within the first 
100 days after infusion of JNJ -68284528 (Section 6.1.2 ).
Rationale: Correction of error s
9.1.6.1 Post -Infusion 
Period Correction to temperature symbols for reporting fever (> updated to ≥).
Rationale : Clarification to the method of treatment response analysis
9.6Efficacy Evaluations The follow ing sentence was deleted: “ Disease progression must be consistently 
documented across clinical study sites using the criteria in Attachment 1 . The 
sponsor w ill use a validated computer algorithm to analyze response to treatment .”
Rationale : Clarification to biomarker evaluation language
9.6.3 Bone Marrow  
ExaminationBone marrow  aspirate or biopsy (acceptable if aspirate is not possible) will be 
performed for clinical assessments . Bone m arrow aspirate will be perform ed for
andbiomarker evalu ations . 
Rationale :Clarification to Patient -Reported Outcome Assessments (Phase 2 only)
9.8 Patient -Reported 
Outcome Assessments 
(Phase 2 only)Language updated as follows: “Full training documentation will be provided to site 
coordinators before the start of data collection. PRO assessments will be conducted 
beyond disease progression or subsequent anticancer therapy . If no site visits are 
schedu led for additional disease evaluations, subjects will have the option of 
completing the PRO assessments after disease progression or subsequent 
anticancer therapy via telephone .”
Rationale: Updates to the efficacy analysis
3.1 Overview  of Study 
DesignThe sponsor w ill establish a data cutoff date for clinical study report (CSR) analyses. 
The first primary analysis will be conducted approximately 6 months after the last 
subject received their initial dose of JNJ -68284528. An update of the analysis will 
be provided at approximately 9 -12 m onths after the last subject received their 
initial dose of JNJ -68284528 and at the end of the study which is defined as 2 
years after the last subject has received their initial dose of JNJ -68284528 
(Section 17.9.1). Subjects w ill be follow ed for survival after the clinical cutoff for 
the primary CSR.  The data cutoff will be communicated to the sites. Study 
completion/end of study will be defined as no later than 2 years after the last subject 
has received their initial d ose of JNJ 68284528 (Section 17.9.1). However, the The
sponsor w ill monitor subjects treated w ith JNJ -68284528 for 15 years for 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
complications of lentiviral integration, including second primary malignancies on a 
long-term follow -up study. 
11.3 Efficacy Analyses Anefficacy analyses end point definition was updated as follow s: “Overall response 
rate (ORR) is defined as the proportion of subjects who achieve a PR or better 
according to the IMWG criteria.10,11,31Response to treatment w ill be analyzed by a 
validated computerized algorithm.9,29
The follow ing sentence as added to the section: “ For efficacy, assessment by the 
IRC will be used as primary.”
The timing of the primary analysis was updated as follows: “The first analysis for 
the primary endpoint, ORR (PR or better), w ill be conducted approximately at 
6months after the last subject has received his or her initial dose of JNJ -68284528, 
and will be based on the mITT analysis set. The response rate and its 95% exact
confidence interval (CI) will be calculated based on binomial distribution, and the 
null hypothesis will be rejected if the lower bound of the confidence interval exceeds 
30%. Analysis of VGPR or better response rate, DOR, PFS, and OS will be 
conducted at the same cutoff as the ORR, and an update of these endpoints will be 
provided at approxim ately 9 - 12 m onths after last subject has received his or her 
initial dose of JNJ -68284528 and at the end of the study, which is defined as 2 
years after the last sub ject has received his or her initial dose of JNJ -68284528. 
Additional safety data will be collected in a long -term follow -up study.”
Details added regarding the type of analysis are as follows: “A sensitivity analysis 
of ORR will be perform ed based on the subjects in the mITT analysis set who 
received the JNJ -68284528 product that m et all of the pre- specified release 
criteria.
The agreem ent on ORR between the determ ination by the IRC and the 
assessment by a validated computerized algorithm developed by the sponsor 
will be evaluated using the kappa statistic and 95% CI will also be provided.”
Rationale: Adverse event template language incorporated for clarity
12.1.3 Severity Criteria The follow ing statement was added: Any adverse event or serious adverse event 
not listed in the NCI CTCAE Version 5.0 will be graded according to 
investigator clinical judgm ent by using the standard grades as follows:
Rationale: Clarification regarding reporting of Adverse Event of Special Interest
12.3.3 Adverse Events of 
Special InterestChange made to the reporting requirements for adverse events of special interest.  
Adverse events of special interest “should be reported to the sponsor in a timely 
manner ”replaces text stating “will be reported to the sponsor within 24 h ours of 
awareness, and may require enhanced data collection ”.
Rationale : Addition to list of study -specific materials
15 Study -Specific 
MaterialsAdded “Thermal printer and barcode scanner (for sites utilizing Vineti chain of 
custody/chain of identity software in Phase 2)” to end of preexisting list.
Rationale: Added an attachment for anticipated adverse events to fulfil the ICSR requirement from FDA.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Attachment 14:  
Anticipated Adverse 
EventsThe attachment of anticipated adverse event was added to specify the definition, 
reporting time of anticipated adverse events, etc.
Rationale: Updates to references
T&E Schedule 
(Table 2 and Table 1 2);
3.3 Dose De- escalation; 
9.2 Safety Evaluations; 
12.1.3 Severity Criteria; 
Attachment 11; 
Attachment 13 Update to reference for ASBMT consensus grading for CRS (Lee 2018 changed to 
Lee 2019). 
References Reference number 9 no longer cited: “Dimopoulos MA, Oriol A, Nahi H, et al. 
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J 
Med. 2016;375:1319 1331.”
Reference number 22 w as updated to: “Lee DW, Santomasso BD, Locke FL, et al. 
ASBMT consensus grading for cytokine release syndrome and neurological toxicity 
associated with immune effector cells. Biol Blood Marrow Transplant.2019 
Apr;25(4):625 -638”.
Reference number 29 no longer cited: “ Palumbo A, Chanan Khan A, Weisel K, et al. 
Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J 
Med. 2016;375:754 766.”
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment 2 (11March 2019 )
The overall reason for the amendment: The overall reason for the amendment is to expand the number of 
subjects enrolled in the Phase 1b portion of the study , update the CRS and neurotoxicity management guidelines, 
update the CRS and neurotoxicity grading system, and add clarity to targeted sections of the protocol.
Applicable Section(s) Description of Change(s)
Rationale: Revisions made to allow  for an expansion in the number of subjects enrolled in the Phase 1b portion 
of the study
Synopsis Overview of 
Study Design and 
Dosage and 
Administration ; 
3.1. Overview  of 
Study Design;
3.4. Dose Escalation;
11.2. Sample Size 
DeterminationThe number of subjects enrolled in the Phase 1b portion of the study was expanded from 
“approximately 24” to “at least 24 and up to 50 subjects”.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Synopsis Dosage and 
Administration;
3.1. Overview  of 
Study DesignThe follow ing text was also added “ Confir mation of the RP2D w ill be based on review  
of data from at least 24 subjects who were administered JNJ -68284528 . Additional 
subjects (up to 50) w ill be enrolled in the Phase 1b portion of the study to generate 
supplemental safety and efficacy data at the R P2D.”  
11.2. Sample Size 
DeterminationAddition of Table 11 to describe the probabilities of observing the adverse events under 
the assumed true incidence rates of the adverse events with the larger sample sizes .
Rationale: Revisions to the CRS toxicity management recommendations and to incorporate ASBMT consensus 
grading system for CRS 
T&E Schedule 
(Table 1 and 
Table 12);
3.3. Dose De -
escalation;
9.2. Safety 
Evaluations;
12.1.3. Safety Criteria
Attachment 11Added that CRS will be evaluated according to the new ASBMT consensus grading 
(Lee et al 2018) per new  Attachment 11.
6.3.1. Management of 
Cytokine Release 
SyndromeRevisions to the guidelines for management of CRS in Table 8 to replace CRS grade 
with presenting symptoms. 
Addition of precautionary language in case of severe unresponsive CRS to evaluate for 
HLH/MAS and consider additional interventions.
Revised sect ion title to remove “prevention” to more accurately reflect that the section 
content is for management of CRS
Added additional language around interventions (tocilizumab and other monoclonal 
antibodies targeting cytokines) for CRS.
Attachment 2 Deleted contents of Attachment 2 as CRS grading has been replaced w ith ASBMT 
consensus grading
Rationale: Revisions to update the neurotoxicity management recommendations, incorporate ASBMT consensus 
grading for Immune Effector Cell -Associated Neurotoxicity Syndr ome (ICANS), and include Immune Effector 
Cell-associated Encephalopathy (ICE) Tool.
T&E Schedule 
(Table 1 and 
Table 12);
3.3. Dose De -
escalation;
9.2. Safety 
Evaluations;
12.1.3. Safety 
Criteria;
Attachment 13Added that CAR -T cell -related neurotoxicity (eg, ICANS) should be graded according 
to the ASBMT consensus grading (Attachment 13).
T&E Schedule 
(Table 1 and Table 
12)Assessment of ICE testadded to Time and Events Schedules Table 1 and Table 11.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
1.7. Potential Safety 
Risks and Mitigation 
StrategiesReplaced “neurological adverse events” entry in potential risks table with Neurological 
adverse events including CAR -T cell -related neurotoxicity (eg, immune effector cell -
associated neurotoxicity syndrome [ICANS ])
Added guidance that hospitalization is required for Grade ≥2 CAR -T cell -related 
neurotoxicity (eg, ICANS).
6.1.4. JNJ -68284528 
Administration;
6.3.2. Neurological 
Adverse EventsSpecified that hospitalization is required for Grade 2, 3, or 4 CAR -T cell -related 
neurotoxicity (eg, ICANS) not all neurotoxicity
6.3.2. Neurological 
Adverse Events;
9.2. Safety 
Evaluations;
Attachment 12Revised section to include definition of ICANS and use of ICE assessment tool. Added 
a description of the neurologic examination and ICE tool to S ection 9.2 .
Added that at first signs of seizures or raised intracranial pressure/cerebral edema that 
subjects should be transferred to the ICU and treated according to institutional 
guidelines.
Revised Table 9; removed grading assessment and replaced wi th presenting symptoms.
Management is determined by the most severe event not attributable to any other cause.
Added Table 10 (Guidelines for the management of raised ICP/ cerebral edema).
ICE tool added as Attachment 12
Rationale: Changes made to safety criteria for clarity
T&E Schedule 
(Table 1 and 
Table 12)Changed “eligibility criteria (predose)” to “safety criteria ” (added as separate section) to 
more accurately reflect the assessment.
3.1. Overview  of 
Study Design;
6.1.1. Criteria for 
ApheresisEligibility criteria required before apheresis now referred to as “safety criteria”. 
Addition of Section 6.1.1 to define the safety criteria to be met before apheresis of the 
subject.
6.1.2. Criteria for 
Conditioning 
Regimen 
(Cyclophosphamide 
and Fludarabine) 
DosingDefined cyclophosphamide and fludarabine as conditioning regimen in the title for 
clarity and replaced “cyclophosphamide and fludarabine” with “conditioning regimen” 
for consistency throughout Section 6.1.2 .
Revised criterion for corticosteroids to align with changes to exclusion criterion # 7. 
Added that the sponsor should be called for approval if a subject receives corticosteroids 
at a dose >10mg per day in the w eek prior to the start of the conditioning regimen.
Added that myel oid growth factors (but not pegylated myeloid grow th factors) are 
permitted up to 1 day prior to the start of the conditioning regimen.
Added cross reference exclusion criterion #4 for w ashout of bridging therapy.
Rationale: Revisions made to biomarker s ample collections in response to emerging data
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
T&E Schedule 
(Table 2 and 
Table 13)Additional collections of immunophenotyping (whole blood) samples on Days 1(pre-
dose) ,2, 3, 7, 10, 42, 78, and every 4 weeks after Day 100 up to 1 year .Removed 
assessment on Day 184.
Added collection for CyTOF (aspirate) (bone marrow ) prior to the first dose of the 
conditioning regimen.
Added sample collection for cytokine profiling on Day 2.
Split “Prior to Subsequent Therapy or Study Completion, Whichever is First” column 
into “At PD” and “At Study Completion for Subjects w ithout PD”
Footnote ‘ c’ now only applies to PK CAR positive T -cell, PK tr ansgene levels, and 
ADA samples to state that additional samples are to be collected at CRS or 
neurotoxici ty event Grade ≥2.
Added additional CyTOF/PBMC/plasma (whole blood) collections on Day 7 and Day 
10.
T&E Schedule 
(Table 2 and 
Table 13);
9.3.1. EvaluationsCollection of additional cytokine profiling samples at onset of CRS or CAR -T cell -
related neuro toxicity (eg, ICANS) (any grade) and then every 24 hours until event is 
stabilized or resolving at which point additional samples are collected at 24, 48, and 72 
hours or as clinically indicated .Addition of footnote ‘g’ (for cytokine profiling) to Table 
2and 
Table 13
Rationale: Revisions made for clarity or consistency
T&E Schedule 
(Table 1 and 
Table 12)Removed the ≤7 day window from the disease characteristics assessment to be 
performed prior to the first dose of conditioning regimen 
Collection of serum 2-microglobulin moved from screening to prior to first dose of 
conditioning regimen to be consistent with collection times of other disease evaluations. 
Additional collection of quantitative immunoglobulins added prior to first dose of
conditioning regimen.
Added “and core biopsy” to “bone marrow  aspirate” row  title under other disease 
evaluations. Replaced “immunofluorescence” with “flow cytometry” as methodology to 
assess sCR. Revised footnote ‘k’ (Table 1) and ‘j’ (Table 12) to state that bone marrow  
morphology is to be assessed locally at all time points.
T&E Schedule 
(Table 1 and 
Table 12);
9.1.6.1. Post -infusion 
PeriodRevised footnote ‘h’ (Table 1) and ‘g’ (Table 12) to indicate that subjects should record 
2 temperatures i ncluding their maximum daily temperature in the diary. Clarified in 
footnote that temperature w ill be checked at least twice a day up to Day 28 .Deleted 
reference to temperature collection from Section 9.1.4.1 due to redundancy.
T&E Schedule 
(Table 1 and 
Table 12);
3.1. Overview  of 
Study Design;
3.5. Safety Evaluation 
Team ;
6.1.4. JNJ -68284528 
AdministrationAdded clarification that the requirement for hospitalization and local stay will be 
evaluated by the SET.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
T&E Schedule 
(Table 1);
6.1.1 . Criteria for 
ApheresisScreening assessments that should be collected for subjects who undergo a second 
apheresis were identified. Included as footnote ‘a’ in T&E.
Clarified in footnote ‘a’ that the ICF must be signed before any study -related procedures 
are performed and remains in effect if the screening evaluation is not performed within 
the 28 day screening phase.
1.4. JNJ -68284528 Revised the following statement to be consistent with emerging data. “The novel design 
of the BCMA targeting domain facili tates binding of 2 epitopes features dual targeting 
dom ains on BCMA,…”
2.1. Objectives and 
Endpoints ;
9.4Biomarker 
EvaluationsRevisions to the secondary endpoint of objective to characterize the pharmacokinetics 
and pharmacodynamics of JNJ -68284528 and exploratory endpoint of objective to 
explore whether the infused CAR -positive T cell subsets impact pharmacodynamics, 
safety, and clinical activity of JNJ -68284528 . Added CD25+to list of biomarker 
evaluations.
3.1. Overview  of 
Study Design ;
3.5. Safety E valuation 
TeamText added to clarify the SET meeting interval in Section 3.5 .Added to Section 3.1, a 
cross reference to details regarding when SET meetings are to occur.
3.1. Overview  of 
Study DesignClarify that clinical data will be shared with the relevant health authorities before 
administration of JNJ -68284528 to subjects in the Phase 2 portion of the study
3.3. Dose De -
escalationClarified that DLTs are those associated with JNJ -68284528
4.1. Inclusion Criteria Added to criterion #3 that local laboratory assessments may be used to establish
measurable disease at Screening, with local laboratory result ≥125% of requirements
4.2. Exclusion 
CriteriaRevised criterion (#7) on prior corticosteroid u se from daily dose to cumulative dose for 
clarity.
Revised criterion (#3) to change to no known active disease present for ≥2 years (change 
from ≥3 years) to be more consistent with ASCO guidance. 
6.1. Study Treatment 
AdministrationAdded that spon sor approval must be obtained to change the conditioning regimen 
schedule. Removed, due to redundancy, statement regarding re -assessment of eligibility 
criteria if cyclophosphamide and fludarabine is delayed ≥10 weeks.
6.3.7. 
Hypersensitivity 
ReactionsAdded for consistency with Table 3 and the Investigator’s Brochure
6.3.8. Second Primary 
MalignancyAdded for consistency with Table 3 and the Investigator’s Brochure
8.1. Permitted 
MedicationsRevised language around bisphosphonate recommendation: Bisphosphonates should
may be initiated (if not already being administered) unless contraindicated within 1 
week prior to the first dose of study treatment and continued until disease progression is 
established.
Added therapies intended to treat CAR -T cell -related toxicity (ie, CRS).
Added that myeloid growth factors are permitted up to 1 day prior to the start of the 
conditioning regimen to be consistent with Section 6.1.2.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
8.2. Prohibited 
TherapiesRemoved “Routine transfusions should not be given on the day of JNJ -68284528 
administration” from list of medications prohibited during the study (ie, routine 
transfusions are allow ed on the day of JNJ -68284528 infusion based on institutional 
practice) .
Added as an exception to prohibited therapies “part of therapy intended to treat CAR -T 
cell-related toxicity”.
Added guidance that based on the clinical judgment low -dose aspirin may be continued 
for thromboprophylaxis.
Added that Pegylated myeloid grow th factors (ie, pegfilgrastim) are prohibited to be 
consistent with Section 6.1.2.
9.4.2. Minimal 
Residual DiseaseRevised the following statement “ Baseline bone marrow  aspirates will be used to define 
the myeloma clones, and post -treatment samples wi ll be used to evaluate MRD 
negativity in those subjects who experience at lease a CR .as MRD testing will be 
performed on all Day 28 samples, not just for subjects in which a CR has been declared.
9.6.1. Myeloma 
Protein 
Measurements in 
Serum and UrineRevisions f or consistency with the guidance provided in the Time and Events Schedule. , 
Cross references added to Table 1 and Table 12.
10.3. Withdraw al 
from the StudyFor consistency with the addition of the guidance added for risk/benefit consideration i n 
the event that a JNJ-68284528 product does not meet pre- specified release criteria 
(Section 6.1), the w ithdrawal from study language was modified to state “ Failure to 
manufacture JNJ-68284528 after 2 apheresis attempts”.
12.3.1. All Adverse 
EventsRemov al of terms for adverse events of special interest ; now refers to Section 12.3.3 for 
complete information .
12.3.3. Adverse 
Events of Special 
InterestEdits made for clarity and consistency with other sections of the protocol.
Attachment 6 Modification to the calculation for estimating glomerular filtration rate to standardize 
the calculation and remove reference to online tools.
Rationale: Deletions made due to redundancy
4. Subject Population Removed “NOTE” at the end of the section. As redundant with addition of Section 6.1.1
9.1.4. 
Cyclophosphamide 
and Fludarabine 
Conditioning 
Regimen
9.1.5. JNJ -68284528 
AdministrationDeleted text and added cross reference as content is described elsewhere in the protocol
9.1.6.1. Post- Infusion 
PeriodDeleted text that is repetitive with other sections of the protocol , cross referenced to 
Table 6.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Rationale: Correction made to eligibility criteria –documentation of disease progression
4.1. Inclusion Criteria Criterion #6 revised to state “ Subject must have documented evidence of progressive 
disease based on investigator’s determination of response by the IMWG criteria on or 
within 12 months of their last regimen (Attachment 1) .Confirmation may be from either 
central or local testing .Also ,subjects w ith documented evidence of progressive disease 
(as above) w ithin the previous 6 months and who are refractory or non -responsive to 
their most recent line of treatment afterwards. ”.
Rationale: Change made to exclude subjects with prior history of CNS multiple myeloma because of suspected 
increased risk of neurologic toxicity
4.2. Exclusion 
CriteriaRevised criterion #9 to state “ Known active , or prior history of central nervous system 
(CNS) involvement or exhibits clinical signs of meningeal in volvement of multiple 
myeloma. ”
Rationale: Changes made to incorporate revised HBV and HCV eligibility requirements to add revised HBV 
monitoring criteria 
T&E schedule 
(Table 1 and Table 
12)Added that events of HBV reactivations should be reported during the first year post -
dosing of LCAR -B38M CAR -T cells. Revised footnotes ‘f’ (Table 1) and ‘e’ (Table 12).
1.7. Potential Safety 
Risks and Mitigation 
StrategiesAdded cross reference to hepatitis B virus screening guide in Attachment 8.
4.2. Exclusion 
Criteria ;
9.2. Safety 
EvaluationsRemoved reference to ASCO guidelines from criterion #14 as it does not represent 
guidance provided in Attachment 8.
Attachment 8 Revised to include guideline for prevention of HBV reactivation specific for subjects 
receiving immunosuppressive therapy
4.2. Exclusion 
CriteriaRevised c riterion #15 to include “HCV -RNA quantitation positive” and added guidance 
for subjects with a known history of HCV infection.
6.3.6. Infections Added w arning that HBV reactivation may occur in subjects with drugs directed against 
B cells.
9.2. Safety 
EvaluationsAdded HBV monitoring recommendations.
12.3.1. All Adverse 
EventsAdded that events of HBV reactivations will be reported during the first year post -
dosing of JNJ -6828 4528.
Attachment 8 Revised hepatitis screening guide for determining subject eligibility.
Rationale: Revision to the timing of when conditioning regimen should be re -administered upon resolution of 
active infection or Grade ≥3 non -hematologic toxicities of the conditioning regimen , to allow  for flexibility
6.1.3. Evaluation 
Prior to 
Administration of 
JNJ-68284528Updated that the conditioning regimen should be re -administered if resolution of 
infection or Grade ≥3 non -hematologic toxicities of the conditioning regimen to Grade 
≤1 takes more than 14 days (changed from 7 days).
Rationale: Correction to serum calcium corrected for albumin; removal of language that is no longer relevant to 
IMWG.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
9.6.2. Serum Calcium 
Corrected for 
AlbuminDeleted the following: Measurem ent of free ionized calcium is an acceptable alternative 
to corrected serum calcium for determining hypercalcemia. In this study, f ree ionized 
calcium levels greater than the ULN indicate hypercalcemia .
Rationale: Additional information provided regarding subject identifiers to be included with infusion bag
14.2. Packaging
16.2.4. Privacy of 
Personal Data
17.3. Subject 
Identification, 
Enrollment, and 
Screening LogsFor tracking and traceability of apheresis material, subject name and date of birth will be 
collected, as allow ed by  local regulations, will be collected to ensure chain of identity of 
the JNJ -68284528 for each subject.
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 1 (20August 2018 )
The overall reason for the amendment: The overall reason for the amendment is to collect additional safety 
information and add clarity to targeted sections of the protocol
Applicable Section(s) Description of Change(s)
Rationale: Revisions made to collect additional safety information and provide an additional inclusion criterion 
(lower limit of lymphocyte count) that may increase potential for successful manufacture of JNJ -68284528.
T&E Schedule (Table 1 
and Table 1 0)Changed w indow  for hematology assessment on day of apheresis from ≤72 hour 
window  to “prior to apheresis (same day)”
Added hematology, chemistry, and vital signs assessments on Day 21 (to correspond 
with PK assessment s added on Day 21).
T&E Schedule (Table 1 
and Table 1 0);
6.1.1. Criteria for 
Cyclophosphamide and 
Fludarabine DosingLanguage added to indicate that subjects who receive bridging therapy that includes 
agents with known cardiac toxicity, assessment of cardiac function should be repeated 
within 7 days prior to the start of the conditioning regimen .
4.1. Inclusion Criteria 
(criterion #8) ;
6.1.1. Criteria for 
Cyclophosphamide and 
Fludarabine DosingAdded lymphocyte count of ≥0.3 x 109/Lto laboratory value criteria at screening to 
allow  for successful apheresis.
6.1.1. Criteria for 
Cyclophosphamide and 
Fludarabine DosingOn the day of the first dose of the conditioning regimen, subjects should be evaluated 
for the presence of an indw elling catheter.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
Rationale: Changed the baseline for efficacy assessment to more accurately reflect response to treatment
T&E Schedule (Table 1 
and Table 1 0)Samples for s erum protein electrophoresis (SPEP) and urine protein electrophoresis 
(UPEP) assessments will be collected to establish baseline disease characteristics 
prior to the first dose of the conditioning regimen .
T&E Schedule (Table 1 
and Table 1 0);
9.6.5. Docum entation of 
Extramedullary 
PlasmacytomasRevised assessment for extramedullary plasmacytomas to be performed ≤14 days 
prior to the first day of the conditioning regimen instead of at screening.
Rationale: Revision made to the window  in the post-treatment period to prevent out of window  visits during the 
extended follow -up
T&E Schedule (Table 1) Window  for post treatment visits (every 28 days after Day 100) changed from ±2 days 
to ±7 days
Rationale: Added infectious disease testing at apheresis to comply with local and regional donor requirements
T&E Schedule (Table 1 
and Table 1 0);
9.2. Study EvaluationsAdded testing at the time of apheresis for HIV, hepatitis B, hepatitis C, HTLV, and 
other infectious diseases as applicable per local regulations
Rationale: Patient reported outcomes (PRO )assessments and Qualitative Intervie ws added to obtain information 
on the benefit of subject’s perceived health -related quality of life in the Phase 2 portion of the study
T&E Schedule (Table 
1);
2.1. Objectives and 
Endpoints;
9.8. Patient -Reported 
Outcomes;
11.8. Patient -Reported 
Outcome AssessmentsAdded the European Organization for Research and Treatment of Cancer 
(EORTC) -QLQ -C30, EuroQol Five Dimension Questionnaire ( EQ-5D-5L), Patient 
Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), 
and single items from EORTC QLQ -MY20 assessments to the Phase 2 part of the 
study ; included as secondary endpoints .
T&E Schedule (Table 
1);
2.1. Objectives and 
Endpoints;
9.9. Qualitative 
InterviewsSubjects enrolled in the Phase 2 part of the study will be given the option to 
participate in qualitative patient experience interviews.
Exploratory objective added for qualitative intervie ws.
Attachment 10 (Patient 
Reported Outcome 
Measures)Added sample PRO assessment documents
Rationale: Correction of errors
T&E Schedule (Table 2
and Table 11)Correction to collection for minimal residual disease (MRD) assessments in subjects 
with CR willoccur “…up to and including disease progression.”
T&E Schedule (Table 
10)Addition of Day 100X ECOG assessment added to be consistent with main T&E 
(Table 1).
Synopsis (Statistical 
Methods); 
11.2. Sample Size 
DeterminationCorrection to the following statement: “With 60 subjects, the study will have 90% 
power to declare the ORR is higher than 30% or higher at the 1 -sided significance 
level of 0.025.”
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
2.1. Objectives and 
EndpointsPFS and OS added to exploratory endpoint “Correlation between MRD negative rate 
and duration of response, PFS, and OS”, to align with corresponding exploratory 
objective.
3.1. Overview  of Study 
DesignCorrection to the timing of bridging therapy “(anti -plasma cell directed treatment 
betw een screening apheresis and the a dministration of JNJ 68284528 first dose of 
the conditioning regimen )” consistent with what is presented in the diagram of the 
study design (Figure 2).
Rationale: Adjustments made to timing of pharmacokinetic and biomarker sample collections to reduce patient 
burden
T&E Schedule (Table 1, 
Table 2, Table 1 0, and 
Table 1 1)Reduced the number of bone marrow  samples to be collected prior to JNJ -68284528 
infusion. A single collection pre -conditioning regimen was added in place of a 
collection at screening a nd pre- dose. Collection of blood samples adjusted to align 
with changes in bone marrow  collections.
Reduced and/or change collection time points for whole blood or serum collections 
for immunophenotyping, CyTOF, and cytokine profiling.
Rationale: Modifications made for clarity or consistency
T&E Schedule (Table 1 
and Table 1 0)Window  for post -treatment assessments changed from ±2 days to ±7 days.
Clarified that serum M -protein electrophoresis, urine protein electrophoresis, serum 
calcium correcte d for albumin and serum FLC and serum/urine immunofixation will 
occur prior to the first dose of conditioning regimen; added ≤7 days.
T&E Schedule (Table 2 
and Table 1 1)To be consistent with guidance in Section 9.3.1, added footnote ‘b’ to ADA sample 
(footnote b) to indicate ADA should be collected if CRS or neurotoxicity Grade ≥2 is 
reported.
Added footnote ‘e’ to CyTOF (bone marrow) and CyTOF/PBMC (whole blood)
Moved placement of footnote ‘d’ for flow to avoid giving the impression that a 
sample wa s to be collected at end of study.
Synopsis Revised the subject population description, for clarity, to include additional 
information from the inclusion criteria in Section 4.1.
Synopsis;
3.5. Safety Evaluation 
Team ;
6.1. Study Treatment 
AdministrationThe term ‘staggered enrollment’ was changed to ‘staggered dosing’ to more correctly 
describe the observational period betw een adm inistration of JNJ -68284528 to the first 
and second, second and third, and third and fourth subjects.
Added that administratio n of the conditioning regimen and dosing with JNJ -68284528 
will be paused betw een dosing of the sixth subject and conclusion of the first Safety 
Evaluation Team ( SET)meeting.
T&E Schedule (Table 2 
and Table 1 1)Pharm acokinetic ( PK) (chimeric antigen receptor [CAR ]-positive T cell assessment) 
to be performed on bone marrow  samples collected to assess PK CAR transgene 
levels. Row  added to clarify the timing of these assessments. 
3.1. Overview  of Study 
DesignAdded that subjects who receive retreatment wil l be monitored in the long -term 
follow -up study for 15 years from  the time of last treatment .
4.1. Inclusion Criteria 
(criterion #4)Added reference to definition of refractory multiple myeloma (IMWG consensus 
criteria).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
4.2. Exclusion Criteria 
(criterion #15)Criterion modified as follows: “ Hepatitis C (anti -hepatitis C virus [HCV] antibody 
positive or HCV RNA  quantitation positive) or known to have a history of hepatitis C. 
If antibody positive, further testing of quantitative levels to rule out positivity is 
required. ”
6.1. Study Treatment 
AdministrationClarified that if conditioning regimen must be delayed ≥10 weeks after apheresis “the 
subject must undergo full rescreening assessment of eligibility criteria prior to 
dosing (with the excep tion that a repeat bone m arrow collection and re- signing of 
the ICF are not required) .
6.2. Pre -infusion 
Supportive TherapyClarified in Table 7 that antihistamine and antipyretic refer to diphen hydramine or 
equivalent and acetaminophen or equivalent , respectively.
9.1.1. Overview Revised approximate blood volume drawn per subject (up to 2 years post treatment) 
to align with revisions in sample collections.
9.1.3. Apheresis Clarification that the target number of PBMCs collected at apheresis is 6 x 109
PBMCs w ith a range of 2 to 20 x 109PBMCs. The volume is no longer specified.
9.4. Biomarker 
Evaluations; 
9.4.1. 
Pharm acody namic/ 
Predictive MarkersRevisions made to clarify and support the biomarker evaluations to be conducted.
Rationale: Revisions to PK and Immunogenicity sections to align with assay requirements and added sampling 
on Day 21 to expand data collection during the first 3 w eeks
T&E Schedule (Table 2 
and Table 1 1)PK CAR positive T cell, CAR transgene, and soluble B cell maturation antigen 
(BCMA )assessments added on Day 21. Immunophenotyping, CyTOF/PBMC/plasma 
(whole blood), and cytokine profiling assessments added on Day 21.
T&E Schedule (Table 1 
and Table 1 0)Assessments for hematology, chemistry, and vital signs added on Day 21 to 
correspond to the visit added for PK collections.
9.3.1. Evaluations Revisions made for clarity. Removed detail that is more appropriate for the lab 
manual. 
9.3.2. Analytical 
Procedures;
9.3.4. Immunogenicity 
Assessment/Antibodies 
to JNJ -68284528Removed statements indicating that immune response analyses (anti-drug antibody 
[ADA ]) may be conducted on PK samples for accuracy , ADA cannot be performed 
on PK samples collected in this study , and are noted separately in the time and events 
schedules .
Rationale: Revision made to allow for red blood cell transfusion after screening maintain hemoglobin levels.
4.1. Inclusion Criteria
(criterion #8)Added a footnote to the clinical laboratory values table stating: “For subjects who 
meet the inclusion criteria at screening, transfusion of RBCs is permitted after 
screening as needed to maintain a hemoglobin level 8.0 g/dL.”
6.1.1. Criteria for 
Cycloph osphamide and 
Fludarabine DosingRevision made to first bulleted statement to be consistent with RBC transfusion 
allow ance added to the inclusion criteria. “Clinical laboratory values required for 
enrollment (Section 4.1), with the following exceptions: ly mphocyte count of ≥0.3 x 
109/L and transfusion of red blood cells or platelets and administration of myeloid 
grow th factor is permitted until 3 days before the hematology laboratory test.”
Rationale: Guidance added for risk/benefit consideration in the event that a JNJ -68284528 product does not meet 
pre-specified release criteria.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Status: Approved ,  Date: 15 June 2022Applicable Section(s) Description of Change(s)
6.1. Study Treatment 
AdministrationGuidance added that the sponsor will evaluate the risk/benefit for administration of a 
JNJ-68284528 product that did not meet pre -specified release criteria and determine if 
the supply of the product to the treating physician could be considered.
Rationale: Revision to allow  for rescreening ofsubjects who do not me et all eligibility criteria
9.1.2. Screening Phase Revised protocol to allow subjects who did not meet all inclusion criteria or who met 
an exclusion criterion to be rescreened once, upon written approval from the sponsor.
Rationale: Revisions made for consistency with the current IMWG criteria
9.6.5. Documentation of 
Extramedullary 
Plasmacytomas; 
Attachment 1. Revised to be consistent with IMWG criteria as presented in Kumar 2016.
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Status: Approved ,  Date: 15 June 2022SUBJECT POPULATION
Eligible subjects are 18 years of age and have a documented diagnosis of multiple myeloma according to 
IMWG diagnostic criteria and an Eastern Cooperative Oncology Group (ECOG) Performance Status grade
of 0 or 1. 
Subjects must satisfy all of the following criteria: 1) Measurable disease at screening as defined by any of 
the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M- protein level 
200mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: 
Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda 
free light chain ratio; 2) Received at least 3 prior lines of therapy or are double refractory to a proteasome 
inhibitor (PI) and an immunomodulatory agent (IMiD) (induction with or without hematopo ietic stem cell 
transplant and with or without maintenance therapy is considered a single regimen), subjects will have 
undergone at least 1complete cycle of treatment for each regimen (unless progressive disease [PD] was the 
best response); 3) Received a PI, an IMiD, and anti-CD38 antibody (prior exposure can be from different 
monotherapy or combination regimens) ; and 4)Documented disease progression during, or within 
12months, of their most recent anti -myeloma therapy.
DOSAGE AND ADMINISTRATION
A conditioning regimen consisting of cyclophosphamide 300 mg/m2intravenously (IV) daily and 
fludarabine 30 mg /m2(IV) daily for 3days will be administered. JNJ-68284528 IVinfusion will take place 
5 to 7 days after the start of the conditioning regimen. In the Phase 1b portion of the study, the target dose 
is 0.75 x 106CAR -positive viable T cells/kg (range: 0.5-1.0 x 106CAR -positive viable Tcells/kg). In the 
event of excess toxicity, a dose de-escalation to dose level -1 (0.3 x 106 CAR -positive viable T cells/kg 
[range: 0.1-0.5 x 106CAR -positive viable T cells/kg]) for new subjects will occur. Additionally, a dose 
escalation to dose level 2 (target dose not to exceed a 3-fold dose escalation [2.25 x 106CAR -positive viable 
T cells/k g,range: ± 30% of the target dose, depending on target dose chosen for dose level 2]) will be 
considered if specified safety criteria are met. Confirmation of theRP2D will be based on review of data 
from at least 24 subjects who were administered JNJ-68284528 in the Phase 1b portion of the study.
Additional subjects (up to approximately 50) will be enrolled in the Phase 1b portion of the study to generate 
supplemental safety and efficacy data at the RP2D .
EVALUATIONS
Safety will be evaluated by adverse events, laboratory test results, vital sign measurements, physical 
examination findings, and assessment of ECOG performance status. Disease status will be evaluated by an 
IRC according to clinical judgement guided by the IMWG consensus recommendations for multiple 
myeloma. Blood and serum samples will be collected for assessment of JNJ-68284528 pharmacokinetics, 
immunogenicity (antibodies to JNJ-68284528), and predictive biomarkers of response or resistance to 
JNJ-68284528.
STATISTICAL METHODS
No formal statistical hypothesis testing will be performed for the Phase 1b portion of the study.
The sample size for the Phase 2 portion of thestudy assumes that the overall response rate for JNJ-68284528
will be 50%. With 60subjects , the study will have 90% power to declare the ORR is higher than 30% at 
the 1 -sided significance level of 0.025.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Status: Approved ,  Date: 15 June 2022Table 1: Time and Events Schedule for Study Procedures/ Assessments
Screening 
PhaseApheresis Cyclophosphamide
and fludarabine 
conditioning 
regimenJNJ-
68284528 
InfusionPost Infusion (Day 1 to Day 100)
(any subject who received an infusion of JNJ -68284528 should continue all 
subsequent assessments)aPost-
treat ment
(Day 1 01 
and up to 
Study 
Completion)
b
≤28 days 
prior to 
apheresis
aUpon 
enrollmentDay -5,* -4, -3 
(assessments may 
be conducted 
≤72 hours predose)
*Window  for start 
of conditioning 
regimen: Day -7 to 
Day -5Day 1
(Infusion
)Day 
3Day 
7 
(±1 
day)Day 
10 
(±1 
day
)Day 
14 
(±1 
day
)Da
y 
21 
(±1 
day
)Day 
28 
(±2 
days)Day 
42 
(±2 
days)Day 
56 
(±2 
days)Day 
78 
(±2 
days)Day 
100 
(±2 
days)
b(every 28 
days after 
day 100)c
(±7 days)
Concomitant 
medicationContinuous from the time of signing of ICF until at least 100 days after last administration of any study treatment .
Concomitant usage for the treatment of adverse events after 100 days should be reported .
Medications for the prevention and treatment of COVID -19 (including vaccines) and HBV reactivation should be reported until 1 year after cilta -cel infusion 
(Attachment 17).
Abbreviations: aPTT=activated partial thromboplastin time; CR=complete response; sCR=stringent complete response; CRS= cytokine release syndrome; CT=computed tomography; 
D=Day; ECOG=Eastern Cooperative Oncology Group; ECG=electrocardiogram; EORTC -QLQ=European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire; EQ-5D-5L=EuroQol Five Dimension Questionnaire; FISH=fluorescence in situ hybridization; FLC=free light chain; HBV=hepatitis B virus; ICANS=immune -effector 
cell-associated neurotoxicity syndrome; ICE=immune effector Cell-associated Encephalopathy; ICF=informed consent form; INR=international normalized ratio; IPPI=investigational 
product preparation instructions; MRD=minimal residual disease; MRI=magnetic resonance imaging; MRU=medical resource utilization; MUGA=multiple -gated acquisition; 
PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PRO=patient reported outcome; PT=prothrombin time; SIPPM=site investigational product 
procedures manual; SOC=standard of care; SPEP=serum protein electrophoresis; UPEP=urine prote in electrophoresis.
aICF must be signed before any study -related procedures are performed, and remains in effect even if the screening evaluation is not performed within the 28 -day Screening Phase. 
Evaluations for eligibility determination performed outside the screening window may need to be repeated. For subjects who require a repeat apheresis see Section 6.1.1 .for 
assessments should be collected before the second apheresis .If the second apheresis falls outside of the 28 day window, all screening assessments (except bone marrow collection)  
must be repeated.
bFor subjects who discontinue the study before Day 100, including those who have not received an infusion of JNJ-6828 4528, the Day 100 assessments should be performed prior to 
withdrawal if feasible. Subjects who discontinue after Day 100 but before study completion should have urine and serum disease assessments performed prior to withdrawal if 
feasible at the time of discontinuation, unless performed within 14 days prior to discontinuation. Study completion is de fined as 2 years after the last subject has received his or her 
initial dose of JNJ -68284528.
cPost-treatment assessments to be obtained until progressive disease is documented or the start of subsequent anticancer therapy, w ith the exception of survival status and subsequent 
anticancer therapy, which are to be collected until study completion.
dDisease characteristics cytogenetics (full karyotyping or FISH as well as molecular genetics [if applicable]), both of which may originate from prior to or during the screening 
period within 42 days before apheresis , or between apheresis and the conditioning regimen, as applicable. A pathologist/cytogeneticist should complete the cytogenetics data 
collection worksheet.
eThe first 6 subjects enrolled wil l be hospitalized for at least 2 weeks after infusion of JNJ -68284528. The requirement for hospitalization and local stay will be evaluated by the SET 
for subsequent subjects. For subjects who are hospitalized, hematology and chemistry laboratory evaluatio ns, vital signs, and oxygen saturation should be performed at least daily 
or more as clinically indicated.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Status: Approved ,  Date: 15 June 2022fSerology results performed as standard of care within 28 day s prior to apheresis are acceptable; Hepatitis B: HBsAg, anti-HBc, anti-HBs, HBV DNA quantification (for subjects 
who are anti-HBs positive without history of vaccination orfor subjects who are anti -HBs positive and anti -HBc positive); Monitor HBV -DNA, AST/ALT every 3 months for one 
year po st-dose of JNJ -68284528 . Hepatitis C : HCV antibod y, HCV -RNA (for subjects who are anti HCV positive); HIV serology . 
gImmediately before the start of infusion, at the end of infusion, and 0.5, 1, 2 hours after end of infusion. Monitor until no rmalized after a CRS event.
hTemperature will be checked at least twice a dayup to Day 28. Subjects will be provided with a thermometer and instructed on the use of the thermometer and entering 2temperatures 
including their maximum daily temperature in a diary. Diary will be reviewed at each visit, then collected on Day 28 and stored with su bject source documents.
iAll subjects will be evaluated for IgG, IgA, IgM. Testing for IgD and IgE will only be performed for su bjects with IgD and IgE -type myeloma.
jUPEP sample collected as part of the standard of care and prior to the subject signing ICF may be used for analysis at the central laboratory. 
kBone marrow morphology from an aspirate and core biopsy to be assessed locally at all time points . Additional bone marrow aspirate samples will be collected for biomarkers (see 
Table 2).
lResults from skeletal survey performed as routine follow -up within 42 days before start of apheresis may be used without these tests being repeated. The skeletal survey is to be 
performed by either roentgenography or low-dose computed tomography (CT) scans without the use of IVcontrast. If a CT is used it must be of diagnostic quality. Additional 
imaging (X -ray, CT, or MRI) will be performed as clinically indicated (eg, to document response or progression).
mExtramedullary plasmacytomas should be assessed for all subjects with a history  of plasmacytomas or if clinically indicated prior to the first dose of the conditioning regimen , by 
clinical examination or radiologic imaging.
nHIV, hepatitis B, hepatitis C, HTLV, and other infectious diseases as applicable per local regulations
oPRO assessments to be collected every 28 day s in the post-treatment Phase . For subjects with disease progression or who initiate subsequent anticancer therapy, PRO assessments 
should be collected every 16 weeks. 
pSubjects enrolled in the Phase 2 portion of the study will have the option of participating in pre -treatment and post -treatment semi -structured qualitative interviews.
qPre-infusion ICE test and handwriting sample should be performed before pre -medication with diphenhydramine
rMedical resource evaluation data will be collected until Day 180 (± 7 days) .
sLocal laboratory assessments may be used under specified circumstances (See Section 9.6).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Status: Approved ,  Date: 15 June 2022Table 2: Time and Events Schedule for Pharm acokinetic and Biomarker Sampling
Screening 
PhaseApheresis Cyclophosp
hamide and 
fludarabine 
conditionin
g regim enJNJ-
68284528 
InfusionPost Infusion (any subject who received infusion of JNJ -68284528 should continue all 
subsequent assessments)aand Post-treatment (Day 101 up to study completion)At 
PDAt
Study 
Complet
ionfor 
subjects 
with out
PD
≤28 days 
prior to 
apheresisUpon 
enroll -
mentDay -5,* -4, 
-3
(assessment
s may be 
conducted 
≤72 hours 
predose) b*Day 1
(Infusion)Day 
2Day 
3 Day 
7 
(±1 
day)Day 
10 
(±1 
day)Day 
14 
(±1 
day)Day 
21 
(±2 
days)Day 
28 
(±2 
days)Day 
42 
(±2 
days)Day 
56 
(±2 
days)Day 
78 
(±2 
days)Day 
100 
(±2 
days)Day 
184
(±7 
days)
MRD 
(aspirate)
(bone 
marrow)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Sample should be collected: 
 For all dosed subjects at Day 28, and at 6 month s, 12 month s, 18 month s(Day 520), and 24months 
(Day 744) (± 16 days) regardless of the status of disease measured in blood and urine .
 For subjects with suspected CR at the time of CR and then yearly for subjects that remain on study up to 
disease progression.
Cytogenetics 
(bone 
marrow)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])X
Replication 
Competent 
Lentivirus 
(RCL)
(whole 
blood)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Pre-dose At approximately 3 (Day 84), 6(Day 168) , and 12 (Day 364) months (±1 month) ; then yearly (±3 months) 
until EOS, and then yearly (±3 months) forup to 15 years after cilta -cel infusion in a separate long -term 
follow -up study. Yearly collection of RCL samples is not required if assessments within the first year are 
nega tive. Additional samples may be collected triggered by events which may be relevant to RCL per clinical 
assessment.
Cytokine 
profilingg
(serum)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Pre-dose, 
2hrs Post 
(±10 
minutes)X X X X X X X X X X X
Abbreviations: ADA=anti -drug antibody; BCMA=B -cell maturation antigen; CAR=chimeric antigen receptor; CR = complete response; CRS=cytokine release syndrome; CyTOF= cytometry 
by time of flight ; PD=progressive disease ; EOI=end of infusion; MRD=minimal residual disease; PBMC=peripheral blood mononuclear cell; PK=pharmacokinetic; sCR=stringent complete 
response 
aFor subjects who discontinue the study post JNJ-68284528 infusion before Day 100, the Day 100 assessments should be performed if feasible.
bWindow for start of conditioning regimen: Day -7 to Day -5
cCollect additional samples when any of the following are suspected or reported: 1) CRS or CAR -T cell-related neurotoxicity (eg, ICANS) Grade ≥2 (at onset of the event, and 24 and 
72 hours after) or as clinically indicated; and 2) as indicated based on emerging data. 
dADA sample should be collected if a subject withdraws from the study after JNJ -68284528 administration but prio r to disease progression or study completion .
eSample should also be collected at suspected CR
fSample should be collected at 12 months, relative to Day 1, for subjects that achieve CR/sCR and remain on study.
gCollect additional samples when any of the follo wing are suspected or reported: 1) CRS or CAR -T cell-related neurotoxicity (eg, ICANS) (any grade) (at onset of the event, and then 
every 24 hours until CRS or ICANS event has stabilized or is resolving at which time additional collections should occur at 24, 48, and 72 hours) or as clinically indicated; and 2) as 
indicated based on emerging data.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Status: Approved ,  Date: 15 June 2022ABBREVIA TIONS
ALL acute ly mphocytic leukemia
ANC absolute neutrophil count
APRIL a proliferation inducing ligand
ASBMT American Society for Blood and Bone Marrow  Transplantation
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
BAFF B-cell activating factor
BCMA B-cell maturation antigen
BNP B-type natriuretic peptide
CAR -T chimeric antigen receptor T (cells)
CBC complete blood count
CBR clinical benefit rate
CI confidence interval
CNS central nervous system
CR complete response
CRS cytokine release syndrome
CSR clinical study report
CT computed tomography
CyTOF cytometry by time of flight 
DLT dose limiting toxicity
DOR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
EORTC European Organization for Research and Treatment of Cancer
EQ-5D-5L EuroQol Five Dimension Questionnaire
FLC free light chain
eCRF electronic case report form
eDC electronic data capture
GCP Good Clinical Practice
G-CSF granulocyte colony -stimulating factor
GVHD graft -versus -host disease
HBV hepatitis B virus
HCV hepatitis C virus
HLH/MAS hemophagocytic lymphohistiocytosis/macrophage activation syndrome
HRQoL health -related quality of life 
ICANS Immune effector cell -associated neurotoxicity syndrome
ICE Immune -effector Cell -associated Encephalopathy
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics c ommittee
Ig immunoglobulins
IL interleukin
IMiD immunomodulatory drug
IMWG International Myeloma Working Group
IPPI investigational product preparation instructions
IRB Institutional Review Board
IRC Independent Review Committee
IV intravenous(ly)
LVEF left ventricular ejection fraction
MedDRA Medical Dictionary for Regulatory Activities
MR minimal response
MRD minimal residual disease
MRI magnetic resonance imaging
MRU medical resource utilization
MUGA multiple -gated acquisition
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Status: Approved ,  Date: 15 June 2022NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NYHA New  York Heart Association
ORR overall response rate
OS overall survival
PBMC peripheral blood mononuclear cell
PD progressive disease
PFS progression -free survival
PGIC Patient Global Impression of Change
PGIS Patient Global Impression of Severity
PI proteasome inhibitor 
POEMS polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes
PQC product quality complaint
PR partial response
PRO patient reported outcomes
QIg quantitative immunoglobulin
RBC red blood cell
RCL replication competent lentivirus
RP2D recommended Phase 2 dose
sBCMA soluble BCMA
sCR stringent complete responses
SET safety evaluation team
SIPPM site investigational product procedures manual
SPEP serum protein electrophoresis
TCR T cell receptor
TLS tumor lysis syndrome
TNF -R tumor necrosis factor receptor
TTR time to response
ULN upper limit of normal
UPEP urine M -protein quantitation by electrophoresis
VGPR very good partial response
β-hCG βhuman chorionic gonadotropin
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Status: Approved ,  Date: 15 June 20221. INTRODUCTION
1.1. Multiple My eloma
Multiple myeloma is characterized by the production of monoclonal immunoglobulin (Ig) proteins 
or protein fragments (M proteins)that have lost their function.20,28The proliferation of multiple 
myeloma cells leads to subsequent displacement ofnormal bone marrow hematopoietic precursors
and overproduction of M-proteins. Hallmarks of multiple myeloma include osteoly tic lesions, 
anemia, increased susceptibility  to infections, hypercalcemia, renal insufficiency  or failure, and 
neurological complications.17,28
Treatment options for multiple myeloma have substantially  improved over time and vary 
depending on the aggressiveness of the disease, underly ing prognostic factors, phy sical condition 
of the patient, and existing co -morbidities. Therapeutic options include agents such as proteasome 
inhibitors (PIs), immunomodulatory  drugs (IMiDs), monoclonal antibodies, and stem cell 
transplantation.
Despite these therapeutic achievements, the disease recurs and remains incurable . Thus , there is a
need for novel therapeutic approaches when the disease is resistant to available therapy .
1.2. BCMA
Bcell maturation antigen (BCMA, also known as CD269 and TNFRSF17) is a 20 kilodalton, 
type IIImembrane protein that is part of the tumor necrosis receptor super famil y.31BCMA is 
predominantly  expressed in B-lineage cells and plays a critical role in B cell maturation and 
subsequent differentiation into plasma cells.31BCMA binds 2 ligands that induce B cell 
proliferation: a proliferation inducing ligand ( APRIL ; CD256) and B-cell activating factor (BAFF ;
CD257) .3,9,29Upon binding ofBCMA monomers to the APRIL trimer ,activation and 
phosphory lation of p38MAPK , ELK,and NF-κB aretriggered through intracellular tumor necrosis 
factor receptor (TNF -R)-associated factor (TRAF) molecules leading to pro-survival gene 
regulation.5,14,16
In multiple myeloma cell lines and patient samples, BCMA is more stably  expressed specifically  
on the B cell lineage than CD138, a key plasma cell marker which is also express edon normal 
fibroblasts and epithelial cells.27The expression characteristics of BCMA make it an ideal 
therapeutic target in the treatment of multiple my eloma .13,31
1.3. CAR-T Therapy
Chimeric antigen receptor T (CAR-T) cell therapy  uses modified autologous T cells that are
activated in a nMHC -independent manner upon binding to their target. This results in lysis of the 
targeted cells. Kymriah® (tisagenl ecleucel), a CD19 directed CAR -T cell-based immunotherapy , 
isapproved in the US for the treatment of pre -B acute lymphocy tic leukemia (ALL )that is 
refractory  or in second or later relapse for patients up to 25 years of age .Yescarta (axicabtagene 
ciloleucel ),another CD19 directed CAR -T based therapy ,is approved in the US for the treatment 
of adult patients with relapsed or refractory  large B-cell lymphoma. An ongoing Phase 1 clinical 
study  with bb2121, a BCMA -directed CAR -T immunotherap y, demonstrated promising results for 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Status: Approved ,  Date: 15 June 20221.5. Summary  of Clinical Studies 
The nonclinical pharmacology  program was designed to characterize the biological activity  and 
mechani sm of action of LCAR- B38M CAR -T cells. In vitro mechanistic proof -of-principle studies 
have assessed target engagement with respect to:
On-target binding (ie, binding of VHH to BCMA)
Off-tumor target activity  (ie, in human non-myeloma cell lines, including lung, liver, breast, 
brain, embry onic kidney  and kidney  expressing hERG)
On-tumor target activity  (ie, in human multiple my eloma cell lines)
In vivo studies have evaluated the safet yand efficacy  of LCAR -B38M CAR -T cells.
Refer to the Investigator’s Brochure for a complete description of the nonclinical study 
information.
Legend-2
Legend -2is a first-in-human, single -arm, open -label, multicenter study  to determine the safet y and 
efficacy of LCAR-B38M CAR -T cells used to treat subjects with relapsed or refractory  multiple 
myeloma . The study  wasconducted in China by Legend Biotech . Study  enrollment was completed 
in November 2017; 74 subjects have been treated on this study . The clinical cutoff for the anal ysis 
presented here was 06February 2018 with updated survival, efficacy  data, and CRS grading 
provided as of 31December 2018. As of the 31December 2018 update, the median follow -up was 
17.41 months (range: 0.4–32.2 months).
All subjects had relapsed or refractory  multiple myeloma with a median of 3 (range: 1-9) prior 
lines of therapy  including PItherap y (73%) , IMiD ( 87.8%) ,and both PIand IMiD(64.9%). Prior 
autologous stem cell transplant (ASCT) was reported for 24.3% of subjects. The median ageat 
study  entry was 54.5 years (range: 27-74 years). The median follow -up was 6.31months (range: 
0.4 – 20.7 months). The median number of LCAR-B38M CAR -positive viable T cells 
administered was 0.513 x 106CAR -positive viable T cells/kg (range: 0.07-2.10 x 106CAR -
posit ive viable T cell s/kg).
Of the 74 subjects included in the Legend 2 study, 68(91.8%) subjects had an adverse event of 
CRS (median time to onset 9 days [range: 1-19 day s]), including Grade 1 for 37 subjects , Grade 2 
for 25subjects, Grade 3 for 5subjects , and Grade 5 for 1subject. The fatal event of CRS occurred 
in a 40-year-old female who experienced CRS andtumor lysissyndrome (TLS) and died on Day 13
after receiving the LCAR -B38M CAR -T cell infusion. For most subjects , symptoms of CRS were 
mild and reversible .Grade 1 neurotoxicity  was reported for 1 subject.
Cytopenia s(thrombocy topenia and neutropenia) were common, however, prolonged Grade 4 
cytopenias with duration exceeding 35 days were infrequent. Infection events were reported in 
7 (9.5%) subjects ; however, therate didnot appear to exceed that expected for subjects with 
multiple my eloma.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Status: Approved ,  Date: 15 June 2022In addition to the subject who died from CRS, 1subject had a fatal adverse event related to 
treatment with LCAR -B38M CAR -T cells. A 54-year old male with a history  of coronary  artery  
disease and extensive anthracy cline therapy  who experienced CRS with a maximum Grade of 2, 
and died on Day 22 after LCAR -B38M CAR -T infusion due to a potential acute pulmonary 
embolism and potential acute coronary  syndrome.
Although the Legend -2 study  was conducted in China, one 56-year old male, Caucasian subject 
from the United States was treated. The subject received similar prior therap y(5 prior lines of 
therap y including PI, IMiD, and anti-CD38 antibody  treatment) asis required on this study . He
experienced Grade 3 CRS after LCAR -B38M CAR -T cell infusion. The CRS resolved after 
treatment with anti-IL-6 receptor antibody  and TNF α inhibitor . The subject achieved a stringent 
complete response (sCR).
As of the 31December 2018 update, the overall response rate (complete response [CR]+very  good 
partial response [VGPR]+partial response [PR]) was 87.8 %. C omplete response was achieved by 
54 (73.0% ) subjects and 49 (66.2%) subjects were negative for MRD as assessed by bone marrow 
8-color flow cytometry assay . The Kaplan -Meier estimate of median duration of response was 
22months (95% confidence interval [CI]: 11.79 -29.14). The median PFS for the overall 
population was 16months (95% CI: 10.61- 28.16) and among the 49 subjects achieving 
MRD -negative CR, the median duration of response was 28months. Administering the CAR -T 
cells as a split dose did not appe ar to have a different safety  or efficacy  profile compared with 
administering it as a single dose (See Section 3.2). There was no apparent association between 
respo nse and the number of total viable T cell s or CAR -positive viable T cells infused.
Study 68284528MMY2001 (study data generated following initiation of the conduct of th is
protocol )
As of the 24 June 2019 data cutoff, 25 subjects had received an infusion of JNJ-68284528 in the 
Phase 1b portion of Study 68284528MMY2001. The safet y profile is consistent with observations 
from the Legend -2 study . 
Twenty -four of the 25 subjects who received JNJ-68284528 had at least 1 treatment -emergent 
adverse event (TEAE). 
The most commonly  reported TEAEs (>20% of subjects) were CRS (88.0%), neutropenia 
(80.0%), anemia (76.0%), thrombocy topenia (72.0%), leukopenia (40.0%), lymphopenia 
(28.0%), fatigue (24.0%), headache (24.0%), cough (24.0%), and diarrhea (20.0%)
Grade 3 or 4 TEAEs were reported for 24 of the 25 subjects. 
The most commonly  reported Grade 3 or 4 TEAEs (>10% of subjects) were neutropenia 
(76.0%), anemia (48%), thrombocytopenia (60.0%), leukopenia (40.0%) , lymphopenia 
(16.0%) ,and CRS (16.0%) . 
Serious adverse events were reported for 6 subjects: 
One subject had serious TEAEs of Grade 3 CAR -T cell-related encephalopathy  syndrome 
(CRES) and Grade 3 CRS.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Status: Approved ,  Date: 15 June 2022One subject had serious TEAEs of CRS , with Grade 5 he mophagocy tic 
lymphohistiocy tosis (HLH) secondary  to CRS, and Grade 4 acute kidney  injury .
One subject had serious TEAEs of Grade 4 thrombocytopenia and Grade 3 pneumonia.
One subject had a serious TEAE of Grade 2 mental status change.
One subject had a ser ious TEAE of Grade 3 encephalitis.
One subject had serious TEAEs of Grade 1 CRS and Grade 1 confusional state.
One subject died on Day  99 due to CRS, with Grade 5 HLH secondary  to CRS. 
Twenty -two of the 25 subjects (88.0% ) experienced CRS. Three subjects experienced Grade 3 
CRS and 1 subject experienced Grade 5 CRS (as noted above).
CAR -T cell -related neurotoxicity  was reported in 4subjects. One subject had Grade 3 CRES, 
the second subject had Grade 1 neurologic adverse events (dysarthria, slow mentation, gait 
disturbance, and somnolence), the third subject had Grade 1 CRES, and the fourth subject had 
a Grade 1 immune effector cell -associated neurotoxicity  syndrome (ICANS) event (difficult y 
in finding words). All events occurred in the setting of CRS.
The median duration of follow -up for the 21 subjects who received JNJ -68284528 and had at least 
1 post-dose disease evaluation as of 24 June 2019 was 2.99 months (range: 1.3 to 9.9months). 
Among these 21 subjects, 19 subjects achieved at least a partial respo nse (PR) with an ORR (PR 
or better) of 90.5% (including unconfirmed responses) with 13 subjects (61.9%) having VGPR or 
better and 6 subjects (28.6%) having CR or better .A stringent complete response (sCR) was 
achieved by 4subjects. Fifteen subjects had post-baseline bone marrow samples available for 
MRD assessment. All 10 subjects (100%) evaluable at the 10-5sensitivity  level were negative for 
MRD by next generation flow cytometry  and/or next generation sequencing (NGS; Adaptive v 
2.0). Two subjects were indeterminate at 10-5due to insufficient cell counts but were MRD 
negative at the sensitivity threshold of 10-4by NGS. No clone identification could be performed 
in 3 subjects by  NGS. Follow -up for response continues, however these preliminary  data sugg est 
compelling efficacy  in this population of heavily  pre-treated subjects.
Other Neurotoxicities
As of 06 March 2020, neurotoxicity  with symptoms suggestive of Parkinsonian features that 
occurred after a period of recovery  from CRS and/or ICANS have been observed in 6 subjects 
from Study  68284528MMY2001 (n=97). Among 6 subjects, 3 subjects had confirm ed 
Parkinsonian -like symptoms with some shared features in their clinical presentation have been 
observed, with initial presentation between Day 19 and Day 101 after JNJ-68284528 infusion. 
Symptoms include altered mental status, feeling or appearing agitat ed, personality  changes (such 
as being more withdrawn, expressing little emotion), lack of facial expression, being less 
communicative (answering questions with 1-word), difficult y with short term memory , slowing of 
movements, difficulty  performing simple tasks (such as buttoning a shirt), difficulty  swallowing, 
joint or muscle stiffness or inflexibility , shuffling gait (walking very slowly  with small steps and 
heav y feet), restlessness, impaired balance, bradykinesia, slight cogwheeling/rigidit y in 
extremi ties, micrographia (small handwriting) and impaired ability  to perform activities of daily 
living (ADLs). On exam, all 3 subjects presented with sy mptoms described as Parkinsonian. The 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Status: Approved ,  Date: 15 June 2022brain MRI  showed no acute abnormalities in these subjects. The remainin g 3 subjects had a mixed 
presentation of neurotoxicities (including some Parkinsonian -like symptoms) which presented 
with complicating comorbidities .All 6 subjects referenced above had previously  experienced CRS 
(4 Grade 2, 2 Grade 3 all of which resolved ) and 5 out of 6 subjects had ICANS (3 Grade 1, 1 
Grade 2, 1 Grade 3). Three subjects referenced above have died. Although these subjects also 
experienced other adverse events which may have contributed to the cause of death, such as 
infection and sepsis, the role of neurotoxicity  cannot be ruled out.
Study 68284528MMY2002 (study data generated following initiation of the conduct of the 
protocol)
Study  68284528MMY2002 is a Phase 2, open -label, multicenter study  in China (sponsored by 
Legend Biotech HK Limited and Janssen R&D; Investigational New Drug holder is Legend 
Biotech) to evaluate the efficacy  and safet y of LCAR- B38M CAR -T cells in adult subjects with 
relapsed or refractory  multiple myeloma. Approximately  60 subjects will be enrolled into the 
study . The primary  objective is to evaluate the efficacy  of LCAR-B38M CAR -T cells. 
The first subject was dosed on 22 March 2019. As of 9 Dec 2019, 25 subjects were enrolled into 
the study  and 13 subjects received LCAR -B38M CAR -T cells. Of the 12 subjects anal yzed in the 
second safet y evaluation team meeting, 12 subjects were reported with CRS, 1 subject had 
Grade 1, 5 had Grade 2, 5 had Grade 3,and 1 had Grade 4 CRS. The median onset to CAR -T 
infusion was 7 days (range: 2-8) and median duration of CRS was 5 days(range: 4-8). One subject 
received an infusion of LCAR -B38M CAR -T cells on 06 May  2019 and died on 12 May 2019 due 
to hemorrhage secondary to thrombocy topenia. The investigator attributed the thrombocy topenia, 
CRS ,and acute renal failure to LCAR-B38M CAR -T cell therapy .The CRS events experienced 
by other subjects all resolved. No neurotoxicity  has been reported as of the cutoff date. Further 
details are pr ovided in the most recent edition of the Investigator’s Brochure.
1.6. Overall Rationale for the Study  
BCMA is a cell surface antigen highl y expressed on cells of the Bcell lineage. Comparative studies 
show a lack ofBCMA in most normal tissues and absence of expression on CD34- positive 
hematopoieti c stem cells.7,15This selective expression and the biological importance for the 
proliferation and survival of myeloma cells makes BCMA a promising target for CAR -T based 
immunotherapy , JNJ-68284528 . Results in 74 subjects from the L egend -2 study  indicate an ORR 
of 87.8% with a CR rate of 64.9%. The observed response rates and the reversible adverse events 
for most subjects, support further investigation of this approach in the current study .
1.7. Potential Safety  Risks and Mitigation Strategies
The potential risks of JNJ-68284528 are identified from the following : 1) results of nonclinical 
studies; 2) mechanism of action; and 3) previous clinical experience with LCAR -B38M CAR -T 
cells.Longer follow -up and treatment of additional subjects, particularly subjects who have 
received fewer prior therapies than subjects in the Legend -2 and 68284528MMY2001 studies, may 
reveal additional risks. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Status: Approved ,  Date: 15 June 2022Objectives Endpoints 
To describe pre -trial goals and 
expectations as well as post -treatment 
experience of JNJ -6828 4528 using 
semi -structured qualitative interviews 
(Phase 2 only)Description of the subject experience with 
JNJ-68284528 through a content analysis of the 
qualitative interview transcripts.
To characterize the impact of JNJ -
68284528 CAR -T process on medical 
resource utilization Number of subjects with type and length of inpatient 
stay and overall medical encounters 
To characterize potential early clinical, 
translational, and imaging markers for 
neurotoxicity (predictive markers)Qualitative changes in handwriting assessment
Tmax, Cmax, and phenotypic analysis of CAR -T cells
Neuroimaging (CT/MRI)
2.2. Hypothese s
Treatment with JNJ-68284528 will demonstrate acceptable safet y and will have significant anti-
myeloma activity  (ie, the lower limit of two-sided 95% confidence interval [CI] for ORR , as 
assessed b y the IRC, is greater than 30% ) at the targeted recommended Phase 2 dose (RP2D) dose 
level in subjects with advanced relapsed or refractory  multiple my eloma.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a Phase 1b-2, open -label, multicenter study of JNJ-68284528 administered to adult subjects
with relapsed or refractory  multiple myeloma. The aim of the study  is to evaluate the safet y and 
efficacy  of JNJ-68284528 . At least 24 and up to approximately  50 subjects will be enrolled in the 
Phase 1b portion of the study  in which a RP2D of JNJ-68284528 will be established. Confirmation
of the RP2D will be based on review of data from at least 24 subjects who were administered JNJ -
68284528. Addi tional subjects (up to approximately  50) will be enrolled in the Phase 1b portion 
of the study to generate supplemental safety and efficacy  data at the RP2D .
Safety  evaluation team (SET) meetings will be convened as described in Section 3.5. All available 
data including safety , pharmacod ynamic, pharmacokinetic, and efficacy data from subjects 
enrolled in Phase 1b study  will be considered. The SET or sponsor may also determine that 
additional subjects are required to further evaluate safety  and dose prior to proceeding to the Phase 
2 portion of the study . Before administration of JNJ -68284528 in the Phase 2 portion of the study , 
clinical data will be shared with the relevant health authorities. The planned sample size for the 
Phase 2 portion w ill be approximately  60subjects.
During the Screening Phase, all subjects will provide written consent for study  participation and 
will be scr eened for study eligibility  within 28 days prior to apheresis. Safety  criteria that must be 
met prior to starting apheresis are presented in Section 6.1.1 .
Eligible subject swill undergo apheresis for collection of peripheral blood mononuclear cells 
(PBMC). Study  enrollment is defined at the day of apheresis. JNJ-68284528 will be generated 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Status: Approved ,  Date: 15 June 2022from T cell s selected from the apheresis . Subject s for whom apheresis or manufacturing fail swill 
be allowed a second attempt at apheresis. 
Bridging therapy  (anti-plasma cell directed treatment between apheresis and the first dose of the 
conditioning regimen) will be allowed when clinically indicated (ie, to maintain disease stability  
while waiting for manufacturing of JNJ-68284528), with the permission of the sponsor. Additional 
cycles of bridging therapy  may be considered based on subject’s clinical status and timing of 
availability  of CAR -T product. Investigator must contact the sponsor for approval. Bridging 
therap y must be a short -term treatment which previously  generated at least a response of stable 
disease for the subject. The sponsor will not permit subjects who are found to be in CR after 
bridging therap y to receive JN J-68284528 .
After meeting safety  criteria for treatment (Section 6.1.2 ),subjects will be admi nistered a 
conditioning regimen of IV cyclophosphamide 300 mg/m2and fludarabine 30 mg/m2daily  for 
3days.JNJ-68284528 will be administered at a total targeted dose of 0.75 x 106CAR -positive 
viable T cells/kg (range: 0.5 -1.0 x 106CAR -positive viable T cells/kg) 5 to 7 days after start of the 
conditioning regimen (Section 6.1). This is a dose range informed by the Legend -2 study  as 
described inSection 3.2. In the event of excess toxicity , a dose de-escalation to dose level -1 
(0.3x 106 CAR -positive viable T cells/kg [range: 0.1-0.5 x 106cells/kg]) for new subjects will 
occur (Section 3.3).Additionally , a dose escalation to dose level 2 (target dose not to exceed a 
3-fold dose escalation [2.25 x 106CAR -positive viable T cells/kg, range: ±30%, depending on 
target dose chosen for dose level 2])will be considered if specified safet y criteria are met
(Section 3.4).
The first 6 subjects enrolled in the Phase 1b portion of the study  will be hospitalized for at least 
2weeks after receiving an infusion of JNJ -68284528. Hospitalization and local stay requirements 
for subsequent subjects will be based on recommendations bythe SET.
For the primary  efficacy  analysis, the disease status evaluation for each subject will be assessed 
by an Independent Review Committee (IRC). Disease status will be evaluated according to clinical 
judgement guided by theIMWG consensus recommendations for multiple myeloma treatment 
response criteria ( Attachment 1). 11,12,32The process and convention of the IRC will be detailed in 
a separate charter .
Safety  evaluatio nswill include a review of adverse events, laboratory  test results, vital sign 
measurements, physical examination findings, handwriting assessments, and assessment of 
Eastern Cooperative Oncology  Group (ECOG) performance status grade. The safety profile will 
be evaluated atSET meetings during the Phase 1bportion of the study . Follow up of subjects for 
disease progression and survival will continue during the Posttreatment Phase. All study 
evaluations will be conducted according to the Time and Events Schedules (Table 1and 
Table 2).
The sponsor will establish a data cutoff date for clinical study  report (CSR) analy ses.The first
analysis will be conducted approximately  6 months after the last subject receives their initial dose 
of JNJ
-68284528 .An update of the analysis will be provided at approximately  9-12 months after 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Status: Approved ,  Date: 15 June 2022No ongoing Grade 3 or higher hematologic toxicity.
No ongoing Grade 2 non- hematologic toxicity  (with the exception of nausea, vomiting, hair 
loss, andconstipation).
At least 6 months between first JNJ- 68284528 infusion and detection of PD .
Subjects must satisfy  all inclusion and exclusion criteria (Section 4), except for exclusion criteria 1 
and 2,to be eligible for retreatment. A maximum of1 retreatment may occur per subject .Bridging 
therap y prior to retreatment may be considered based on subject’s clinical status and timing of 
availability  of CAR -T product.  I nvestigator must contact the sponsor for approval.
A staggered strategy  for retreatment will be applied. There must be an observation period of at 
least 2weeks between retreatment with JNJ -68284528 to the first and second subject, the second 
and third ,and third and fourth subjects, respectively .
Time and events schedules for retreatment are provided in Attachment 9(Table 12and 
Table 13).Subjects who received retreatment with JNJ -68284528 and are in follow -up at the end 
of the study  (2 years after the last subject receives the initial dose of JNJ-68284528) will be 
monitored in the long-term follow -up study  for 15 years from the time of last treatment (see 
Section 9.1.6.3 ). 
3.2. Rationale of Dose and A dministration Schedule Selection
The conditioning regimen of cyclophosphamide 300 mg/m2and fludarabine 30 mg/m2daily for 
3doses will lead to lymphodepletion and help promote CAR -T cell expansion in the subject.
Cyclophosphamide 300 mg/m2and fludarabine 30 mg/m2before JNJ-68284528 infusion (Day  1) 
is consistent with the ly mphodepletion regimen used in the marketed CAR -T products Ky mriah19
and Yescarta34. 
JNJ-68284528 will be administered at a targeted infused dose of 0.75 x 106CAR -positive viable 
T cells/kg (range: 0.5-1.0 x 106CAR -positive viable T cells/kg with a maximum total dose of 1.0 x 
108CAR -positive viable T cell s) for this Phase 1b -2 study . This dose is informed by  the Legend -
2 clinical study  performed at4study  sites across China. The number of viable CAR -positive T 
cells prepared for the74 subjects from the Legend -2 study  ranged from 0.07 to 2.10 x 106CAR -
positive viable T cell s/kg (mean 0.642 x 106cells/kg, median 0.513 x 106cells/kg).
Across all 74 subjects , the safet y profile supports doses up to 1.5 x 106cells/kg with regards to 
occurrence of CRS (Table 4).Anal ysis of the safety  of doses above 1.5 x 106in the Legend -2 study  
is not possible due to the very small number of subjects who received a dose above this 
concentration . As discussed in Section 1.4, the JNJ-68284528 drug product expresses the same 
CAR protein and is produced using a modified manufacturing process relative to the drug product 
used in the Legend -2 study . Differences in clinical activity  and safety  profiles due to the updated 
manufacturing process are possible. Thus, the targeted infused dose (post -freeze) of 0.75 x 106
CAR -positive viable T cells/kg proposed for JNJ-68284528 was reduced to half of the prepared
dose (pre-freeze) of 1.5 x 106cells/kg supported bythe safet y analysis summarized in Table 4. 
Acknowledging that each CAR -T cell product may have unique factors that influence the safet y 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Status: Approved ,  Date: 15 June 2022If >1 out of the first 6 subjects at any dose level meets DL T criteria during the 21-day evaluation 
period, a dose de-escalation to a target dose (dose level -1) of 0.3x 106 CAR -positive viable 
T cells/kg (range: 0.1-0.5x 106cells/kg ) for future subject s will be mandated as determined by the 
SET (see Section 3.5). For the duration of the Phase 1b portion of the s tudy, a dose de-escalation 
will be mandated if, at the time of the SET meeting, DLT criteria are met for 20% of subjects for 
any dose level reaching the evaluation milestone ( eg, 6, 12, or 18 subjects). 
Adverse events should be evaluated according to National Cancer Institute Common Terminology  
Criteria for Adverse Events (NCI -CTCAE Version 5.0), with the exception of CRS and CAR -T 
cell-related neurotoxicity (eg, ICANS ).CRS should be evaluated according to the ASBMT
consensus grading (Lee 2019)22(Attachment 11).CAR -T cell-related neurotoxicity  (eg,ICANS) 
should be graded using the ASBMT consensus grading (Attachment 13).Assessments for ICE 
should be performed as specified in the Time and Events Schedule ( Table 1and Table 12) in both 
the Phase 1b and Phase 2 portion s of the study .
3.4. Dose Escalation
At the time of the SET meeting, if fewer than 20% of subjects enrolled in thestudy at the target 
starting dose (dose level 1)meets DLT criteria during the 21-day dose de-escalation evaluation 
period described above, the SET may approve a dose escalation (dose level 2). The target dose 
level and range for doselevel 2 will be decided by the SET after review of all available safet y, 
pharmacokinetic, pharmacody namic, and preliminary  efficacy  data, and will not exceed a 3-fold 
dose escalation of the initial target dose ( 2.25 x 106CAR -positive viable T cell s/kg [range: ±30%, 
depending on target dose chosen for dose level 2]) (see Table 6).Dose escalation beyond dose 
level 2 will not be permitted. After dose escalation, the same criteria for dose de-escalation 
described in Section 3.3 willbe used for mandated de -escalation back to 0.75 x 106cells/kg (dose 
level 1 ).
The RP2D will be confirmed by theSET after evaluation of safet y, preliminary  efficacy , 
pharmacokinetic , and pharmacod ynamic data from at least 24 Phase 1b subjects . The RP2D will 
be a dose level examined in Phase 1b at which <20% of subjects experienced a DLT. If there is 
more than one dose level that meets this safety  threshold, the preliminary overall response rate 
among subjects that have had at least two post- infusion efficacy  assessments will be considered 
with additional consideration given to the rate and level of JNJ-68284528 CAR -T cell persistence.
3.5. Safety  Evaluation Team
To ensure safet y monitori ng and sponsor oversight of the study , the sponsor will establish a SET. 
The SET will be chaired by the sponsor Study  Responsible Physician . Membership will include 
the study  principal investigators, a sponsor clinical scientist, safety  physician, statistician, clinical 
pharmacologist, andadditional sponsor staff, as appropriate. SET meetings will occur only during 
the Phase 1b portion of the study . Written documentation of meeting outcomes will be maintained 
by the sponsor. Decisions with the potential to impact subjects’ safet y (eg,unfavorable change in 
risk/benefit assessment) will be prom ptly communicated to regulatory  authorities and study  sites 
as appropriate.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Status: Approved ,  Date: 15 June 2022SET meetings will occur approximately after 6 subjects at the same dose level have completed the 
21-day dose evaluation period: 1) during the Phase 1b study  to evaluate for escalation and de-
escalation of dose level after completion of the DL T evaluation period of every  6 subjects through 
24 subjects and every 12 subjects thereafter , and 2) after SET evaluation of at least 24subjects 
evaluated, administration of JNJ-68284528 to subjects in the Phase 2 portion of the study  may
begin concurrently with ongoing administration of JNJ-68284528 to subjects in the Phase 1b 
portion of the study . Ad-hoc SET meetings may be convened at the discretion of the sponsor. 
Administration of the conditioning regimen and dosing with JNJ-68284528 will be paused 
between dosing of the sixth subject and the conclusion of the first SET meeting. These meetings 
will ensure the safet y of subjects is maintained prior to continued dosing of subjects and will 
consider the need to reduce the dose and if it is safe to escalate the dose for upcoming subjects. 
This SET will consider all available treatment emergent data (eg, pharmacokinetic, 
pharmacod ynamics, safety , efficacy ) for these decisions. The SET may advise on modifications in 
study  conduct, including whether hospitalization ,local stay, or staggered dosing with
JNJ-68284528 is required for subsequent subjects or stopping further enrollment if treatment -
emergent toxicity  is believed to result in an unfavorable risk-benefit profile . All SET decisions 
will be communicated to all study  sites and archived in writing in the Trial Master File.
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within 28 day s prior to apheresis. The inclusion 
and exclusion criteria for enrolling subjects in this study  are described in the following 
2subsections. If there is a question about the inclusion or exclusion criteria, the investigator must 
consult with the Study  Responsible Physician, Study  Responsible Scientist or delegate and resolve 
any issues before enrolling a subject in the study . Waive rs are not allowed.
4.1. Inclusion Criteria
Each potential subject must satisfy  all of the following criteria to be enrolled in the study : 
1.18 years of age.
2.Documented diagnosis of multiple myeloma according to IMWG diagnostic criteria
(Attachment 3).
3. Criterion modified per Amendment 2
3.1. Measurable disease at Screening as defined by an y of the following:
Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein 
level  200 mg/24 hours; or
Light chain multiple myeloma without measurable disease in the serum or the 
urine: Serum immunoglobulin free light chain 10 mg/dL  and abnormal serum 
immunoglobulin kappa lambda free light chain ratio.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Status: Approved ,  Date: 15 June 2022Note: Local laboratory  assessments may be used to establish measurable disease at 
Screening, with local laboratory  result ≥125% of requirements
4. Criterion modified per Amendment 1
4.1. Criterion modified per Amendment 3
4.2. Received at least 3 prior multiple myeloma treatment lines of therapy or are double 
refractory  to an IMiD and PI(refractory  multiple myeloma as defined by IMWG consensus 
criteria30). Note: induction with or without hematopoietic stem cell transplant and with or 
without maintenance therapy  is considered a single line of therap y.
Undergone at least 1 complete cycle of treatment for each line of therap y, unless PD 
was the best response to the line of therap y.
5. Criterion modified per Amendment 3
5.1 Received as part of previous therapy  a PI, an IMiD, and an anti- CD38 antibody (prior 
exposure can be from different monother apy or combination lines of therapy).
6.Criterion modified per Amendment 2
6.1. Criterion modified per Amendment 3
6.2. Subject must have documented evidence of progressive disease based on investigator’s 
determination of response by the IMWG criteria on or within 12 months of their last line 
of therap y (Attachment 1 ).Confirmation may  be from either central or loc al testing . Also, 
subjects with documented evidence of progressive disease (as above) within the previous 
6 months and who are refractory  or non-responsive to their most recent line of therap y
afterwards are eligible .
7.ECOG Performance Status grade of 0 or 1 (Attachment 5).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Status: Approved ,  Date: 15 June 2022Who is sexually  active with a woman who is pregnant must use a condom
Women and men must agree not to donate eggs (ova, oocy tes) or sperm, respectivel y, 
during the stud y and for 1 yearafter the last dose of study  treatment . 
Note: Hormonal contraception may  be susceptible to interaction with the study  treatment, 
which may  reduce the efficacy  of the contraceptive method.
11.Subject must sign an ICF indicating that he or she understands the purpose of procedures 
required for the study  and is willing to participate in the study .Consent is to be obtained 
prior to the initiation of any  study -related tests or procedures that are not par t of standard-
of-care for the subject ’s disease.
12.Willing and able to adhere to the prohibitions and restrictions specified in this protocol.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study :
1. Prior treatment with CAR -T therap y directed at any  target. 
2. Any therapy  that is targeted to BCMA .
3. Criterion modified per Amendment 2
3.1. Diagnosed or treated for invasive malignancy  otherthan multiple myeloma , except:
Malignancy  treated with curative intent and with no known active disease present 
for 2years before enrollment; or 
Adequatel y treated non-melanoma skin cancer without evidence of disease.
4. Prior antitumor therap y as follows, prior to apheresis:
Targeted therapy , epigenetic therapy , or treatment with an investigational drug or 
used an invasive investigational medical device within 14 daysor at least 5half-
lives, whichever is less.
Monoclonal antibody  treatment for multiple my eloma within 21 day s. 
Cytotoxic therapy  within 14 days. 
Proteasome inhibitor therapy  within 14 day s. 
Immunomodulatory  agent therapy  within 7 day s.
Radiotherap y within 14 days. However, if the radiation portal cov ered 5% of the 
bone marrow reserve, the subject is eligible irrespective of the end date of 
radiotherap y.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Status: Approved ,  Date: 15 June 20225. Toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 
or less except for alopecia or peripheral neuropathy .
6. Thefollowing cardiac conditions:
New York Heart Association (NYHA) stage III or IV congestive heart failure
Myocardial infarction or coronary  artery  bypass graft (CABG) 6 months prior to 
enrollment
History  of clinicall y significant ventricular arrhythmia or unexplained syncope, not 
believed to be vasovagal in nature or due to deh ydration
History  of severe non -ischemic cardiom yopath y
Impaired cardiac function (LVEF <45%) as assessed by echocardiogram or 
multiple -gated acquisition (MUGA) scan (per formed 8 weeks of apheresis) .  
7. Criterion revised per Amendment 2
7.1. Received a cumulative dose of corticosteroid sequivalent to ≥70 mg of prednisone 
within the 7 days prior to apheresis
8. Received either of the following:
An allogenic stem cell transplant within 6 months before apheresis. Subjects who 
received an allogeneic transplant must be off all immunosuppressive medications 
for 6 weeks without signs of graft -versus- host disease (GVHD) .  
An autologous stem cell transplant 12 weeks before apheresis 
9. Criterion modified per Amendment 2
9.1. Known active , or prior history  of central nervous system (CNS )involvement or 
exhibits clinical signs of meningeal involvement of multiple my eloma.
10. Stroke or seizure within 6 month s of signing ICF.
11. Plasma cell leukemia at the time of screening (>2.0 x 109/L plasma cells by standard 
differential), Waldenström’s macroglobulinemia, POEMS syndrome (polyneuropath y, 
organomegal y, endocrinopathy, monoclonal protein, and skin changes), or primary  AL 
amyloidosis.
12. S eropositive for human immunodeficiency  virus (HIV).
13. Vaccinated with live, attenuated vaccine within 4 weeks prior to apheresis .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Status: Approved ,  Date: 15 June 202214. Criterion modified per Amendment 2
14.1. Hepatitis B infection as defined according to Attachment 8). In the event the 
infection status is unclear , quantitative levels are necessary  to determ ine the infection 
status.
15. Criterion modified per Amendment 1
15.1. Criterion modified per Amendment 2
15.2. Hepatitis C infection defined as (anti-hepatitis C virus [HCV] antibody  positive 
or HCV -RNA  positive ) or known to have a history  of hepatitis C.For subjects with 
known history  of HCV infection, confirmation of sustained virologic response [SVR] 
is required for study  eligibility , defined as ≥24 weeks after completion of antiviral 
therap y.
16. S upplemental ox ygen use to maintain adequate ox ygen ation.
17. Known life threatening allergies , hypersensitivity , or intolerance to JNJ-68284528 or 
its excipients, including DMSO (refer to Investigator’s Brochure) .
18. S erious underl ying medical condition, such as:
Evidence of serious active viral, bacterial, or uncontrolled systemic fungal 
infection
Active autoimmune disease or a history  of autoimmune disease within 3 y ears
Overt clinical evidence of dementia or altered mental status
19. Any issue that would impair the ability  of the subject to receive or tolerate the planned 
treatment at the investigational site, to understand informed consent or any condition 
for which, in the opinion of the investigator, participation would not be in the best 
interest of the subject (eg, compromise the well-be ing) or that could prevent, limit, or 
confound the protocol- specified assessments.
20. Criterion modified per Amendment 3
20.1 Pregnant or breast -feeding, or planning to become pregnant while enrolled in this 
study  or within 1 y earafter receiving study  treatment.
21. Criterion modified per Amendment 3
21.1 Plans to father a child while enrolled in this study  or within 1 yearafter receiving 
study  treatment .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Status: Approved ,  Date: 15 June 202222. Major surgery  within 2 weeks prior to apheresis, or has surgery  planned during the study 
or within 2 weeks after study  treatment administration. (Note: subjects with planned 
surgical procedures to be conducted under local anesthesia may  participate.) 
5. INTERVENTION ALLOCA TION AND BLIN DING
Randomization will not be used in this study . Subjects will receive study  treatment if all 
inclusion/exclusion criteria are met. As this is an open -label study , blinding procedures are not 
applicable.
6. DOSA GE, A DMINISTRA TION, AND GUIDANCE
For this study , study treatment refers to both cyclophosphamide /fludarabine and JNJ-68284528 . 
All dosing information must be recorded in the Dosage Administration page of the electronic case 
report form (eCRF). 
6.1. Study Treatment Administration
Approximately  4 weeks after aph eresis, and after the site is notified in writing by the Janssen team 
that manufacture and quality  testing of JNJ-68284528 has been completed , each subject will 
receive a conditioning regimen of intravenous (IV)cyclophosphamide 300 mg/m2and fludarabine 
30mg/m2at 3 dail y doses; sponsor approval must be obtained to change the conditioning regimen 
schedule .JNJ-68284528 will be administered as a single infusion 5 to 7days after the start of the 
conditioning regimen (the first day of cond itioning is Day -7to Day -5, and the day of JNJ-
68284528 infusion is Day 1).Cyclophosphamide and fludarabine should be administered using 
administration procedures and supportive care according to the site’s standard of care. JNJ-
68284528 should be administered as described in the site investigational product procedures 
manual (SI PPM) and investigational product preparation instructions (IPPI).
A strategy  of staggered dosing with JNJ -68284528 will be applied. There must be an observation 
period of at least 4 weeks between administration of JNJ-68284528 tothe first and second subject, 
and an observation period of atleast 2 weeks between administration of JNJ-68284528 to the 
second and third and third and fourth subjects, respectivel y.No observation periods are mandated 
after the fourth subject receives JNJ-68284528. Administration of the conditioning regimen and 
dosing with JNJ -68284528 will be paused between JNJ -68284528 dosing of the sixth subject and 
conclusion of the first SET meeting.
Exceptional Release Criteria
In the event a JNJ-68284528 product that did not meet pre-specified release criteria is produced 
during the manufacturing procedures, the sponsor will evaluate the risk/benefit for administration 
of the affected product and determine if the supply  of the product to the treating physician could 
be considered. If required, approval from the relevant health authorities for use of the product will 
be obtained. In the event the supply of the affected product is deemed appropriate, the investigator 
should inform the study  subject that the product did not meet release specifications prior to 
administration.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Status: Approved ,  Date: 15 June 20226.1.1. Criteria for A pheresis
The investigator should contact the sponsor if evidence of rapid disease progression or suspected 
CNS involvement is observed between screening and apheresis. Subjects must meet the following 
criteria to proceed with apheresis:
Clinical laboratory  values required for enrollment ( inclusion c riterion 8, Section 4.1)resulted 
within 24 -hoursprior to apheresis
No plasma cell leukemia at the time of apheresis (>2.0 x 109/L plasma cells by standard 
differenti al)(exclusion criterion 11, Section 4.2).
ECOG performance status grade of 0 or 1
Negative pregnancy test for women of childbearing potential up to 72 hours prior to apheresis
No antitumor therap y within timeframe detailed in Section 4.2and presented below:
Targeted therapy , epigenetic therapy , or treatment with an investigational drug or used an 
invasive investigational medical device within 14 days or at least 5 half-lives, whichever 
is less.
Monoclonal antibody  treatment for multiple my eloma within 21 day s. 
Cytotoxic therapy  within 14 day s. 
Proteasome inhibitor therapy  within 14 day s. 
Immunomodulatory  agent therapy  within 7 day s.
Radiotherap y within 14 days. However, if the radiation portal covered ≤5% of the bone 
marrow reserve, the subject is eligible irrespective of the end date of radiot herap y.
Cumulative dose of corticosteroids should not exceed equivalent to ≥70 mg prednisone within 
the 7 days prior to the first dose of conditioning regimen
No evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection. 
Subjec ts on anti-infective agents within 7 days prior to apheresis must receive approval to 
proceed from s ponsor.
No major surgery  2 weeks prior to apheresis
No live, attenuated vaccines ≤4 weeks prior to apheresis
No supplemental ox ygen use to maintain adequat e oxy genation
No new arrhy thmia or other cardiac adverse events unless controlled with medical 
management and approved by  the medical monitor
For subjects who require a repeat apheresis, the following screening assessments should be 
collected before the second apheresis: weight, hematology  laboratory  assessments, chemistry  
laboratory  assessments, and echocardiogram or MUGA (if clinically  indicated). If the second 
apheresis falls outside of the 28-day window, all screening assessments (except bone marrow 
collection) must be repeated).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Status: Approved ,  Date: 15 June 20226.1.2. Criteria for Conditioning Regimen ( Cyclophosphamide and 
Fludarabine )Dosing
The investigator should contact the sponsor if evidence of rapid disease progression is observed 
between apheresis and cyclophosphamide and fludarabine dosing. Subjects must meet the 
following criteria to proceed with cy clophosphamide and fludarabine dosin g:
Clinical laboratory  values required for enrollment (Section 4.1), with the following exception: 
lymphocy te count of ≥0.3 x 109/L. Transfusion support is permitted to maintain a hemoglobin 
of ≥8.0 g/dl (≥5mmol/L) as needed, and platelets of ≥50 x 109/L until 3 days before the 
hematology  laboratory  test, preceding lymphodepletion. Myeloid growth factors are permitted 
up to 1 day prior to the start of the conditioning regimen. Pegy lated myeloid growth factors 
(ie, pegfilgrastim) are prohibited.
Echocardiogram or MUGA scan for subjects who receive bridging therapy  that includes 
agents with known cardiac toxicity , including but not limited to anthracy clines and
carfilzomib (per prescribing information), verification of non-impaired cardiac function 
(LVEF ≥45%) should be performed after completion of bridging therap y and prior to the first 
dose of the conditioning regimen.
ECOG performance status grade of 0 or 1
Negative pregnancy  test for women of childbearing potential up to 72 hours prior to the first 
dose of the conditioning regimen
No antitumor therap y within timeframe detailed in Section 4.2and presented below :
Targeted therapy , epigenetic therapy , or treatment with an investigational drug or used an 
invasive investigational medical device within 14 days or at least 5 half-lives, whichever 
is less.
Monoclonal antibody  treatment for multiple my eloma within 21 day s. 
Cytotoxic therapy  within 14 day s. 
Proteasome inhibitor therapy  within 14 day s. 
Immunomodulatory  agent therapy  within 7 day s.
Radiotherap y within 14 days. However, if the radiation portal covered 5% of the bone 
marrow reserve, the subject is eligible irrespective of the end date of radiotherapy .
No active Grade 3 toxicity  to any  bridging therapy
No cumulative dose of corticosteroids equivalent to ≥70 mgprednisone within the 7days prior 
to conditioning regimen dosing . The sponsor should be called for approval if a subject receives 
corticosteroids at a dose >10 mg per day in the week prior to the start of the conditioning 
regimen.
No signs of active infection . For subjects requiring systemic anti- microbial treatment or with 
temperature ≥38.0 Celsius within 7 days prior to the first dose of conditioning regimen, the 
investigator must receive approval to proceed from the sponsor.
No major surgery  2 weeks prior to conditioning regimen dosing
No live , attenuated vaccines within 4 weeks prior to conditioning regimen dosing
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Status: Approved ,  Date: 15 June 2022No supplemental ox ygen use to maintain adequate ox ygen ation 
No new arrhy thmia or other cardiac adverse events unless controlled with medical 
management and approved by  the medical monitor
Washout from bridging therap y completed as specified in Section 4.2, criterion 4.
Subjects should be evaluated for the presence of an indwelling catheter prior tothe first dose of 
the conditioning regimen. 
6.1.3. Evaluation Prior to Administration of JNJ -68284528
JNJ-68284528 Dosing Delay s: 
Subjects will be evaluated for safety  on the day  of JNJ-68284528 infusion. If a significant health 
status change (eg ,clinical deterioration, rapidly  progressing disease) occurs following the start of 
the conditioning regimen (see Section 6.1.2 ), the investigator should contact the sponsor prior to 
dosing. 
Infusion of JNJ -68284528 must be delayed if an y of the following events occur:
Signs of active infection . Do not admini ster JNJ-68284528 to subjects with active infection. 
For subjects requiring systemic anti-microbial treatment, or with temperature ≥38.0 Celsius 
within 48 hours before JNJ-68284528 infusion, investigator must consult with the sponsor 
prior to dosing.
Grade 3 non -hematologic toxicities of cyclophosphamide and fludarabine conditioning 
(except for Grade 3 nausea, vomiting, diarrhea, or constipation). Investigator must consult 
with the sponsor prior to JNJ-68284528 dosing.
If resolution of these events to Grad e ≤1 takes more than 14 days, the conditioning regimen should 
be re-administered (cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2daily  for 3days)after 
a minimum of 21 days following the first dose of the first conditioning regimen
(cyclophosphamide and fludarabine ).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Status: Approved ,  Date: 15 June 20226.1.4. JNJ-68284528 A dministration
JNJ-68284528 will be administered as summarized in Table 6.
Table 6
: JNJ-68284528 Adm inistration
Dose JNJ-68284528 will be administered in one infusion. The target dose is 0.75 x 106CAR -
positive viable T cells/kg (range: 0.5 -1.0 x 106CAR -positive viable T cells/kg) as described 
inSection 3.2. The maximum total dose of cells to be administered to any subject is 1.0 x 108
CAR -positive viable T cells (ie, the maximum weight adjusted dose calculated for a 100-kg
subject). If the dose level is de -escalated to dose level -1 or escalated to dose level 2, the 
maximum total dose of cells would be adjusted accordingly as the maximum weight adjusted 
dose (CAR-positive viable T cell s/kg) calculated for a 100-kg subject at that dose level. The
dose and administration schedule may be altered for safety purposes based on emerging data.  
If after apheresis and CAR -T cell preparation the quantity of JNJ -68284528 manufactured is 
not sufficient for dosing at the lower end of the dosing range, dosing for that subject may 
proceed, provided that a measurable quantity of JNJ -68284528 CAR-positive viable T cells 
that pass quality testing are generated .
Route/Regimen JNJ-68284528 IV infusion is to be administered under the supervision of site staff. Refer to 
the IPPI for JNJ -68284528 infusion instructions.
Dosing Instructions The actual dose for study treatment administration will be based on the subject ’s weight (kg)
at apheresis . 
Schedule of Administration One intravenous infusion
Hospitalization 
RequirementsThe first 6 s ubjects enrolled will be hospitalized for at least 2 weeks after receiving an 
infusion of JNJ -68284 528 and will be asked to remain within a 1-hour travel time of the 
hospital and in the company of a competent adult at all times for 1 additional week after 
discharge.
Subjects who are not hospitalized will be asked to remain within a 1 -hour travel time of the 
hospital and in the company of a competent adult at all times for the 2 weeks following study 
treatment. Hospitalization and local stay requirements will be evaluated by the SET for 
subsequent subjects.
At the first sign of CRS (such as fever), subjects should be immediately hospitalized for 
evaluat ion. Further details reg arding management of CRS are described in 
Table 8.
Hospitalization is required for Grade 2, 3,or 4 CAR -T cell-related neurotoxicity (eg, ICANS)
temporally associated with CRS. Hospitalization for neurotoxicity that is not temporarily 
associated with CRS, or any other neurologic adverse events, is at the discretion of the 
investigator .
Vital Sign and Clinical 
Safety MonitoringMonitor vital signs as indicated in the Time and Events Schedule (Table 1).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Status: Approved ,  Date: 15 June 20226.2. Pre-infusion Supportive Therapy
Prior to JNJ-68284528 infusion, subjects should receive premedication as noted below (Table 7). 
Corticosteroids should not be used during pre-infusion . 
Table 7: Pre-infusion Medications
Medication Dose Administration
Antihistamine diphenhydramine (50 mg) or 
equivalentOral –administer 1 hour (±15 minutes) prior to JNJ -68284528 infusion
Or
IV– start infusion 30 minutes (±15 minutes) prior to JNJ -68284528 
infusion
Antipyretic acetaminophen (650 mg to 
1,000 mg) or equivalentOral or IV -administer 30 minute s (±15 minutes) prior to 
JNJ-68284528 infusion
6.3. Management Guidelines for Potential Risks 
6.3.1. Management of Cy tokine Release Sy ndrome
In the Legend -2study , CRS was reported in approximately  92% of subjects who received LCAR -
B38M CAR -T cells. Most events were Grade 1 or Grade 2. All events of CRS started with fever 
after the infusion of CAR -T therap y(See Section 1.5). Of the subjects who developed CRS, 
approximatel y 84% experienced transiently  increased aspartate aminotransferase (AST). AST 
increase was Grade 3 or Grade 4 in 31% and 6% of subjects with CRS , respectively . Subjects 
should be monitored for increased AST, and consumptive coagulopath y, indicated by  anincreas e 
inD-dimersand adecrease infibrinogen if CRS is suspected.
Symptoms indicative of CRS may include ,but are not limited to, fever (with or without rigors ), 
arthralgia, nausea, vomiting, tachypnea , hypoxia, tachycardia, hypotension, headache, confusion, 
tremor, delirium, dyspnea, pulmonary  edema, and capillary  leak.21Potentially  life-threatening 
complications of CRS may include cardiac dysfunction, adult respiratory  distress syndrome, 
neurologic toxicity , renal failure, hepatic failure, and disseminated intravascular coagulation.
Laboratory  testing to monitor for disseminated intravascular coagulation, a manifestation of CRS , 
should be carried out in addition to daily  monitoring of chemistry  and hematology  assessments 
(including ferritin and CRP) when fever or other signs of potential CRS are present (see Table 1). 
In addition, pulmonary , renal and hepatic function will be monitored closely  (see Table 1). 
Cytokine release syndrome will be captured as an adverse event of special interest (see 
Section 12.3.3 ).
Rarel y, severe CRS can evolve into a presentation consistent with hemophagocy tic 
lymphohistiocy tosis/macrophage activation syndrome (HLH/MAS ) that may require additional 
therap y. In these cases, laboratory  testing may reveal high serum levels of ferritin, lactate 
dehy drogenase, soluble CD25, and cytokines (such as IFNγ and IL-6), and low serum levels of 
fibrinogen (Neelapu 2018 )25.Severe thrombocy topenia, low fibrinogen, and often DIC may be 
features of HLH, all of which combined may increase the risk of severe bleeding in these subjects. 
If HLH is suspected, anticoagulation should be avoided or modified based on institutional 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Status: Approved ,  Date: 15 June 2022guidelines depending on platelet count and renal function. Subjects with HLH should have their 
platelet count and coagulation parameters very  closely  monitored and maximal support should be 
provided to avoid major bleeding complications. For example, consider platelet transfusion if 
platelets are less than 50 × 109/L. Under these circumstances, investigators should consider treating 
the subject in the ICU, so that maximal monitoring and support can be carried out during this 
period.
Trained clinical personnel should be prepared to intervene in the event of CRS. Resources 
necessary  for resuscitation (ie, agents such as epinephrine and aerosolized bronchodilator; medical 
equipment such as oxygen, tracheostom y equipment, and a defibrilla tor) should be readily  
available. Tocilizumab must be available prior to administration of JNJ-68284528 . Vital signs and 
laboratory  parameters must be monitored at regular intervals until normal .Additional specimens 
forpharmacokinetic and pharmacod ynamic testing should be collected as per the schedule outlined 
in Table 2. 
Infection and CRS may have a similar presentation . Therefore, investigators arestrongl y 
encouraged to evaluate for an infection at the first signs or symptoms of CRS. Cultures and 
imaging should be obtained: the clinical signs and symptoms should determine which tests are 
appropriate. 
Recommendations for the clinical management of CRS are provided in Table 8. At the first sign 
of CRS (such as fever) subjects should be immediately  hospitalized for evaluation. The use of 
myeloid growth factors, particularl y granulocy te colony -stimulating factor (G-CSF), should be 
avoided during CRS. Tocilizumab intervention may be considered with presenting symptom of 
fever per investigator discretion when other sources of fever have been eliminat ed and early 
tocilizumab should be considered in subjects at high risk of severe CRS (for example, high baseline 
tumor burden, early fever onset, or persistent fever after 24 hours of symptomatic treatment). Other 
monoclonal antibodies targeting cy tokines (for example, anti -IL1 and/or anti -TNF)may be used 
based on institutional practice, especially  for cases of CRS which does not respond to tocilizumab. 
Therap y directed at reduction or elimination of CAR -T cells, including chemotherap y, may be 
considered in consultation with the sponsor for subjects who develop high grade CRS with 
laboratory  findings overlapping with HLH/MAS (including hyperferrit inemia) that remains severe 
or life -threatening following prior therapies, including tocilizumab and corticoste roids.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Status: Approved ,  Date: 15 June 2022Supportive care for CRS (including but not limited to anti-pyretic agents, IV fluid support, 
vasopressors, supplemental oxygen) should be administere d according to the clinical 
manifestations of the subject’s illness. Similarly , ancillary  testing such as B-type natriuretic 
peptide (BNP )assessment , echocardiograms, arterial blood gas, assessments of coagulation 
laboratory  tests, should be performed if clinicall y indicated. 
6.3.2. Neurologic Toxicities
Based on the specific mode -of-action of JNJ-68284528, severe or serious neurological toxicities 
(including CAR -T cell-related neurotoxicity , eg,ICANS [Immune Effector Cell-Associated 
Neurotoxicity  Syndrome]) may occur (Section 6.3.2.1 ). Subjects should be monitored for 
neurotoxicity  for 1 -year post JNJ -68284528 infusion (Section 6.3.2.2 ). 
6.3.2.1. CAR-T Cell -related Neurotoxicity  (Immune Effector Cell -Associated 
Neurotoxicity  Syndrome [ICA NS])
Subjects should have the Immune Effector Cell-associated Encephalopathy  (ICE) Assessment 
Tool (ICE-Tool; Attachment 12) performed at baseline (within 24 hours prior to infusion of 
JNJ-68284528 infusion) and dailyafter the first symptoms of CAR -T cell-related neurotoxicity 
(eg, ICANS) are suspected and until resolution. Consider performing ICE-Tool more frequentl y 
until neurotoxicity  symptoms resolve. Consider performing neuroimaging (eg, magnetic resonance 
imaging [MRI ])at screening and/or neurol ogyconsultation if pre-existing disease is suspected; 
see Section 9.2 Safet y Evaluation.
Subjects should be monitored for neurological toxicities including, but not restricted to, speech 
disorders, aphasia, convulsions, disturbances in consciousness, confusion, disorientation, or 
coordination and balance disorders. If these or other neurological toxicities are observed, 
regardless of causalit y, then the sponsor’s medical monitor must be consulted. Hospitalization is 
required for Grade 2, 3, or 4 CAR -T cell -related neurotoxicity  (eg, ICANS) temporally  associated 
with CRS .
At the first sign of neurotoxicity , neurology  consultation and evaluation should be considered for 
all neurological toxicities . Rule outalternative etiologies including infectious etiologies (eg, viral 
origin such as, human herpesvirus [HHV] HHV- 6, HHV- 7) if clinically  indicated. Subjects who 
have a lumbar puncture as part of their neurologic work up should have a sample of cerebral spinal 
fluid for additional testing (eg,pharmacokinetic or biomarkers) as clinically  indicated. For signs 
of seizures or raised intracranial pressure (ICP)/cerebral edema, consider neuroimaging (CT/MRI), 
transfer the subject to the intensive care unit (I CU) and treat according to institutional guidelines 
or practices.
General management for CAR -T cell-related neurotoxicity  (eg, ICANS )with or without 
concurrent CRS is summarized in Table 9. All neurological adverse events, including CAR -T 
related neurotoxicity  (eg, ICANS ), will be captured as an adverse event of special interest (see 
Section 12.3.3 ).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Status: Approved ,  Date: 15 June 2022difficulty  with short term memory
slowing of movements
difficulty  performing simple tasks
difficulty  swallowing
joint or muscle stiffness or inflexibility
shuffling gait
restlessness
micrographia
Early detection, workup and intervention, may be important to prevent neurologic toxicity  from 
worsening. The following is a list of potential diagnostics that should be considered in subjects 
with new neurologic s ymptoms:
Positron emission tomograph y/computerized tomograph y (PET/CT) of the brain and/or brain 
MRI  with perfusion and an electroencephalogram (EEG) 
Lum bar puncture to rule out infection (in particular John Cunningham virus [JCV], herpes 
zoster virus [HZV], herpes simplex virus [HSV] -1/2, HHV-6, HHV -7, Epstein -Barr virus 
[EBV], cy tomegalovirus [CMV]).
Serologic testing for HHV- 6 and HHV -7 by PCR for viremia. 
CSF flow cy tometry  and cy tology  should be considered to rule out leptomeningeal disease. 
Cerebral spinal fluid ( CSF)analy sis to rule out paraneoplastic s yndromes . 
Thiamine level (consider empiric thiamine replacement while awaiting results)24
Therap y directed at reduction or eliminati on of CAR -T cells, including chemotherap y, may be 
considered in consultation with the sponsor for subjects who develop neurotoxicity  that remains 
unresponsive to other interventions.
Per Section 9.4of the protocol, if cerebral spinal fluid (CSF) or other relevant biological sample 
analysis is clinicall y indicated, a sample of CSF may be requested for additional analy sis by the 
sponsor , as allowed b y local regulations.
Per section 9.7of the protocol, qualitative changes in handwriting since baseline are being explored 
by the sponsor as a potential earl y clinical predi ctive marker for neurotoxicity .
6.3.3. Tumor Lysis Syndrome
Although TLS is uncommon in subjects with multiple myeloma, one subject in the Phase 1 
Legend -2 Study  experienced fatal TLS. Subjects must be monitored closely  for symptoms of TLS. 
Management of TLS, including hyperkalemia, hyperuricemia, hyperphosphatemia, and 
hypocalcemia, is highly recommended. It is also required that high-risk subjects, ie, those with a 
high tumor burden (60% plasma cell infiltrate on the bone marrow biopsy or aspirate [ whichever
is higher] or a subject with multiple extramedullary  disease sites or plasmacy tomas), be treated
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Status: Approved ,  Date: 15 June 2022prophy lacticall y in accordance with local standards (eg, extra hydration; diuretics; allopurinol 
300mg daily and primary  or secondary  uricosuric agents, as indicated). TLS will be captured as 
an adverse event of special interest (see Section 12.3.3 ).
6.3.4. Cytopenia
Subjects may exhibit cy topenias for several weeks following ly mphodepleting chemotherapy  and 
JNJ-68284528 infusion. In the Legend -2 study , Grade 3 and 4 cytopenias included leukopenia 
(25.7%), thrombocy topenia (18.9%), anemia (14.9%), and neutropenia (2.7%). Prolonged 
neutropenia may increase the risk of infection. Blood counts should be monitored after 
JNJ-68284528 infusion. The use of myeloid growth factors, particularly  granuloc yte 
colony -stimulating facto r (G-CSF), should be avoided during CRS.
Parvovirus B19 monitoring by PCR should be considered in subjects experiencing prolonged 
neutropenia or a decline in neutrophil counts following recovery .
6.3.5. Hypogammaglobulinemia
Hypogamma globulinemia may occur in subjects receiving JNJ-68284528 . Monitor 
immunoglobulin levels after treatment as detailed in the Time and Events Schedule ( Table 1)and 
more frequently  if clinically  indicated and treat according to local guidelines, including 
administration of immunoglobulin replacement and monitoring for infection.
Subjects with IgG < 400 mg/dL  and recurrent infections may receive prophy lactic IVIG as per 
institutional guidelines.
6.3.6. Infections
Administration of JNJ-68284528 may increase the risk of infection due to cytopenias or 
hypogammaglobulinemia. Subjects should be monitored frequent ly for infection and should have 
blood cultures obtained and empiric antibiotics administered per institutional standards. Extended 
use of anti-microbial therapies for at least 6 month (or longer as per institutional guidelines) or 
consistent with post ASC T consensus guidelines after CAR -T dosing are recommended (see 
Attachment 16). Perform screening for HBV, HCV, and HIV and monitor as clinicall y indicated
(see HBV monit oring recommendations in Section 9.2and Attachment 8, and initiate treatment as 
appropriate. HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and 
death, may occur in subjects treated with drugs directed against B cells such as JNJ-68284528. 
HBV reactivation has occurred in subjects who appear to have resolved hepatitis B infection.
Subjects receiving cilta -cel are possibl y at a higher risk of severe/fatal outcomes from COVID -19 
infection compared with patients who are receiving standard of care therapy . Subjects should be 
reminded of the importance of vaccines and other preventative measures. Investigators should 
consider proph ylaxis (eg, Evusheld, if available) and antiviral medications (eg, Paxlovid, if 
available) for patients diagnosed with COVID -19 infection, as noted in Attachment 17.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Status: Approved ,  Date: 15 June 20226.3.7. Hypersensitivity  Reactions
Allergic reactions may occur with the infusion of JNJ-68284528. Serious hypersensitivity 
reactions including anaphy laxis, may be due to dimethyl sulfoxide (DMSO), dextran 40, or 
residual ampicil linor kanam ycin in JNJ-68284528. Subjects should be treated urgentl y per 
institutional standards, avoiding corticosteroid use if possible. Subjects should receive 
premedication prior to JNJ -68284528 dosing as noted in Section 6.2.
6.3.8. Second Primary  Malignancy
Second primary  malignancy  is a theoretical possibility  due to the risk of lentiviral insertion. Second 
primary  malignancies should be managed per institutional standards. Second primary 
malignancies must be reported during the duration of the study , irrespective of when they occur, 
and subsequentl y will be collected in a long-term follow -up study  yearly until 15 years post dosing 
of JNJ -68284528. A tumor sample s hould be collected and DNA, RNA or protein analysis ma y be 
performed to investigate the presence of lentiviral elements.
7. INTERVENTION COMPLIA NCE
Apheresis and infusion of JNJ-68284528 will be done in the controlled environment of a qualified 
clinical site,under the direct observation of qualified study -site personnel. The details of 
administration will be recorded in the eCRF (including date, dose of cells, start, and stop times of 
the IV infusion, and volume infused). Precautions associated with the use of the study  treatment 
and concomitant medications will be reviewed by the sponsor.
Refer to the SIPPM for a description of the chain of identity  and chain of custod yprocedures 
associated with the apheresis product and JNJ- 68284528.
8. PRESTUDY AND CONCOMITA NT THERAPY 
Throughout the stud y, investigators may prescribe concomitant medications or treatments (except 
for those listed in Section 8.2) deemed necessa ry to provide adequate supportive care. All 
medications (including prescription and over-the-counter products, and transfusions ofblood 
products )different from the study  treatment must be recorded throughout the study  beginning with 
the signing of the ICF until at least 100 days after infusion of JNJ-68284528 , or until the start of 
subsequent systemic anticancer treatment, if earlier. After 100 days, only adverse events that are 
considered related to study  drug need to be reported until the end of the study. This includes 
concomitant therap yand any medication used to treat or support adverse events or serious adverse 
events (within or beyond 100 days after infusion). Exceptions include medications used to prevent 
(including vaccines) and treat COVID -19 and HBV reactivation, which should be reported until 1 
year after cilta-cel infusion, regardless of severity  or causality  (Attachment 17). Recorded
information will include a description of the type of the drug, dosing regimen, route of 
administration, duration of treatment, and its indication. All medications, including details of 
previous anticancer treatment, should be documented in the appropriate s ection of the eCRF.
Anti- myeloma therap y (medications which the subject has previously  received) is permitted during 
bridging therap y (see Section 3.1) ( Attachment 4).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Status: Approved ,  Date: 15 June 20228.1. Permitted Medications
The following are examples of supportive therapies that may  be used during the study :
Standard supportive care therapies (antiemetics, antidiarrheals, anticholinergics, 
antispasmodics, antipy retics, antihistamines, analgesics, antibiotics and other anti microbials, 
histamine receptor [H2]antagonists or proton pump inhibitors, and other medications intended 
to treat symptoms or signs of disease) and therapies intended to treat CAR -T cell-related 
toxicity  (ie,CRS) as clinically  indicated, according to institutional standards and as deemed 
necessary  by the investigator.
Bisphosphonates may be initiated (if notalread y being administered) unless contraindicated 
within 1 week prior to the first dose of study  treatment and continued until disease progression 
is established. In the case of severe adverse events such ashypercalcemia, bisphosphonates 
may be administ rated as clinically  indicated, according to institutional standards and as 
deemed necessary  by the investigator.
Hematopoietic growth factor support and transfusions (irradiated blood products) are 
permitted to treat symptoms or signs of neutropenia, anemi a or thrombocy topenia according 
to local standards of care. Non-pegy lated myeloid growth factors are permitted up to 1 day 
prior to the start of the conditioning regimen (Section 6.1.2 ).
Documented infectious complications should be treated with oral or IV antibiotics or other 
anti-infective agents as considered appropriate by the treating investigator, according to 
standar d institutional practice. 
Chemotherap y agents used to treat CAR -T cell-related toxicit iesare permitted upon 
consultation with the sponsor (see Section 6.3).
8.2. Prohib ited Therapies
The following medications are prohibited during the study . The sponsor must be notified in 
advance (or as soon as possible thereafter) of any instances in which prohibited therapies are (to 
be) administered.
Corticosteroid use should be avoi ded, except for the treatment of CRS or CAR -T cell -related 
neurotoxicity  (eg,ICANS) , as described in Table 8and Table 9. Alternative therapies, if 
feasible, should be given prior to corticoster oids.
Any chemotherapy , anticancer immunotherapy  (other than JNJ-68284528 ), or experimental 
therap y, except as described in Section 3.1(bridging therapy ), or protocol -specific therapies 
which may  be used in conjunction with JNJ -68284528.
While in follow -up, emergency  orthopedic surgery or radiotherap y is generally  prohibited, but 
may be allowed in the absence of disease progression. Cases must be discussed and approved 
by the sponsor. Such emergency  radiotherap y may consist of localized radiotherapy  for pain 
control or for stabilization of an extensive bone lesion at high risk of pathologic fracture or 
damage to surrounding tissues.
Nonsteroidal anti-inflammatory  agents should be avoided to minimize the risk of exacerbation 
of potential sub -clinical my eloma -related kidney  disease. Based on the investigator’s clinical 
judgement, low -dose aspirin may  be continued for thromboprophy laxis.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Status: Approved ,  Date: 15 June 2022Other immunosuppressant agents unless used as protocol -specified pre-or post-treatment 
medications to treat an adverse event (eg,CRS) .
Vaccination with live, attenuated vaccine after signing consent and in the 4 weeks prior to 
the infusion of JN J-68284528 ,and for 1 00days after infusion of JNJ -68284528 .
The use of IV contrast infusions should be avoided to prevent myeloma -related kidney 
disease .If administration of IV contrast is necessary , then adequate precautions including 
hydration are indicated.
Pegy lated myeloid growth factors (ie, pegfilgrastim) are prohibited within the first 100 days 
after infusion of JNJ -68284528 (Section 6.1.2 ).
8.3. Subsequent Anticancer Therapy
Subsequent anticancer therap y administered after JNJ-68284528 should beonly administered after 
confirmed PD per IMW G criteria andrecorded in the eCRF. The start and end date and best 
response should be documented in the eCRF, if availa ble.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule ssummarizes the frequency  and timing of procedures and 
assessments applicable to this study  (Table 1and Table 2); for subjects who are eligible for 
retreatment with JNJ-68284528, follow the Time and Events Schedules in Attachment 9
(Table 12 and Table 13).
All planned assessments, including laboratory  tests, on the day of JNJ-682845 28dosing must be 
completed and the results reviewed prior to the start of the infusion. Treatment decisions will be 
based on safet y assessments performed at the local laboratory and disease assessments performed 
at the central laboratory .
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures 
be performed in the following sequence: electrocardiogram ( ECG ), vital signs, blood draw. Blood 
collections for biomarkers and pharmacokinetic assessments should be kept as close to the
specified time as possible. Actual dates and times of assessments will be recorded in the source 
documents and the laboratory requisition form. Within 24 hours of stud y treatment infusion, if the 
study  treatment is infused peripherall y, blood samples must be drawn from a vein contralateral to 
the arm into which JNJ-68284528 isinfused. If the study  treatment is infused via a central vein 
line, blood samples over the subsequent 24 hours must be drawn from a vein in either arm. 
The approximate volume of blood drawn from each subject in this study  (up to 2 years’post-
treatment) is 958mL.Repeat or unscheduled samples may be taken for safet y reasons or for 
technical issues with the samples. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Status: Approved ,  Date: 15 June 2022Based on emerging data, adjustments to the planned schedule of assessments may be made b y the 
sponsor to protect subject safet y. These decisions will be documented in writing by the SET (see 
Section 3.5)and appropriatel y communicated to participating investigators prior to 
implementation.
9.1.2. Screening Phase
All subjects must sign an I CF prior to the conduct of any  study -related procedures. The screening 
phase begins when the first screening assessment is performed. Screening procedures will be 
performed up to 28 days before apheresis. If an assessment was performed as part of the subject’s 
routine clinical evaluation and not specificall y for this study , it does not need to be repeated after 
signed informed consent has been obtained provided the assessments fulfill the study  requirements 
and are performed within the specified timeframe prior to the first dose of study  treatment. 
Retesting of abnormal screening values thatlead to exclusion are allowed only once during the 
screening phase (to reassess eligibility ). The last result obtained prior to apheresis will be used to 
determine eligibility .Subjects who do not meet all inclusion criteria or who meet an exclusion 
criterion may, at the discretion of the investigator, be rescreened once upon the sponsor’s written 
approval. Subjects who are to be rescreened must sign a new informed consent before rescreening. 
Rescreening and subsequent activities must be conducted in accor dance with protocol defined time 
windows.
9.1.3. Apheresis
Prior to apheresis, review of safet y assessments should be completed perTime and Events 
Schedules (Table 1and Table 2). Apheresis should be performed according to institutional 
standards, with a collection t arget of 6 x 109PBMCs (range: 2 to 20 x 109PBMCs ); twoapheresis 
collections may be performed to attain this target. Instructions for processing and shipping 
apheresis product are provided in the SI PPM.
9.1.4. Cyclophosphamide and Fludarabine Conditioning Regim en
At the completion of manufacture and qualit y testing of JNJ-68284528, notification will be sent to 
the clinical site. Prior to dosing with cyclophosphamide and fludarabine, review of eligibility , 
safet y assessments and disease characteristics should be completed per Section 6.1. The details 
regarding safet y monitoring and study  visits during this phase are included in the Time and Events 
Schedules ( Table 1 and Table 2). 
9.1.5. JNJ-68284528 A dministration
Administration of JNJ- 68284528 is fully  described in Table 6.
9.1.6. Post -treatment Phase 
The post-treatment phase starts after the completion ofJNJ
-68284528 infusion and includes the 
post-infusion period and the post -treatment period.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Status: Approved ,  Date: 15 June 20229.1.6.1. Post -infusion Period
The post -infusion period starts after the completion of JNJ -68284528 infusion onDay 1 and lasts 
until Day 100 . Any subject who receives an infusion of JNJ-68284528 should continue all 
subsequent post-infusion assessments as per the Time and Events Schedules (Table 1and 
Table 2). During this period, subjects will be monitored closel y for safet y and disease assessments. 
Subjects will be asked to check their temperature at least twice daily (entering 2 temperatures 
including their maximum daily  temperature on the provided diary )and will be instructed to report 
any fever (≥100.4oF or ≥38oC) to the study  doctor immediately  to initiate monitoring for 
development of CRS. 
Hospitalization requirements are described in Table 6. Subjects will be provided a "wallet (stud y) 
card" with pertinent information about the study  and be asked to carry  this card with them for the
duration of the post-infusion and post -treatment period.
9.1.6.2. Post -treatment Period
The post-treatment period starts on Day 101 and lasts until study  completion , defined as 2 years 
after the last subject has received his or her initial dose of JNJ-68284528 . Assessments are to be 
performed per the Time and Events Schedules (Table 1and Table 2), and include safety  and 
disease assessments every  28 days. Disease evaluation should continue to be performed until 
confirmed disease progression, death, start of a new anticancer treatment, withdrawal of consent
for study  participation, or end of the study , whichever occurs first. Once disease progression is 
confirmed, subsequent disease assessment is not required unless the subject receives retreatment 
with JNJ-68284528 (see Attachment 9 ).
After disease progression is documented, survival status and subsequent anticancer therapy  will 
be obtained every 16 weeks until the end of stud y, unless the subject has died, is lost to follow -up, 
or has withdrawn consent. If the information is obtained via telephone contact, written 
documentation of the communication must be available for review in the source documents. If the 
subject has died, the date and cause of death will be collected and documented on the eCRF, if or 
when available. Where allowed by  local law, public records may  be used to document death or to 
obtain survival status.
9.1.6.3. Long -term Follow -up
Second primary  malignancies will be reported for the duration of the study ,defined as 2 years after 
the last subject has received his or her initial dose of JNJ -68284528 . Following completion of this 
study , assessment for replication competent lentivirus (RCL ) and second primary  malignancies 
will continue for up to 15 years afterdosing with JNJ-68284528 on a follow- up study .In addition, 
subjects who received retreatment with JNJ -68284528 and are in follow- up at the end of the stud y
(2 years after the last subject receives his or her initial dose of JNJ-68284528 ) will be monitor ed
in this long-term follow -up study .A tumor sample should be collected and DNA, RNA or protein 
analysis may  be performed to investigate the presence of lentiviral elements.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Status: Approved ,  Date: 15 June 20229.2. Safety  Evaluations
Safety  will be measured by adverse events, laboratory  test results, vital sign measurements, 
physical examination findings (including neurological examination) , assessment of ICE-Tool 
scores, handwriting assessments, and assessment of ECOG performance status grade . Clinically  
relevant changes occurring during the study  must be recorded on the adverse event section of the 
eCRF. Clinically  significant abnormalities persisting at the end of the stud y/earl y withdrawal will 
be followed by the investigator until resolution or until a clinically  stable endpoint is reached. 
Safety  monitoring assessments may  be performed more frequently , if clinically  indicated.  
The study will include the following evaluations of safet y according to the time points provided in 
the Time and Events Schedules (Table 1 and Table 2).
Adverse Events
Adverse events (except for neurological adverse events, second primary  malignancy ,HBV 
reactivation , and COVID -19 infection ) will be reported (or, when appropriate, by a caregiver, 
surrogate, or the subject's legally  acceptable representative) from the time a signed and dated 
informed consent is obtained until 100 days after last administration of any study  treatment or until 
the start of subsequent anticancer therapy , if earlier. Second primary  malignancies will be reported 
for the duration of the study  and, subsequentl y, will be collected on a long-term follow -up study 
yearly until 15 years’post dosing of JNJ -68284528. Events of HBV reactivations and COVID -19 
infections, and new neurological adverse events or exacerbation of existing neurologic aladverse 
events will be reported during the first y ear post -dosing of JNJ-682845 28.See Attachment 18for 
additional adverse event reporting guidance for this study .
Adverse events will be followed by the investigator as specified in Section 12, Adverse Event 
Reporting and graded according to the National Cancer Institute Common Terminology  Criteria 
for Adverse Events (NCI-CTCAE Version 5.0),with the exception of CRS and CAR -T cell-related 
neurotoxicity  (eg, IC ANS). CRS should be evaluated according to the ASBMT consensus grading 
(Lee 2019)22(Attachment 11). CAR -T cell-related neurotoxicity  (eg, ICANS) should be graded 
using the ASBMT consensus grading (Attachment 13). Subjects with Grade 3 or higher toxicity  
or unresolved adverse events thatlead to treatment discontinuation will continue to be assessed 
until recovery  to Grade 1 or baseline, the event is deemed irreversible, the end of the study ,or a 
maximum of 6 months, whichever comes first. 
In addition to capturing ICANS and CRS adverse events (graded by ASTCT consensus grading), 
all individual symptoms of CRS (eg, fever, hypotension) and ICANS (eg, depressed level of 
consciousness, seizures) must be captured as individual adverse events and graded by CTCAE 
criteria. Neurotoxicity  that is not temporarily  associated with CRS, or any other neurologic adverse 
events that do not qualify as ICANS , will be graded by CTCAE criteria. Events of neurotoxicity  
or exacerbation of existing neurologic adverse events will be reported for 1-year post infusion of 
JNJ-68284528.
Changes in handwriting (ie,micrographia, dysgraphia, or agraphia) should be graded using the 
criteria outlined in Attachment 15and reported as an adverse event in the eCRF. Should a subject 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Status: Approved ,  Date: 15 June 2022Physical Examination 
The screening physical examination will include, at a minimum, subject ’s height, general
appearance, examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, 
musculoskeletal system, and lymphatic system. Thereafter, a symptom -directed physical 
examination will be conducted as clinicall y indicated at subsequent timepoints. Abnormalities will 
be recorded in the appropriate section of the eCRF. Body  weight will be measured prior to infusion 
ofJNJ-68284528 (see the Time and Events Schedule Table 1). Clinicall y significant post -baseline 
abnormalities should be recorded as adverse events.
ECOG Performance Status
The ECOG performance status scale will be used to grade changes in the subje ct’s daily living 
activities ( Attachment 5)and will be assessed as noted in the Time and Events Schedule Table 1.
Neurologic Examination
(Phase 1b and Phase 2)
Magnetic resonance imaging (MRI) at screening or neurology  consultation should be considered 
if pre-existing disease is suspected. For subjects with prior pertinent neurologic disease (eg, stroke, 
encephalitis) consider baseline MRI  of brain and an EEG. At the first sign of neurotoxicity , 
neurology  consultation and evaluation should be considered. CAR -T cell-related neurotoxicity  (eg,
ICANS) should be graded using ASBMT consensus grading. Other neurological adverse events 
not associated with ICANs should be graded based on CTCAE version 5.0throughout both phases 
of the study .Findings from neurological testing that support CAR -T cell-related neurotoxicity  
(eg,ICANS) should be reported in the CRF.
Immune -effector Cell -associated Encephalopathy (ICE) Tool Score s
The ICE test was developed to provide objectivity  for the grading of multiple overlapping 
encephalopath y terms currentl y included on the approved CAR -T products (Lee 2019)22
(Attachment 12). The ICE tool will be collected as noted in the Time and Events Schedule ( Table 
1and Table 12) to guide management throughout both phases of the study . It will also be used to
grade the severit y of ICANS (Attachment 13).All ICE-Tool scores, must be reported in the eCRF. 
Handwriting Assessment
Qualitative changes in handwriting since baseline are being explored b y the sponsor as a potential 
early clinica l predictive marker for neurotoxicity . Currently  no standardized CTCAE toxicity  
gradings are available in the NCI-CTCAE v5.0. for these type of changes in handwriting. 
Therefore, the sponsor has developed a handwriting assessment criterion to assess subjec ts for 
occurrence of the following types of changes in handwriting: micrographia, dysgraphia, or 
agraphia, as potential early indicators for neurotoxicity  (Attachment 15).
Handwriting assessments will be collected on a writing log according to the Time and Events 
Schedule (Table 1) and as instructed by the sponsor. Subjects unable to write at baseline are 
excu sed from this assessment during study . The sponsor’s medical monitor should immediately  be 
notified when changes in handwriting are detected. This will prompt discussion about additional 
assessments to further evaluate for other neurotoxicity  symptoms, further workup, as well as the 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Status: Approved ,  Date: 15 June 2022potential initiation of interventions. All cases of handwriting abnormalities (ie,micrographia, 
dysgraphia, or agraphia) must be reported as an adverse event in the eCRF. Should a subject 
experience a serious CAR -T associated neurotoxicity  (either I CANS or other neurotoxicity ), then 
a copy  of the handwriting assessment log should be submitted with the serious adverse event
report.
9.3. Pharmacokinetics and Immunogenicity
The goal of the pharmacokinetic assessment of JNJ-68284528 in this study  is to evaluate 
pharmacokinetic parameters, and immunogenicity  effects on the pharmacokinetic profiles and 
parameter values. Pharmacokinetic/pharmacodynamics, dose-response (safet y and efficacy ) 
relationships will be explored. The recommended dose regimen for dose expansion will be 
determined based on information including the pharmacokinetic and pharmacod ynamic 
information obtained in Phase 1b. Immunogenicity  assessments will also be utilized in these 
evaluations. See Section 9.1.1 for sample collection instructions .
9.3.1. Evaluations 
Blood and serum samples will be collected for JNJ-68284528 pharmacokinetics, and 
immunogeni city (antibodies to JNJ-68284528 )assessment as specified in the Time and Events 
Schedule (Table 2). Also, pharmacokinetic and immunogenicit y samples will be collected at the 
time onset of suspected CRS or CAR -T cell-related neurotoxicity  (eg, ICANS )regardless of 
causality  (as specified inTable 2and Table 13). In addition, pharmacokinetic and immunogenicity 
samples will becollected following the end of study  treatment as shown in Table 2. The exact 
dates and times of blood sampling must be recorded on the laboratory  requisition form. Refer to 
the Laboratory Manual for sample collection requirements. Collected samples must be stored 
under speci fied controlled conditions for the temperatures indicated in the Laboratory  Manual.
Venous blood samples will be collected for measurement of CAR -T positive cellular concentration 
and transgene levels of JNJ-68284528 .
Bone marrow samples will be collected for measurement of transgene levels and cellular 
concentrations of JNJ-68284528 (see Time and Events schedule s,Table 2and Table 13). 
Blood samples will be collected for exploratory  evaluations of soluble circulating BCMA 
(sBCMA). This d ata may be used for mechanistic pharmacokinetic/pharmacody namic modeling.
Additional information about the collection, handling, and shipment of biological samples can be 
found in the Laboratory Manual.
9.3.2. Analytical Procedures
Pharmacokinetics
Post-dose b lood and bone marrow samples will b e anal yzed to determine CAR -T positive cellular 
concentration and transgene levels of JNJ-68284528 using specific and sensitive assay  methods 
that are validated by  or under the supervision of the sponsor.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Status: Approved ,  Date: 15 June 2022Immunogenicity
The detection and characterization of antibodies to JNJ-68284528 will be performed using a 
validated assay  method by or under the supervision of the sponsor. Other analyses may be 
performed to characterize immunogenicit y.
9.3.3. Pharmacokinetic Parameters
Blood and bone marrow samples will be collected for the measurement of JNJ-68284528 cellular 
concentrations and transgene levels for pharmacokinetic analy ses (Time and Events Schedule
Table 2). Pharmacokinetic parameters will be estimated for individuals, and descriptive statistics 
will be calculated. Correlation of Cmaxand AUC with dose may also be explored. Pharmacokinetic 
parameters include, but are not limited to, AUC inf, AUC (0-t), AUC tau, C max, half-life, and Tmax
parameters will be calculated if sufficient data are available for estimation.
9.3.4. Immunogenicity  Assessment /Antibodies to JNJ-68284528
Antibodies to JNJ-68284528 will be evaluated in serum samples collected during the Treatment 
Phase (Table 2). Additionally , serum samples should also be collected at the final visit from 
subjec tswho discontinued treatment or were withdrawn from the study . These samples will be 
tested by  the sponsor or sponsor's designee.
JNJ-68284528 transgene concentration will also be determined to aide in the interpretation of 
immunogenicit y data. These samples will be stored and evaluated if deemed necessary .
Serum samples will be screened for antibodies binding to JNJ-68284528 and the titer of confirmed 
positive samples will be reported. Other analy ses may be performed to verify  the stability  of 
antibodies to JNJ-68284528 or further characterize the immunogenicit y of JNJ-68284528 . 
9.4. Biomarker Evaluations
Biomarker assessments will focus on several objectives: 1) evaluate infused CAR -T cell subsets 
and activation markers including, but not limited to, CD4+, CD8+, CD25+, central memory , 
effector memory  cells; 2)determine the abilit y of JNJ-68284528 to induce MRD negativity  in 
subjects with relapse/refractory  multiple myeloma who have achieved CR; 3) serum or plasma
proteomic profiling of cytokines (such as IL-6, IL-15, and IL-10) and other immune related 
proteins (such as perforin and granzy mes); 4) immunophenot yping ofbiomarkers of 
response/resistance on myeloma cells (such as BCMA and PD-L1); 5) determine the clinical 
benefit (ORR, DOR, TTR, PFS, and OS) ofJNJ-68284528 in subjects with cytogenetic 
modifications (del17p, t(4;14), t(14;16), or other high-risk molecular subty pes); and 
6)immunophenoty ping of immune cells subsets such as CD4+and CD8+Tcells, regulatory  T 
cells, B and NK cells. Additional biom arker samples may be collected to help understand an 
unexplained adverse event including but not limited to serum or peripheral blood mononuclear 
cells (PBMCs) from whole blood . Additional sample(s) for cytokines will be collected as clinically 
indicated ( Table 2 ).
The potential presence ofRCL will be evaluated from wholeblood samples of subjects treated 
with JNJ-68284528 .RCL will be evaluated using a qPCR assay  against the lentiviral vesicular 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Status: Approved ,  Date: 15 June 2022stomatitis virus -G gene yearly for up to 15years inthe present study  or a separate long-term 
follow -upstudy ..If all post-infusion samples for an individual subject are negative forRCL  during 
the first year after treatment, no additional samples will be c ollected and RCL assessments will be 
terminated. Yearl y review of medical history  will generally  be sufficient for the subject . If any 
post-infusion samples are positive, further RCL  analysis and more extensive subject follow -up 
should be undertaken . Additional event triggered testing for RCL  may  be conducted as clinicall y 
indicated, as specified in the Schedule of Activities (SoA).
Peripheral blood mononuclear cells will be retained for exploratory  analysis of the immune system 
which may include retroviral insertion analysis, T cell receptor (TCR) analy sis (both clonalit y 
and/or diversit y of TCR), functional in vitro assay s, or other . Biomarker analy ses are dependent 
upon the availability  of appropriate biomarker assay s and may be deferred or not performed if 
during or at the end of the stud y it becomes clear that the anal ysis will have no scientific value, or 
if there are not enough samples or not enough responders to allow for adequate biomarker 
evaluation. In the event the study  is terminated early  or shows poor clinical efficacy , completion 
of biomarker assessments is based on theintended utility  of the data .
Based on emerging scientific evidence, the sponsor may request additional material from 
previously  collected bone marrow samples during or after study  completion for a retrospective 
analysis. For subjects diagnosed with a SPM, a tumor sample should be collected. Additionally , 
the sponsor should receive a sample of plasmacy toma if a plasmacy toma biopsy  is performed for 
any reason, including during screening. Subjects who have a lumbar puncture as part of their 
neurologic work up should have cerebral spinal fluid for additional test by the sponsor . Inthis case, 
such analyses would be specific to research related to the study  treatment(s) or diseases being 
investigated. If a subject dies and an autopsy  is performed, specimens may be requested by the 
sponsor for analy sis, as allowe d by local regulations.
9.4.1. Pharmacody namic/Predictive Markers 
The baseline of the JNJ-68284528 subsets and dynamic changes/persistence and activation of 
CAR -positive viable T cells may be associated with the depth and durability  of response. An 
evaluation of these cell populations may be performed by  flow cy tometry  or cy tometry  by time of 
flight (CyTOF) or both and correlated with response. Additional immunophenoty ping may be 
performed on bone marrow aspirate and whole blood sample sto evaluate expression of biomarkers 
on myeloma cells (such as BCMA and PD-L1) and immune cell populations (such as CD4+and 
CD8+T cells) by flow cytometry ,orCyTOF ,or next generation sequencing (whole exome and 
RNA sequencing) or both. T cell receptor (TCR) sequencing may be performed to study  T cell 
clonality  that may affect drug response. Samples may be characterized by gene expression 
profiling and somatic mutation analy sis by next generation sequencing (whole exome and RNA 
sequencing) to evaluate potentia l biomarkers that may correlate with response. Samples may be 
evaluated by other similar technologies to evaluate protein or RNA expression or for somatic DNA 
analysis.
Circulating serum biomarkers present following chemotherap y conditioning and following 
infusion of CAR -T cells have been associated with response to some CAR -T cell based therapies. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Status: Approved ,  Date: 15 June 2022Evaluation ofcytokines (such as IL-6, IL-15, IL-10, and IFN-)andother circulating proteins 
(such as granzy mes and perforin) will be analyzedto identify  potential pharmacod ynamic and 
predictive biomarkers of response or resistance.
9.4.2. Minimal Residual Disease 
Minimal residual disease (MRD) negativity  is being evaluated as a potential surrogate for PFS and 
OSin multiple myeloma treatment . MRD will be monitored i n subjects using next generation 
sequencing (NGS) on bone marrow aspirate DNA. Baseline bone marrow aspirates will be used to 
define the my eloma clones, and post- treatment samples will be used to evaluate MRD negativit y. 
A fresh bone marrow aspirate will b e collected prior to the first dose of conditioning regimen ( ≤7 
days). If the NGS MRD method is unavailable, or determined to be scientifically  inferior , then 
alternative methods for MRD assessment may be utilized. Additional timepoints for MRD 
assessment are reflected in the Time and Events schedule ( Table 2).
In the event fresh bone marrow aspirate will not be collected at Baseline, or if the fresh aspirate 
does not yield a usable clone, non-decalcified diagnostic tissue (bone marrow aspirate slides or 
formalin -fixed paraffin embedded tissue) should be collected for calibration of myeloma cells to 
facilitate the assessment of the MRD endpoints by NGS.
9.5. Pharmacokinetic/Pharmacody namic Evaluations 
Pharmacokinetic/pharmacody namic modeling will be e xplored to understand and characterize the 
dose-response relationship.
9.6. Efficacy  Evaluations 
Disease evaluations must be performed as specified in the Time and Events Schedule Table 1. 
Disease evaluations will be performed by a central laboratory  (additional samples may be collected 
for analysis by the local laboratory ) until disease progression, death, start of a new anticancer 
treatment, withdrawal of consent for study participation, or end of the study , whichever occurs 
first. However, if a subject receives retreatment with JNJ-68284528 after a confirmed disease 
progression (see Section 3.1), then disease evaluations will continue according to the Time and 
Events schedule provided in Attachment 9. This study  will use the IMWG- based response 
criteria.30If it is determined that the stud y treatment interferes with the immunofixation assay , CR 
will be defined as the disappearance of the original M-protein associated with multiple myeloma 
on immunofixation, and the determination of CR will not be affected by unrelated M- proteins 
secondary  to the study  treatment .11
For quantitative immunoglobulin (QIg) at baseline, M-protein, immunofixation, and free-light 
chain (FLC)measurements in serum and 24-hour urine, the investigator will use results provided 
by the central laboratory. Disease progression must be consistently  documented across clinical 
study  sites using the criteria in Attachment 1. 
All efforts should be made to collect efficacy  data centrally . However, local laboratory  data may 
be collected if central laboratory  data is not available at a particular timepoint, however this does 
not include screening assessments. Documentat ion of the local laboratory  data should be sent to 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 92
Status: Approved ,  Date: 15 June 2022the Principal Investigator and filed in the medical record. It is the Principal Investigator’s 
responsibility  to ascertain that these results are reviewed and entered into the subject’s medical 
record and the eCRF.
9.6.1. Myeloma Protein Measurements in Serum and Urine
Blood and 24-hour urine samples for M-protein measurements will be sent to and analyzed by a 
central laboratory . Only  one serum and one 24-hour urine sample per time point are required by 
the central laboratory  to perform the following tests. Assessments will be performed as specified 
in the Time and Events Schedule ( Table 1and Table 12).
Serum quantitative Ig 
Serum protein electrophoresis (SPEP)
Serum immunofixation electrophoresis
Serum FLC assay (for subject in suspected CR/sCR and every  disease assessment for subjects
with serum FLC only  disease)
24-hour urine M -protein quantitation by  electrophoresis (UPEP)
Urine immunofixation electrophoresis 
Serum β 2-microglobulin 
Blood and 24-hour urine samples will be collected as specified in the Time and Events Schedul e 
Table 1and Table 12until the development of confirmed disease progression. Disease progression 
based on one of the laboratory  tests alone must be confirmed by at least 1 repeat investigation. 
Disease evaluations will continue beyond relapse from CR until disease progression is confirmed. 
Serum and urine immunofixation and serum free light chain assays will be performed at screening 
and thereafter when a CR is suspected (when serum or 24-hour urine M-protein electrophoresis 
[by SPEP or UPEP] are 0 or non-quantifiable). For subjects with light chain multiple myeloma, 
serum and urine immunofixation tests will be performed routinel y as per the Time and Events 
Schedule (Table 1and Table 12).
9.6.2. Serum Calcium Corrected for Albumin
Blood samples for calculating serum calcium corrected for albumin will be collected and analyzed 
centrall y until the development of confirmed disease progression. Development of hypercalcemia 
(corrected serum calcium >11.5 mg/dL [>2.9mmol/L ]) may indicate disease progression or 
relapse if it is not attributable to any other cause . Calcium binds to albumin and only  the unbound 
(free) calcium is biologically  active; therefore, the serum calcium level must be adjusted for 
abnormal albumin levels (“corrected serum calcium”). The formula for ad justm ent is presented in 
Attachment 7.
9.6.3. Bone Marrow Examination
Bone marrow aspirate or biopsy  (acceptable if aspirate is not possible) will be performed for 
clinical assessments. Bone marrow aspirate will be performed for biomarker evaluations. Clinical 
staging (morphology , cytogenetics, and immunohistochemistry  or immunofluorescence or flow 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Status: Approved ,  Date: 15 June 2022cytometry ) should be done by a local laboratory . Aportion of the bone marrow aspirate will be 
sent to the central laboratory  for immunophenotyping and to monitor BCMA, checkpoint ligand 
expression in CD138- positive multiple myeloma cells, and checkpoint expression on T cells. If 
feasible, bone marrow aspirate also will be performed to confirm CR and sCR and at disease 
progression. In addition ,MRD will be evaluated as specified in the Time and Events schedules.
9.6.4. Skeletal Survey
A skeletal survey (including skull, entire vertebral column, pelvis, chest, humeri, femora, and an y 
other bones for which the investigator suspects involvement by disease) is to be performed during 
the screening phase and evaluated b y the local laboratory b yeither roentgenography  (“X-rays”)or 
low-dose computed tomography  (CT)scans with out the use of IV contrast. If a CT scan is used it 
must be of diagnostic quality . Following JNJ-68284528 infusion, and before disease progression 
is confirmed, X-raysor CT scans should beperformed locally ,whenever clinically  indicated based 
on symptoms, to document response or progression. Magnetic resonance imaging (MRI )is an 
acceptable method for evaluation of bone disease, and may be included at the discretion of the 
investigator; however, it does not replace the skeletal survey  (see the disea se response criteria in 
Attachment 1). If a radionuclide bone scan is used at screening ,in addition to the complete skeletal 
survey , then both methods must be used to document disease status. These tests must be performed 
at the same time. Note: a radionuclide bone scan does not replace a complete skeletal survey.
If a subject presents with disease progression manifested by symptoms of pain due to bone 
changes ,then disease progression may be documented by skeletal survey  or other radiographs, 
depending on the s ymptoms that the subject experiences. If the diagnosis of disease progression is 
obvious by radiographic investigations, then no repeat confirmatory  X-rays are necessary .If 
changes are equivocal, then a repeat X -ray isneeded in 1 to 3 weeks.
9.6.5. Documentation of Extramedullary  Plasmacytomas
Sites of known extramedullary  plasmacy tomas must be documented ≤14 days prior to the first 
dose of the conditioning regimen . Clinical examination or MRI may be used to document 
extramedullary  sites of disease. CT scan evaluations are an acceptable alternative if there is no 
contraindication to the use of IV contrast. Positron emission tomography  scan or ultrasound tests 
are not acceptable to document the size of extramedullary plasmacy tomas. However, PET/CT 
fusion scans can be used to document extramedullary  plasmacy tomas if the CT component of the 
PET/CT fusion scan is of sufficient diagnostic quality .
Extramedullary  plasmacy tomas should be assessed for all subjects with a history  of 
plasmacy tomas or if clinically  indicated at ≤14 days prior to the first dose of the conditioning 
regimen, by clinical examination or radiolog ic imaging. Assessment of measurable sites of 
extramedullary  disease will be performed , measured, and evaluated locally  every 4 weeks (for 
physical examination) for subjects with a history  of plasmacy tomas or as clinicall y indicated 
during treatment for other subjects until development of confirmed CR or confirmed disease 
progression. If assessment can only be performed radiologically , then evaluation of extramedullary  
plasmacy tomas may be done every  12 weeks. The methodology  used for evaluation of each disease 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Status: Approved ,  Date: 15 June 2022site should be consistent across all visits. Irradiated or excised lesions will be considered not 
measurable, and will be monitored only  for disease progression.
To qualify  for VGPR or PR/minimal response (MR), the sum of products of the perpendicul ar 
diameters of the existing extramedullary  plasmacy tomas must have decreased by over 90% or at 
least 50%, respectivel y, and new plasmacy tomas must not have developed (see the disease 
response criteria inAttachment 1). To qualify  for disease progression, either the sum of products 
of the perpendicular diameters of the existing extramedullary plasmacy tomas must have increased 
by at least 50%, or the longest diameter of previous lesion >1cm in short axis must have increased 
at least 50%, or a new plasmacy toma must have developed. When not all existing extramedullary  
plasmacy tomas are reported, but the sum of products of the perpendicular diameters of the reported 
plasmacy tomas have increased by  at least 50%, th en the criterion for disease progression is met .
9.7. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. Instructions for the collection, handling, storage, and shipment of samples are 
found in the Laborator y Manual that will be provided. Collection, handling, storage, and shipment 
of samples must be under the specified, and where applicable, controlled tempe rature conditions 
as indicated in the Laboratory  Manual. Refer to the Time and Events Schedule 
(Table 1 and Table 2) for the timing and frequency  of all sample collections.
9.8. Patient -reported Outcome A ssessments (Phase 2 Only)
The subjects’ HRQoL (disease -related symptoms, functioning, and general well-being) will be 
captured using patient -reported outcome (PRO )measures. The PRO measures will be administered
for the Phase 2 part of the study , during site visit s, to understand how thePRO endpoints change 
over time. These measures will be administered according to the Time and Events Schedule (Table 
1); to becompleted by the subjects before any clinical tests, procedures, or other consultations that 
would influence subject’s perceptions of their current health state. The PRO measures will be 
provided in the local language. If a subject requires assistance completing the PRO assessment , a 
study  coordinator may assist but should not prompt the subject in selecting their response. At 
completion, the study  coordinator should verify that the questionnaires are completed in full or 
document the reason for missing information . Full training documentation will be provided to site 
coordinators before the start of data collecti on.PRO assessments will be conducted beyond disease 
progression or subsequent anticancer therapy . If no site visits are scheduled for additional disease 
evaluations, subjects will have the option of completing the PRO assessments after disease 
progression or subsequent anticancer therap y via telephone.
Samples of the PRO measures are provided in Attachment 10:
EORTC QL Q-C30
EORTC QL Q-MY20: 4 single items
EQ-5D- 5L
PGIS 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Status: Approved ,  Date: 15 June 2022PGIC 
The EORTC -QLQ -C30 version 3 includes 30 items in 5 functional scales (physical, role, 
emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, 
nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, 
diarrhea, and financial difficulties). The recall period is 1 week (“past week”) and responses are 
reported using a verbal rating scale. The item and scale scores are transformed to a 0 to 100 scale. 
A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. The 
EORTC QLQ-C30 has been widel y used among patients with multiple myeloma. Reliability , 
validity , and clinicall y meaningful change have been demonstrated.32,33The EORTC QLQ -MY20 
was designed to use alongside the EORTC QLQ -C30 to address issues of more relevance to 
myeloma patients.8Four single items from the EORTC QLQ -MY20 will be administered to assess 
emotional health status (feel restless or agitated, thinking about your illness, worried about dying, 
worried about health in the future). Recall, response options, and interpretation are similar to the 
EORTC QL Q-C30.
The EQ-5D- 5L is a generic measure of health status. For purposes of this study , the EQ-5D- 5L 
will be used to generate utility  scores for use in cost- effectiveness analyses. The EQ-5D- 5L is a 
5-item questionnaire that assesses 5 domains including mobility , self-care, usual activities, 
pain/discomfort and anxiety /depression plus a visual analog scale rating “health today ” with 
anchors ranging from 0 (worst imaginable health state) t o 100 (best imaginable health state). The 
scores for the 5 separate questions are categorical and cannot be analyzed as cardinal numbers. 
However, the scores for the 5 dimensions are used to compute a single utility  score ranging from 
zero (0.0) to 1 (1.0) representing the general health status of the individual (values less than 0 are 
possible when using the UK scoring algorithm) . The EQ-5D- 5L asks respondents to select their 
response based on their current health (“today ”) and takes less than 5 minutes to complete.
The Patient Global Impression of Severit y (PGIS) is a single item to assess severit y of pain. 
Subjects are asked to rate the severity  of their current pain on a 5-point verbal rating scale. The 
Patient Global Impression of Change (PGIC) is a single item to assess the subject’s perception in 
change of their overall health status using a 7-point verbal rating scale. The PGIC is only 
administered post -infusion.
9.9. Qualitative Interviews (Phase 2 Only )
Subjects enrolled in Phase 2 portion of the study  will have the option of participating in pre-
treatment (at screening ) and post-treatment (Day 100 and approximately  6 m onths post infusion 
with JNJ -68284528 ) semi -structured interviews.
Pre-and post-treatment interviews have been used in early  phase clinical trials to inform 
exploratory  insight into subject experiences. The data from these interviews will not be reconciled 
with the safety  database of the study . These interviews are semi -structured and are designed to 
allow subjects to provide their own impressions of JNJ-68284528 and not be restricted to items 
included in standard questionnaires. Interviewers will be trained on the interview guide and
provided with note -taking pages to capture subject responses. Interviews will take place in the 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Status: Approved ,  Date: 15 June 2022local language and will be audiotaped with approval of the subject for transcription and content 
analysis. The content analy sis will present the qualitative themes that emerge from the narrative 
data.
9.10. Medical Resource Utilization
Health economics data such as medical resource utilization data, associated with medical 
encounters, will be collected in the CRF by the investigator and study -site personnel for all Phase 2 
subjects throughout the study . Protocol -mandated procedures, tests, and encounters are excluded. 
As per Table 1, all medical care encounters since the previous collection will be collected for all 
Phase 2 subjects. Medical resource evaluation data will be collected until Day 180 (± 7 days). 
Health economics data such as costs associated with the medical encounters will be collected 
separately from the eCRF. All health economic data will be used onl y in a de -identified manner.
The data collected may  be used to conduct exploratory  economic analy ses and will include:
Number and duration of medical care encounters, including surgeries, radiographic 
diagnostics, laboratory  tests, and other selected procedur es (inpatient and outpatient)
Duration of hospitalization (total days length of stay, including duration by wards; eg, 
intensive care unit)
Number and character of diagnostic and therapeutic tests and procedures
Outpatient medical encounters and treatments (including physician or emergency  room visits, 
tests and procedures, and medications)
10. SUBJECT COMPLETION/DISCONTINUA TION OF STUDY TREATMENT/ 
WITHDRA WAL FROM THE STUDY
10.1. Completion
A subject will be considered to have completed the study  if he or she dies before the end of the 
study ,has not been lost to follow -up or has not withdrawn consent for study  participation before 
the end of the study , defined as 2 y ears after the last subject has received his or her initial dose of 
JNJ-68284528 .
10.2. Discontinuation o f Study Treatment 
A subject should not receive JN J-68284528 if:
The investigator believes that for safet y reasons or tolerability  reasons (eg,adverse event) it 
is in the best interest of the subject to discontinue study treatment
Grade 3 nonhematologic toxicity  related to cyclophosphamide and fludarabine occurs, and 
precludes retreatment with cyclophosphamide and fludarabine prior to JNJ-68284528 infusion 
per Section 6.1
The subject received concurrent (non-protocol) anticancer treatment (with exception of 
sponsor -approved bridging therap y)
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Status: Approved ,  Date: 15 June 2022Confirmed disease progression per IMWG criteria (Attachment 1) between the time of 
conditioning therap y and infusion of JN J-68284528 . 
Subject refuses further study  treatment
Noncompliance with study  treatment or procedure requirements
The primary  reason for treatment discontinuation will be documented in the eCRF and source 
documents, and the subject should be followed per standard of care until recovery  from bridging 
therap y or cyclophosphamide and fludarabine conditioning regimen. If a subject's study  treatment 
is discontinued for any  reason, this will not result in automatic withdrawal of the subject from the 
study .
10.3. Withdrawal f rom the Study
A subject will be withdrawn from the study  for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
Failure to manufacture JNJ-68284528 after 2 apheresis attempts
The sponsor discontinues the study  
The reason(s) for subject withdrawal will be recorded on the eCRF and source documents. If a 
subject is lost to follow -up, every  reasonable effort must be made by the study -site personnel to 
contact the subject and determine the reason for discontinuation/withdrawal. The measures taken 
to follow -up must be documented.
If a subject withdraws consent following dosing with JNJ-68284528, study assessments for the 
last visit in the post-infusion period (Table 1: Day 100; Table 2: Day 100) should be completed 
prior to withdrawal of consent, if feasible.
10.4. Withdrawal f rom the Use of Research Samples
Withdrawal from the use of samples is future research
The subject may withdraw consent for use of samples for future research (refer to Section 16.2.5 , 
Long -Term Retention of Samples for Additional Future Researc h). If this occurs , then samples 
will be destroyed after they are no longer needed for the clinical study. Details of sample retention
for research are presented in the ICF.
11. STATISTICA L METHODS 
Statistical analy sis will be done by the sponsor or under theauthority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Status: Approved ,  Date: 15 June 2022Continuous variables will be summarized using the number of observations, mean, standard 
deviation, coefficie nt of variation, median, and range as appropriate. Categorical values will be 
summarized using the number of observations and percentages as appropriate.
The efficacy  and safet y data will be summarized separately  for Phase 1b and Phase 2 part. Pooling 
of the two parts maybe considered when appropriate. Specific details will be provided in the 
Statistical Analy sis Plan. 
11.1. Subject Information
The anal ysis populations for this study  are defined as follows:
Modified Intent -To-Treat (mITT) Analysis Set :This set consists of subjects who received 
a JNJ-68284528 infusion at the targeted RP2D dose and will be considered as the primary 
analysis set for all efficacy  summaries.
All Treated Analysis Set: This set consists of subjects who received JNJ-68284528 infusion
andwill be considered as the primary analy sis set for safety summaries.
Pharmacokinetic Analysis Set: This set consists of all subjects who receive dJNJ-68284528
infusion and have at least 1 post -dose pharmacokinetic sample.
Immunogenicity Analysis Set: This set consists of all subjects who receive dJNJ-68284528
infusion and have at least 1 post- dose immunogenicity  sample.
11.2. Sample Size Determination
At least 24 and up to approximately  50 subjects will be treated in Phase 1b part to establish the 
RP2D and assess safety . With 24 treated subjects, if the true incidence rate of certain adverse 
events (refer toTable 3) is 10%, the probability  of observing at least one subject experiencing 
event is more than 90%. The probability  of detecting at least one subject experiencing a certain 
adverse event under the assumed true incidence rate based on plausible sample sizes is provided
in Table 11.
Table 11: Sample Size Scenarios in Phase 1b
Sample Size in Phase 1bTrue incidence rate of the adverse 
eventProbability of observing at least one subject 
experiencing the adverse event
24 10% 92%
40 6% 91.6%
50 5% 92.3%
For therapies available to treat subjects with relapsed orrefractory  multiple myeloma at the time 
that this protocol was written (including daratumumab), the reported ORR is 30% or less.
The sample size for the Phase 2 portion of the study assumes that the overall response rate will be 
at least 50%. With 60 subjects treated with JNJ-682845 28 in the Phase 2 portion of the study , there 
will beapproximately  90% power to declare the ORR is higher than 30% at the 1-sided 
significance level of 0.025. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Status: Approved ,  Date: 15 June 202211.3. Efficacy  Analyses 
Endpoint Definitions :
Overall response rate (ORR) is defined as the proportion of subjects who achieve a PR or better 
according to the IMWG criteria.10,11,30
VGPR or better response rate (sCR+CR+VGPR) is defined as the proportion of subjects who 
achiev e a VGPR or better response according to the IMWG criteria.10,11,30
Duration of response (DOR) will be calculated among responders (with a PR or better response) 
from the date of initial documentation of a response (PR or better) to the date of first documented 
evidence of progressive disease, as defined in the IMWG criteria. Relapse from CR by positive 
immunofixation or trace amount of M-protein is not considered as disease progression. Disease 
evaluations will continue beyond relapse from CR until disease progression is confirmed. For 
subjects who have not progressed, data will be censored at the last disease evaluation before the 
start of an y subsequent anti -myeloma therapy .
Time to response (TTR) is defined as the time between date of the initial infusion of JNJ-68284528
and the first efficacy  evaluation that the subject has met all criteria for PR or better. For subjects
without response, data will be censored e ither at the date of progressive disease, or in the absence 
of progressive disease, at the last disease evaluation before the start of subsequent anti-myeloma 
therap y.
Progression- free survival (PFS) defined as the time from the date of the initial infusion of 
JNJ-68284528 to the date of first documented disease progression, as defined in the IMWG 
criteria, or death due to any cause, whichever occurs first. For subjects who have not progressed 
and are alive, data will be censored at the last disease evaluat ion before the start of any subsequent 
anti-myeloma therap y.
Overall survival (OS) is measured from the date of the initial infusion of JNJ-68284528 to the date 
of the subject ’s death. If the subject is alive or the vital status is unknown, then the subject ’s data 
will be censored at the date the subject was last known to be alive.
For efficacy , assessment by  the IRC will be used as primary .
The first analysis for the primary  endpoint, ORR (PR or better), will be conducted approximately 
at 6months af ter the last subject has received his or her initial dose of JNJ -68284528 , and will be 
based on the mI TTanalysis set . The response rate and its 95% exact confidence interval (CI) will 
be calculated based onbinomial distribution, and the null hy pothesis w ill be rejected if the lower 
bound of the confidence interval exceeds 30%. Analy sis of VGPR or better response rate, DOR , 
PFS, and OS will be conducted at the same cutoff as the ORR, and an update of these endpoints 
will be provided at approximately  9-12 months after the last subject has received his or her initial 
dose of JNJ -68284528 and at the end of the stud y, which is defined as 2 years after the last subject
has received his or her initial dose of JNJ-68284528. Additional safety  data will be collected in a 
long-term follow -up study .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Status: Approved ,  Date: 15 June 2022A sensitivity  analysis of ORR will be performed based on the subjects in the mITT analysis set 
who received the JNJ -68284528 product that met all of the pre -specified release criteria.
The agreement on ORR between the determination by  the IRC and the assessment by  a validated 
computerized algorithm developed by the sponsor will be evaluated using the kappa statistic and 
95% CI  will also be provided.
The distribution (median and Kaplan -Meier curves) of DOR will be provid ed using Kaplan -Meier 
estimates for subjects who achieved response during the study. Similar analysis will be performed 
for OS,PFS,and TTR for the mITT analy sis set . 
11.4. Safety  Analyses
All safety  anal yses are to be performed on data from the all treated analysis set. The baseline value 
for safety  assessment is defined as the value collected at the time closest to, but prior to, the start 
of JNJ-68284528 infusion . The safety  parameters to be evaluated are the incidence, severity , and 
type of adverse events, clinically  significant changes in the subject ’s physical examination 
findings, vital signs measurements, and clinical laboratory  results. Exposure to investigational 
product and reasons for discontinuation of study  treatment will be tabulated. Adverse even ts will 
be summarized by  system organ class, preferred term, worst grade e xperienced by the subject , and 
by dose level.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the Medical Dictionar y for Regulatory  Activities (MedDRA) . Treatment -emergent adverse 
events are adverse events with onset after JNJ-68284528 infusion or that are a consequence of a 
pre-existing condition that has worsened since baseline. All reported treatment -emergent advers e 
events will be included in the analysis. For each adverse event, the percentage of subjects who 
experience at least 1 occurrence of the given event will be summarized by  dose group.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, experience an adverse event of special interest, discontinue treatment due to an 
adverse event, or who experience a severe or a serious adverse event.
Adverse event s that occur after administration of the conditioning regimen and before 
JNJ-68284528 infusion will be summarized and listed separatel y.
Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analysis Plan or Data Presentation Plan) will be used 
in the summary  of laboratory  data. Descriptive statistics will be calculated for each laboratory 
analyte at baseline and for observed values and changes from baseline at each scheduled time 
point. Worst toxicity  grade during treatment will be presented according to NCI -CTCAE Version 
5.0. Change from baseline to the worst toxicity  grade experienced by  the subject during the study 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Status: Approved ,  Date: 15 June 2022will be provided as shift tables. A listing ofsubjects with any laboratory  results outside the 
reference ranges will be provided.
Electrocardiogram 
The interpretation of the ECGs as determined by a qualified physician (investigator or qualified 
designee) will be summarized at scheduled time points.
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory  rate, and blood pressure (systolic 
and diastolic) values and changes from baseline will be summarized at each scheduled time point. 
The percentage of subjects with values bey ond clinically  important limits will be summarized.
11.5. Pharmacokinetic A nalyses
All concentrations below the lowest quantifiable concentration or missing data will be labeled as 
such in the concentration database. Concentrations below the lowest quantifiable concentration 
will be treated as zero in the summary  statistics. Descriptive statistics will be used to summarize 
CAR -T positive cell count and transgene level at each sampling timepoint .
Description on the planned anal yses for Cmax, AUC, Tmax, 
Responder vs. non-responder anal yses
If sufficient data are available, population -PK analysis of peripheral JNJ-68284528 cellular 
concentration and transgene level -time data of JNJ-68284528 may be performed. If the population -
PK analy sis is conducted, details will be given in a population- PK anal ysis plan and the results of 
the analysis will be presented in a separate report. Exposure -response analyses may also be 
performed; if performed, details will be provided in a separate anal ysis plan and report.
11.6. Pharmacokinetic/Pharmacody namic A nalyses
If sufficient data are available, then other PK/ph armacod ynamic modeling may be performed, 
including exploring the relationship between JNJ-68284528 cellular concentrations, transgene 
levels , pharmacod ynamic markers (eg, sBCMA, M -protein) and endpoints of clinical efficacy and 
safet y. If performed, details and results of the analysis will be presented in a separate report.
11.7. Immunogenicity  Analyses
The incidence of anti-JNJ-68284528 antibodies will be summarized for all subjects who receive 
JNJ-68284528 and have appropriate samples for detection of antibodie s to JNJ-68284528
(ie,subjects with at lea st 1 sample obtained after theinfusion of JNJ-68284528 ).The results will 
be summarized by  dose level for subjects with appropriate samples for the detection of antibodies 
to JNJ-682 84528 .
Immunogenicit y analyseswill be descriptive in nature and will include the number and percentage 
of subjects who developed anti-JNJ-68284528 antibodies. The effect of anti-JNJ-68284528
antibodies on pharmacokinetics, safet y, and efficacy may  also be evaluated.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Status: Approved ,  Date: 15 June 202211.8. Patient -reported Outcome A ssessments (Phase 2 Only)
The EORTC QLQ-C30, EORTC QLQ -MY20 (4items), EQ-5D- 5L utility  and visual analog 
scores , PGIC, and PGIS will be descriptivel y summarized at each time point. Meaningful and 
sustained improvement in subject’s HRQoL comparative to their baseline health status will be 
evaluated using established meaningful change thresholds .12Within -group change of the PRO 
endpoints will be assessed by change from baseline (screening phase) using mixed models for 
repeated measures. 
11.9. Medical Resource Utilization
Medical resource utilization data will be summarized in descriptive statistics of medical encounters 
(eg, length of stay , inpatient, outpatient, test, and reason). 
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requireme nts worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Ev ent
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non -investigational) product, whether or not related 
to that medicinal (investigational or non-investigational) product. (Definition per International 
Conference on Harmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse event recording).
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Status: Approved ,  Date: 15 June 2022Serious Adverse Event
A serious adverse event based on ICH and European Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is an y untoward medical occurrence that at any  dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or pr olongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientif ic judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be immediatel y 
life threatening or result in death or hospitalization but may  jeopardize the subjector may require 
intervention to prevent one of the other outcomes listed in the definition above. These should 
usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  treatment and the event (eg, death from anaphy laxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a component 
of the study endpoint (eg, all -cause mortality ). 
Unlisted (Unexpected) Adver se Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For JNJ-68284528 , the expectedness of an adverse event 
will be determined b ywhether or not it is listed in the I nvestigator's Brochure. 
Adverse Event Associated w ith the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by the definitions listed in Section 12.1.2 , Attribution Definitions .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Status: Approved ,  Date: 15 June 2022Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive. 
An alternative explanation is less likely , eg, concomitant drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explai ned 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship in 
time is very  suggestive.
12.1.3. Severity Criteria
An assessment of severity  grade will be made by the investigator according to the NCI CTCAE
Version 5.0, with the exception of CRS and CAR -T cell-related neurotoxicity  (eg, ICANS). CRS 
should be evaluated according to the ASBMT consensus grading (Lee 2019 )22(Attachment 11). 
CAR -T cell-related neurotoxicity  (eg, ICANS) should be graded using the ASBMT consensus 
grading (Attachment 13).Any adverse event or serious adverse event not listed in the NCI CTCAE 
Version 5.0 will be graded according to investigator clinical judgment by using the standard grades 
as follows:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental activities of daily living.*
Grade 3 Severe or medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care activities of daily 
living .**
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to adverse event .
Activities of Daily Living (ADL)
* Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.
** Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Status: Approved ,  Date: 15 June 202212.2. Special Reporting Situations
Safety  events of interest on a sponsor study  treatment that may require expedited reporting or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  treatment
Suspected abuse/misuse of a sponsor study  treatment
Accidental or occupational exposure to a sponsor study  treatment
Medication error involving a sponsor product (with or without subject /subjec texposure to the 
sponsor study  treatment , eg, name confusion)
Exposure to a sponsor study  treatment from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious advers e event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events (with the exception of neurological adverse events, second primary 
malignancies, see Section 12.3.3 , HBV  reactivation , and COVID -19 infection ) and special 
reporting situations, whether serious or non-serious, will be reported from the time a signed and 
dated ICF is obtained until 100 days after last administration of any study treatment or until the 
start of subsequent systemic anticancer therapy , ifearlier , andmay include contact for follow -up 
of safety .After 100 days, only  adverse events that are considered related to study  drug need to be 
reported until the end of the study . Events of HBV reactivations and COVID -19 infection, and
new neurologica l adverse events or exacerbation of existing neurologic adverse events will be 
reported during the first y ear post -dosing of JNJ-68284528 . Adverse events of special interest are 
defined in Section 12.3.3 . Anticipated adverse events are defined in Attachment 14.
Serious adverse events, including those spont aneously  reported to the investigator must be reported 
using the Serious Adverse Event Form. The sponsor will evaluate any safety  information that is 
spontaneously  reported by an investigator beyond the time frame specified in the protocol . All 
events thatmeet the definition of a serious adverse event will be reported as serious adverse events, 
regardless of whether they are protocol -specific assessments. See Attachment 18for additional 
adverse event reporting guidance for this study .
All adverse events, regardless of seriousness, severity , or presumed relationship to study  treatment, 
must be recorded using medical terminology  in the source document and the eCRF. Whene ver 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory  infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study  therapy . All measures required for adverse event 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Status: Approved ,  Date: 15 June 2022management must be recorded in the source document and reported according to sponsor 
instructions.
Exceptions:
Expected progression of disease should not be considered an adverse event (or serious adverse 
event ). However, if determined by the investigator to be more likely  related to the study  
treatment than the underly ing disease, the clinical signs or symptoms of progression and the
possibility  that the study treatment is enhancing disease progression, should be reported per 
the usual reporting requirements (see Section 12.1).
All deaths not related to disease progression, regardless of attribution, should be reported to the 
sponsor following expedited reporting procedures.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorit ies. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions . 
The investigator (or sponsor where required) must report suspected unexpected serious adverse 
reactions to the appropriate I ndependent Ethics Committee/I nstitutional Review Board (IEC/I RB) 
that approved the protocol unless otherwise required and documented b y the IEC/I RB.
For all studies with an outpatient phase, including open -label studies, the subject must be provided 
with a "wallet (study )card" and instructed to carry  this card with them for the duration of the study  
indicating the following (at minimum) :
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject numb er
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact person b ystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed b y a physician from the study  site, and 
transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious adverse 
event should be made b y facsimile (fax) .
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Status: Approved ,  Date: 15 June 2022All serious adverse events that have not resolved by the end of the study , or that have not resolved 
upon discontinuation of the subject 's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  treatment or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)
Suspected transmission of an infectious agent b y a medicin al product will be reported as a serious 
adverse event. An y event requiring hospitalization (or prolongation of hospitalization) that occurs 
during the course of a subject 's participation in a study  must be reported as a serious adverse event , 
except hospi talizations for the following:
Routine monitoring h ospitalizations post-infusion required per protocol
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons such 
as pending placement in long- term care facility )
Surger y or procedure planned before entry  into the study  (must be documented in the eCRF ). 
Note: Hospitalizations that were planned before the signing of the ICF, and where the 
underly ing condition for which the hospitalization was planned has not worsened ,willnot be 
considered serious adverse events. Any adverse event that results in a prolongation of the 
originall y planned hospitalization is to be reported as a new serious adverse event.
The administration of blood or platelet transfusions. Hospitalization or prolonged 
hospitalization for a complication of such transfusion remains a reportable serious adverse 
event.
12.3.3. Adverse Events of Special Interest
Cytokine release syndrome, neurotoxicity  (including CAR -T cell-related neurotoxicity  
[eg,ICANS] and other neurotoxicities), TLS,and second primary  malignancy  of any grade will 
be followed as part of standard safety  monitoring activities by the sponsor, regardless of severit y 
or causality . These events should be reported to the sponsor in a timely  manner, irrespective of 
seriousness (eg,serious and nonserious adverse events). Events of CRS , TLS, and neurotoxicity
(anygrade) must be reported until 100 days after last administration of any study treatment or until 
the start of subsequent anticancer therap y, if earlier, and followed until recovery  or until there is 
no further improvement. 
Second primary  malignancies must be reported for the duration of the study , irrespective of 
treatment emergent status, and subsequentl y will be collected in a long-term follow -up study  
yearly until 15 years post dosing of JNJ -68284 528.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Status: Approved ,  Date: 15 June 2022The following events must be reported to the sponsor using the Serious Adverse Event Form within 
24 hours of awareness of the event, irrespective of seriousness or causality (eg, seriou s and 
nonserious adverse events): 
≥Grade 3 CRS,
≥Grade 3 neurotoxicity , 
≥Grade 3 tumor l ysis syndrome, 
Any grade movement and neurocognitive toxicity  (ie, parkinsonism),
Any grade second primary  malignancies.
Adverse events of special interest that are considered to be non-serious by the investigator are to 
be included on the serious adverse event form and in the eCRF. All adverse events of special 
interest of any grade should be followed until recovery  or until there is no further improvement.
12.3.4. Pregnancy
All initial reports of pregnancy in female subjects or partners of male subjects must be reported to 
the sponsor by the study -site personnel within 24 hours of their knowledge of the event using  
appropriate pregnancy  notification form. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, and ectopic pregnancy ) are considered 
serious adverse events and must be reported using the Serious Adverse Event Form. Any subject
who becomes pregnant during the study  must discontinue further study  treatment. Because the 
effect of the study  treatment on sperm is unknown, pregnancies in partners of male subjects included 
in the study  will be reported as noted above. Follow -up information regarding the outcome of the 
pregna ncy and any  postnatal sequelae in the infant will be required.
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed in the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects , investigators, 
and the sponsor , and are mandated b y regulatory  agencies worldwide. The sponsor has established 
procedures in conformity with regulatory requirements worldw ide to ensure appropriate reporting 
of PQC information; all studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Status: Approved ,  Date: 15 June 202213.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be maintained 
for further investigation if requested b y the sponsor.
13.2. Contacting Sponso r Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed in the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY TRE ATMENT INFORMA TION
14.1. Physical Description of Study Treatment
JNJ-68284528 therapy is a BCMA -directed geneticall y modified autologous T cell 
immunotherapy  that involves reprogramming a subject ’s T cells with a transgene encoding a 
chimeric antigen receptor (CAR) to identify  and eliminate BCMA -expressing malignant and 
normal cells. Upon binding to BCMA -expressing cells, the CAR transmits a signal to promote T 
cellexpansion, activation, target c ell elimination, and persistence of the JNJ-68284528 .
14.2. Packaging
JNJ-68284528 will be provided in an infusion bag with specific subject identifiers. 
JNJ-68284528 will be provided in an infusion bag with specific subject identifiers, this will include 
subject number and subject apheresis identification number or donor identification number (DIN), 
subject name and subject date of birth, as allowed by  local regulations.
14.3. Labeling
Study  treatment labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage 
JNJ-68284528 isprovided in a single -dose unit containing CAR -positive viable T cells based on 
the subject weight reported at the time of apheresis.
JNJ-68284528 therapy  contain s human cells geneticall y modified with a lentiviral vector . Follow 
local biosafet y guidelines applicable for handling and disposal of such products. The product is 
prepared from autologous blood collected by apheresis. JNJ-68284528 may carry a risk of 
trans mitting infectious viruses to healthcare professionals handling the product. Accordingl y, 
healthcare professionals should employ  universal precautions to avoid potential transmission of 
infectious diseases when handling the product.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Status: Approved ,  Date: 15 June 2022Detailed instructions for storage conditions and handling will accompany  clinical drug supplies to 
the clinical study  sites. The storage conditions and expiry  dates are indicated on the label. Refer to 
the IPPI for additional guidance on study  treatment preparation ,handling , and storage .
14.5. Drug A ccountability
Information in this section relates to study  treatment that is supplied to investigational sites from 
the study  sponsor.
The investigator is responsible for ensuring that all study  treatment received at the site is 
inventoried and accounted for throughout the study . The study  treatment administered to the 
subject must be documented on the drug accountability  form. All study  treatment will be stored 
and disposed of according to the sponsor's instructions. Study-site personnel must not combine 
contents of the study  treatment containers.
Study  treatment must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area under appropriate environmental 
cond itions. Unused study  treatment must be available for verification by the sponsor's study  site 
monitor during on -site monitoring visits. The return to the sponsor of unused study  treatment will 
be docu mented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes , infusion bags, andvials 
containing hazardous liquids, should be disposed of immediatel y in a safe manner and therefore 
will not be retained for drug accountability  purposes. 
Study  treatment should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel , or by a hospital/ clinic pharmacist. Study  treatment will be 
supplied only  to subjects participating in the study. The investigator agrees neither to dispense the 
study  treatment from, nor store it at, any site other than the study  sites agreed upon with the 
sponsor.
15. STUDY -SPECIFIC MATER IALS
The investigator will be provided with the follow ing supplies:
Study  protocol
Investigator 'sBrochure
ECG machine and manual
IPPI/ SIPPM (includes apheresis and cell processing instructions)
Laboratory  Manual
Interactive web response sy stem manual
Electronic data capture (eDC) manual
Sample I CF
Subject diaries and instructions/educational materials
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 111
Status: Approved ,  Date: 15 June 2022PRO instruments and completion guidelines (Phase 2)
Thermal printer and barcode scanner (for sites utilizing Vineti chain of custody /chain of 
identity  software in Phase 2)
16. ETHICA L ASPECTS
16.1. Study -specific Design C onsiderations 
Thorough scientific evaluation of any promising treatment before market authorization is an 
ethical requirement. In the continuing search for medications with improved efficacy  and safet y 
profiles, it is necessary  to fully  investigate and understand new products before exposure to the 
public . As discussed in Section 1.5, 74 subjects with relapsed or refractory  multiple myeloma have 
received treatment with LCAR -B38M CAR -T cells in a clinical study  setting. An analy sis of safet y 
data for these subjects demonst rated a manageable safet y profile consistent with its known 
mechanism of action. In view of the Legend 2 study  results and the prognosis forthe subject 
population being considered for thisstudy ,a positive risk-benefit profile is anticipated . Subjects 
will be closely  monitored throughout the study , as discussed throughout this protocol, for both 
safet y and clinical benefit.
Apheresis risks may include hypotension, faintness, blurry  vision, dizziness, coldness, sweating, 
infection, abnormal blood clottin g, allergic reaction, bleeding, seizures, abdominal cramps, and 
tingling in the limbs. Subjects will be closely  monitored during the procedure and will be evaluated 
for hospitalization in the case of CRS .
The blood sample collection scheme was designed to collect theminimum number of blood 
samples that accurately  and completel y describe the pharmacokinetic/pharmacody namic 
characteristics of the study  treatment. This minimizes the number of venipunctures and the total 
volume of blood collected from each subject during the study . The volume of blood to be drawn 
is considered to be customary  and acceptable for subjects participating in a cancer clinical study  
and is deemed reasonable over the timeframe of the study , based upon the standard of the American 
Red Cross. 
Potential subjects will be fully informed of the risks and requirements of the study  prior to enrollment 
and, during the study , subjects will be given any additional information that may affect their decision 
to continue participation. They  will be told that their consent to participate in the study  is voluntar y 
and may be withdrawn at any time with no reason given and without penalty or loss of benefits to 
which they would otherwise be entitled. Only subjects who are fully able to understand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntaril y will be 
enrolled.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 112
Status: Approved ,  Date: 15 June 202216.2. Regulatory  Ethics Compliance 
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that origina ted in the Declaration of 
Helsinki and that the study data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and comple te copies of the following documents (as required by  local regulations):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unl ess not required, as documented 
by the IEC/IRB)
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
subjects, data or study  conduct, unless required locally ), the ICF, applicable recruiting materials, 
and subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During t he study ,the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequenc es for subjects, data or study  conduct)
Revision(s) to I CF and any  other written materials to be provided to subjects
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 113
Status: Approved ,  Date: 15 June 2022If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries orpayment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the study 
treatment
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediat e hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct) , the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required.
At the end of the study , the investigator (or sponsor where required) will notify the IEC/IRB about 
the study completion (if applicable, the notification will be submitted through the head of 
investigational institution). 
16.2.3. Informed Consent 
Each subject must give written consent according to local requirements after the nature of the study  
has been fully expla ined. The ICF(s) must be signed before performance of any study -related 
activity . The ICF(s) that is/are used must be approved by both the sponsor and by the reviewing 
IEC/IRB and be in a language that the subject can read and understand. The informed consent 
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH 
and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw consent 
to participate at an y time. They  will be informed that choosing not to participate will not affect the 
care the subject will receive for the treatment of his or her disease. Subjects will be told that 
alternative treatments are available if they refuse to take part and that such refusal will not 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 114
Status: Approved ,  Date: 15 June 2022prejudice future treatment. Finally , they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow -up if needed and that their records may 
be accessed by health authorities and authorized sponsor personnel without violating the 
confidentiality of the subject, to the extent permitted by  the applicable law(s) or regulations. 
By signing the ICF the subject isauthorizing such access , which includes permission to obtain 
information about his or her survival status. It also denotes that the subject agrees to allow his or 
her study  physician to recontact the subject for the purpose of obtaining consent for additi onal 
safet y evaluations, and subsequent disease -related treatments, if needed. The physician may also 
recontact the subject for the purpose of obtaining consent to collect information about his or her 
survival status.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. After 
this explanation and before entry  into the study , consent should be appropriately  recorded by means 
of the subject's personally  dated signature. After having obtained the consent, a copy of the ICF 
must be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and 
should personally  date and sig n the ICF after the oral consent of the subject is obtained.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be limited 
to those data that are necessary  to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. 
For tracking and traceability  of the apheresis material and investigational product, subject name 
and date of birth, as allowed by local regulations, will be collected to ensure chain of identit y of 
the investigational product for the subject. Sponsor personnel whose responsibilities require access 
to personal data agree to keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original medical 
records (source data/documents) for study -related monitoring, audit, IEC/I RB review, and 
regulatory  inspection. This consent also addresses the transfer of the data to other entities and to 
other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps will 
be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 115
Status: Approved ,  Date: 15 June 2022Exploratory  biomarker, pharmacokinetic, and immunogenicit y research is not conducted under 
standards appropriate for the return of data to subjects. In addition, the sponsor cannot make 
decisions as to the significance of any findings resulting from explorato ry research. Therefore, 
exploratory  research data will not be returned to subjects or investigators, unless required by  law 
or local regulations. Privacy  and confidentiality  of data generated in the future on stored samples 
will be protected b y the same st andards applicable to all other clinical data.
16.2.5. Long -term Retention of Samples for A dditional Future Research 
Samples, including apheresis product, collected in this study  and JNJ-68284528 that was 
manufactured but not administered to a subject may be storedfor up to 15 years (or according to 
local regulations) for additional research. Samples will only be used to understand JNJ-6828452 8, 
understand multiple myeloma, understand differential drug responders, and develop tests/assay s 
related to JNJ-6828452 8. The research may begin at any time during the study  or the post-study 
storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.4, Withdrawal from the Use of Samples in Future 
Research).
16.2.6. Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise help 
ensure access to the developed product if the need for the product persists, unless explicitly  
addressed as a specific ethical consideration in Section 16.1, Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQUI REMENTS 
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify this proto col without a formal amendment b y 
the sponsor. All protocol amendments must be issued b y the sponsor, and signed and dated b y the 
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the subjects, in which case the amendment must be 
promptly  submitted to the IEC/IRB and relevant competent authorit y. Documentation of 
amendment approva l by the investigator and IEC/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IEC/I RB (where 
required) onl y needs to be notified.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 116
Status: Approved ,  Date: 15 June 2022During the study , when a departure from the protoco l is unavoidable, the investigator or other 
physician in attendance will contact the appropriate sponsor representative listed in the Contact 
Information page(s), which will be provided as a separate document. Except in emergency  
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source docum ents 
will reflect an y dep arture from the protocol, and the source documents will describe this departure 
and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  treatment to 
the study  site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) b y the chairma n or authorized designee.
Name and address of the IEC/IRB, including a current list of the I EC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person di d not participate in the deliberations or in the vote/opinion 
of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualificati ons (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulati ons
The following documents must be provided to the sponsor before enrollment of the first subject:
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 117
Status: Approved ,  Date: 15 June 2022Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), i f applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
reports andcommunications relating to the study  will identify  subjects by subject identification 
and date of birth (as allowed by  local regulations) . In cases where the subject is not enrolled into 
the study , the date seen and date of birth (as allowed by  local regulations) will be used.
For tracking and traceability  of the apheresis material and investigational product, subject name 
and date of birth, as allowed by local regulations, will be collected to ensure chain of identit y of 
the investigational product fo r the subject.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documents consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by the 
protocol; record of all adverse events and follow -up of adverse events; concomitant medication; 
drug receipt/dispensing/ret urn records; study  treatment administration information ; and date of 
study  completion and reason for early discontinuation of study  treatment or withdrawal from the 
study , if applicable. 
The author of an entry  in the source documents should be identifiabl e.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document).
The minimum source docum entation requirements for Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify a need for documented medical history are as follows:
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 118
Status: Approved ,  Date: 15 June 2022Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospital or clinic record to document medical care (eg, electronic source documents) as well as the 
clinical study -specific data fields as determined by the protocol. This data is electronically 
extracted for use b y the spons or. If the electronic source s ystem is utilized, references made to the 
eCRF in the protocol include the electronic source system but information collected through the 
electronic source s ystem may not be limited to that found in the eCRF. Data in this sy stem ma y be 
considered source documentation.
17.5. Case Report Form Completion
Case report forms are prepared and provided by  the sponsor for each subject in electronic format. 
All eCRF entries, corrections, and alterations must be made by the investigator or authorized 
study -site personnel. The investigator must verify  that all data entries in the eCRF are accurate and 
correct.
The study  data will be transcribed by study-site personnel from the source documents onto an 
eCRF, if applicable. Study- specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documents. Data must be entered into 
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
If necessary , queries will be generated in the eCRF tool. If corrections to an eCRF are needed after 
the initial entry  into the eCRF , this can be done in either of the following way s:
Investigator and study -site personnel can make corrections in the eCRF tool at their own 
initiative or as a response to an auto query  (generated by  the eCRF tool).
Sponsor or sponsor delegate can generate a query  for resolution by the investigator and study -
site personnel.
17.6. Data Quality  Assurance/Quality  Control 
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualifi ed 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by the sponsor, and where 
applicable direct transmission of clinical laboratory  data from a central laboratory  into the 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 119
Status: Approved ,  Date: 15 June 2022sponsor's data base. Written instructions will be provided for collection, handling, storage, and 
shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -site personnel before 
the start of the study. The sponsor will review eCRF for accuracy and completeness during on -site 
monitoring visits and after transmission to the sponsor; any discrepancies will be resolved with the 
investigator or designee, as appropriate. After upload of the data into the study database they  will 
be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by the applicable regulatory  requirement(s). The 
investigator/inst itution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an I CH region or until at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period 
if required by the app licable regulatory  requirements or by an agreement with the sponsor. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such reports.
17.8. Monitoring 
The sponsor will use a combination of monitoring techniques (central, remote, or on-site 
monitoring) to monitor this study .
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRF with the source documents 
(eg,hospital/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 120
Status: Approved ,  Date: 15 June 2022eCRF are known to the sponsor and study -site personnel and are accessible for verification by the 
sponsor study -site contact. If electronic records are maintained at the study  site, the method of 
verification must be discussed with the study -site personnel. 
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review w ill 
be discussed with the study -site personnel. The sponsor expects that, during monitoring visits, the 
relevant study -site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study-related documents. The monitor will 
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct.
In addition to on -site monitoring visits, remote contacts can occur. It is expected that during these 
remote cont acts, study -site personnel will be available to provide an update on the progress of the 
study  at the site. 
17.9. Study Completion/Termination
17.9.1. Study Completion/End of Study
The end of the study  will be defined as 2 years after the last subject has received his or her initial 
dose of JNJ -68284528 . The final data from the study  site will be sent to the sponsor (or designee) 
after completion of the final subject assessment at that study  site, in the time frame specified in the 
Clinical Trial Agreement.
17.9.2. Study Termin ation
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study  sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been collected 
and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at a ny time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study  site by the sponsor or investigator may include but are not 
limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  treatment development
17.10. On-site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 121
Status: Approved ,  Date: 15 June 2022with regulatory  guidelines and company  policy . These audit s will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be respected. 
The investigator and study -site personnel are responsible for being present and available for 
consultation during routinely scheduled study -site audit visits conducted by the sponsor or its 
designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or she has 
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication 
All information, including but not limited to information regarding JNJ-68284528 or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and an y data, including exploratory  biomarker research data, generated as a 
result of this study , areconsidered confidential and remain the sole property  of the sponsor. The 
investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of JNJ-68284528 , and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a CSR generated by  the sponsor and will contain data 
from all study  sites that participated in the study  as per protocol. Recruitment performance or 
specific expert ise related to the nature and the key assessment parameters of the study  will be used 
to determine a coordinating investigator for the study . Results of exploratory  biomarker analyses 
performed after the CSR has been issued will be reported in a separate r eport and will not require 
a revision of the CSR. Study  subject identifiers will not be used in publication of results. Any work 
created in connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by the investigator as provided for below) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, t he sponsor shall have the right to publish such primary  (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 122
Status: Approved ,  Date: 15 June 2022writing, the investigator will withhold such publication for up to an additional 60days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulator y compliance, the sponsor will review these issues with the investigator. The sponsor will 
not mandate modifications to scientific content and does not have the right to suppress information.
Formulticenter stud y designs and substud y approaches, secondary results generall y should not be 
published before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study by not submitting for publication data derived 
from the individual study  site until the combined results from the completed study have been 
submitted for publication, within 18 months of the availability  of the final data (tables, listings, 
graphs), or the sponsor confirms there will be no multicenter study  publication. Authorshi p of 
publications resulting from this study  will be based on the guidelines on authorship, such as those 
described in the ICMJE Recommendations for the Conduct, Reporting, Editing and Publication of 
Scholarly  Work in Medical Journals, which state that the named authors must have made a 
significant contribution to the conception or design of the work; or the acquisition, analy sis, or 
interpretation of the data for the work; and drafted the work or revised it critically  for important 
intellectual content; andgiven final approval of the version to be published; and agreed to be 
accountable for all aspects of the work in ensuring that questions related to the accuracy  or integrity 
of an y part of the work are appropriatel y investigated and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required 
by law.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 123
Status: Approved ,  Date: 15 June 2022REFERENCES
1. ACTEMRA® (tocilizumab). Prescribing Information. South San Francisco, CA: Genentech, Inc;2017 .
2. Aleman A, Van Oekelen O, Upadhyaya B, et al. Augmentation of humoral and cellular immune responses after 
third -dose SARS -CoV- 2 vaccination and viral neutralization in myeloma patients. Cancer Cell. 
2022;40(5):441 -443.
3. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from 
human memory B cells. J Clin Invest. 2003;112(2):286 -297.
4. Berdeja JG, Lin Y, Raje NS, et al. Durable clinical responses in heavily pretreated patients w ith 
relapsed/refractor y multiple myeloma: Updated results from a multicenter study of bb2121 anti -BCMA CAR T 
cell therapy. American Society for Hematology. Meeting Abstract. December 9 -12, 2017.
5. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 
2006;18(5):263 -275.
6. Burtis CA. Section IV Pathophysiology. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry. 
3rd ed. Philadelphia, PA: WB Saunders .1999; 1400.
7. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B -cell maturation antigen is a promising target for adoptive 
T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048 -2060.
8. Cock K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease -
specific ques tionnaire module (the QLQ -MY20) in assessing the quality of life of patients with multiple 
myeloma. Eur J. Cancer. 2007;43: 1670 -1678.
9. Darce JR, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell 
differentiation into Ig -secret ing cells. J Immunol. 2007;178(9):5612 -5622.
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. 
Leukemia. 2006;20(9):1467 -1473.
11. Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of com plete response in multiple 
myeloma. Leukemia. 2015;29(12):2416 -2417. 
12. EORTC Quality of Life Group. Guidelines for assessing quality of life in EORTC clinical trials. 
http://groups.eortc.be/qol/manuals . Accessed 22 July 2018.
13. Frigyesi I, Adolfsson J, Ali M, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 
2014;123(9):1336 -1340.
14. Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) 
associates with TNF receptor -associated factor (TR AF) 1, TRAF2, and TRAF3 and activates NF -kappa B, 
elk-1, c-Jun N -terminal kinase, and p38 mitogen -activated protein kinase. J Immunol. 2000;165(3):1322 -1330.
15. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treat ment of 
multiple myeloma. Clin Cancer Res. 2008;14(9):2775 -2784.
16. Kim berley FC, Hahne M, Medema JP. "APRIL hath put a spring of youth in everything": Relevance of APRIL 
for survival. J Cell Physiol. 2009;218(1):1 -8.
17. Korde N, Kristinsson SY, Landgren O. Mono clonal gammopathy of undetermined significance (MGUS) and 
smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. 
Blood. 2011;117(21):5573 -5581.
18. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response 
and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328 -e346.
19. Kymriah package insert. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2017 .
20. Kyle RA, Rajkumar SV. Criteria f or diagnosis, staging, risk stratification and response assessment of multiple 
myeloma. Leukemia. 2009;23(1):3 -9.
21. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release 
syndrome. Blood. 2014;124(2):188 -195.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 124
Status: Approved ,  Date: 15 June 202222. Lee DW, Santomasso BD, Locke FL, et al. ASBMT consensus grading for cytokine release syndrome and 
neurological toxicity associated w ith immune effector cells. Biol Blood Marrow  Transplant.
2019 Apr;25(4):625 -638.
23. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in 
renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247 -254.
24. MD Anderson Cancer Center. IEC Therapy Toxicity Assessment and Management . 2019. Appendix J. 
https://www.mdanderson.org/documents/for -physicians/algorithms/clinical -management/clin -management-
cytokine -release -web-algorithm.pdf
25. Neelapu SS, Tummala S, Kebriaei P. Chimeric antigen receptor T -cell therapy –assessment and managemen t 
of toxicities. Nat Rev Clin Oncol. 2018;15(1):47 -62.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology 
Group. Am J Clin Oncol. 1982;5(6):649 -655.
27. Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syn decan -1) expression in health and disease. Histol 
Histopathol. 2014;29(2):177 -189.
28. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046 -1060.
29. Patel DR, Wallw eber HJ, Yin J, et al. Engineering an APRIL -specific B cell maturation antigen. J Biol Chem. 
2004;279(16):16727 -16735.
30. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical 
trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691 -4695.
31. Tai Y T, Anderson KC. Targeting B -cell maturation antigen in multiple myeloma. Immunotherapy. 
2015;7(11):1187 -1199.
32. Wisloff F, Eika S, Hippe E, et al. Measurement of health -related quality of life in multiple myeloma. Nordic 
Myelom a Study Group. Br J Haematol. 1 996;92:604 -613.
33. Wisloff F, Hjorth M. Health -related quality of life assessed before and during chemotherapy predicts for 
survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97:29 -37.
34. Yescarta package insert. Santa Monica, CA: Kite Pharma, Inc.; 2017.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 126
Status: Approved ,  Date: 15 June 2022bIn some cases it is possible that the original M protein light -chain isotype is still detected on im munofixation 
but the accompanying heavy -chain component has disappeared; this would not be considered as a CR even 
though the heavy -chain component is not detectable, since it is possible that the clone evolved to one that 
secreted only light chains. Thus, if a patient has IgA lambda myeloma, then to qualify as CR there should be 
no IgA detectable on serum or urine immunofixation; if free lambda is detected w ithout IgA, then it must be 
accompanied by a different heavy chain isotype (IgG, IgM, etc .).
cClarifications to the criteria for coding progressive disease: bone marrow  criteria for progressive disease are 
to be used only in subjects without measurable disease by M -protein and by FLC levels; “25% increase” 
refers to M -protein, and FLC, and does not refer to bone lesions, orsoft tissue plasmacytomas and the 
“lowest response value” does not need to be a confirmed value.
Notes: All response categories (CR, sCR, VGPR, PR, MR, and progressive disease) require 2 consecutive 
assessments made at any time before the institution of any new  therapy; CR, sCR, VGPR, PR, MR, and stable 
disease categories also require no known evidence of progressive or new  bone lesions if radiographic studies were 
performed. VGPR and CR categories require serum and urine studies regardless of whether disease at baseline 
was measurable on serum, urine, both, or neither.
Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments need not 
be confirmed. For progressive disease, serum M -component increases of ≥1 g/dL are sufficient to define relapse if 
lowestM-component is ≥5 g/dL.
Source: Adapted from Durie (2015) and Rajkumar (2011)11,30, Kumar (2016)18
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 127
Status: Approved ,  Date: 15 June 2022Attachment 2: Deleted 
Attachment content removed in Amendment 2
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 128
Status: Approved ,  Date: 15 June 2022Attachment 3: International Myeloma Working Group Diagnostic Criteria
Diagnostic criteria for myel oma must be met when the patient was diagnosed. Multiple myeloma is defined 
as clonal bone marrow plasma cells ≥10% or biopsy -proven bony or extramedullary plasmacytomaaand 
any one or more of the following myeloma defining events:
 Myeloma defining events:
 Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative 
disorder, specifically:
o C:Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of 
normal or >2.75 mmol/L (>11 mg/dL)
o R:Renal insufficiency: creatinine clearance <40 mL per minbor serum creatinine 
>177 μmol/L (>2 mg/dL)
o A:Anemia: hemoglobin value of >20 g/L below the lower limit of normal, or a h emoglobin 
value <100 g/L 
o B:Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET -CTc,d
 Any one or more of the following biomarkers of malignancy: 
 Clonal bone marrow plasma cell percentagea≥60%
 Involved:uninvolved serum free l ight chain ratioe≥100
 >1 focal lesions on MRI studiesf
aClonality should be established by showing κ/λ -light-chain restriction on flow cytometry, 
immunohistochemistry, or immunofluorescence. Bone marrow  plasma cell percentage should preferably 
be estima ted from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the 
highest value should be used.
bMeasured or estimated by validated equations. 
cIf bone marrow  has less than 10% clonal plasma cells, more than one bone lesion is required to distinguish 
from solitary plasmacytoma with minimal marrow  involvement.
dPET-CT=18F-fluorodeoxyglucose PET w ith CT.
eThese values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The 
involved free li ght chain must be ≥100 mg/L. 
fEach focal lesion must be 5 mm or more in size.
Source: Rajkumar (2011)30
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 129
Status: Approved ,  Date: 15 June 2022Attachment 4: Prior Cancer Therapy for Multiple Myeloma and Refractory Myeloma Definition
Prior Therapy
A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one 
or more planned cycles of single -agent therapy or combination therapy, as well as a sequence of treatments 
administered in a planned manner. For exam ple, a planned treatment approach of induction therapy  
followed by autologous stem cell transplantation, followed by maintenance is considered one line of 
therapy. A new line of therapy starts when a planned course of therapy is modified to include other treatment 
agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new line of therapy  
also starts when a planned period of observation off therapy is interrupted by a need for additional treatment 
for the disease. 
Refra ctory Myeloma
Refractory myeloma is defined as disease that is nonresponsive while on primary or salvage therapy, or 
progresses within 60 days of last therapy. Nonresponsive disease is defined as either failure to achieve 
minimal response or development of progressive disease (PD) while on therapy. There are 2 categories of 
refractory myeloma: “relapsed -and-refractory myeloma” and “primary refractory myeloma.”
Relapsed and refractory myeloma
Relapsed and refractory myeloma is defined as disease that is nonr esponsive while on salvage therapy, or 
progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better 
at some point previously before then progressing in their disease course.
Source: Rajkumar (2011 )30
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 131
Status: Approved ,  Date: 15 June 2022Attachment 6: Formulas for Estimating Glomerular Filtration Rate
Modified Diet in Renal Disease (MDRD) Formula 
For serum creatinine in mg/dL, the estimated glomerular filtration rate (eGFR) for the MDRD formula is:
eGFR (MDRD) mL/min per 1.73m2= 175 x [serum creatinine (mg⁄dL)]-1 154x [age]-0 203x [1.212 if 
black] x [0.742 if female]
For serum creatinine in µmol/L , the eGFR for the MDRD formula is:
eGFR (MDRD) mL/min per 1.73m2= 175 x [serum creatinine ( mol/L)/88.4]-1 154 x [age]-0 203x [1.212 
if black] x [0.742 if female] 
Sources: 
Levey (2006)23
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 132
Status: Approved ,  Date: 15 June 2022Attachment 7: Serum Calcium Corrected for A lbumin
If calcium is expressed in mg/dL and albumin is expressed in g/dL:
Corrected calcium (mg/dL) = 
Serum calcium (mg/dL) + 0.8 × (4 -serum albumin [g/dL])
If calcium is expressed in mmol/L and albumin is expressed in g/L:
Corrected calcium (mmol/L) = 
Serum calcium (mmol/L) + 0.02 × (40 -serum albumin [g/L])
Source: Burtis (1999 )6
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 139
Status: Approved ,  Date: 15 June 2022effector cell-associated neurotoxicity syndrome; ICE=immune effector Cell -associated Encephalopathy; ICF=informed consent form; INR=international normalized ratio; 
IPPI=investigational produ ct preparation instructions; MRD=minimal residual disease; MRI=magnetic resonance imaging; MUGA=multiple -gated acquisition; PRO=patient reported 
outcome; PT=prothrombin time; SIPPM=site investigational product procedures manual; SOC=standard of care; SPEP= serum protein electrophoresis; UPEP=urine protein 
electrophoresis.
aFor subjects who discontinue the study before Day 100X, the Day 100X assessments should be performed prior to withdrawal of c onsent if feasible. Subjects who discontinue after 
Day 100X but before study completion should have urine and serum disease assessm ents performed prior to withdrawal of consent if feasible at the time of discontinuation, unless 
performed within 14 days prior to discontinuation. For subjects who receive retreatment with JNJ -68284528 and are in follow -up at the end of the study (2 years after the last 
subject receives the initial dose of JNJ -68284528), monitoring will continue in the long -term follow -up study (Section 9.1.6.3 ).
bPost-treatment assessments to be obtained until progressive disease is documented or the start of subsequent anticancer therapy, w ith the exception of survival status and 
subsequent anticancer therapy, which are to be collected until study completion.
cDisease characteristics cytogenetics (full karyotyping or FISH as well as molecular genetics [if applicable]), both of which m ay originate from prior to or during the screening 
period within 42 days before apheresis, or between apheresis and the conditionin g regimen, as applicable.
dFor subjects who are hospitalized for potential CRS, hematology and chemistry laboratory evaluations should be performed at l east daily or more as clinically indicated
eSerology results performed as standard of care within 28 days prior to apheresis are acceptable. Hepatitis B : HBsAg, anti -HBc, anti -HBs, HBV DNA quantification (for subjects 
who are anti-HBs positive without history of vaccination orfor subjects who are anti -HBs positive and anti -HBc positive); Monitor HBV -DNA, AST/ALT every 3 months for one 
year post -dose of JNJ -68284528. Hepatitis C : HCV antibody, HCV -RNA (for subjects who are anti HCV positive); HIV serology
fImmediately before the start of infusion, at the end of infusion, and 0.5, 1, 2 hours after end of infusion. Monitor until normalized after a CRS event
gTemperature will be checked at least twice a day up to Day 28X. Subjects will be provided with a thermometer and instructed on the use of the thermometer and entering 
2temperatures including their maximum daily temperature in a diary. Diary will be reviewed at each visit, then collected on Day 28 and stored with su bject source documents. 
hAll subjects will be evaluated for IgG, IgA, IgM. Testing for IgD and IgE will only be performed for su bjects with IgD and IgE -type myeloma.
iUPEP sample collected as part of the standard of care and prior to the subject signing ICF may be used for analysis at the ce ntral laboratory. 
jBone marrow morphology from an aspirate and core biopsy to be assessed locally at all time points. Additional bone marrow aspirate samples will be collected for biomarkers (see 
Table 13).
kResults from s keletal survey performed as routine follow -up within 42 days before start of apheresis may be used without these tests being repeated. The skeletal survey is to be 
performed by either roentgenography or low -dose computed tomography (CT) scans without the use of IV contrast. If a CT is used it must be of diagnostic quality. Additional 
imaging (X -ray, CT, or MRI) will be performed as clinically indicated (eg, to document response or progression).
lExtramedullary plasmacytomas should be assessed for all subj ects with a history of plasmacytomas or if clinically indicated prior to the first dose of the conditioning regimen, by 
clinical examination or radiologic imaging.
mHIV, hepatitis B, hepatitis C, HTLV, and other infectious diseases as applicable per loca l regulations.
nPre-infusion ICE test and handwriting sample should be performed before pre -medication with diphenhydramine
oMedical resource evaluation data will be collected until Day 180X (± 7 days)
pLocal laboratory assessments may be used under specified circumstances (see Section 9.6)
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 142
Status: Approved ,  Date: 15 June 2022Screening 
PhaseApheresis Cyclophosp
hamide and 
fludarabine 
condition ing 
regimenJNJ-
68284528 
InfusionPost Infusion (any subject who received infusion of JNJ -68284528 should continue all 
subsequent assessments)aand Post-treatment (Day 101X up to study completion)At 
PDAt End 
of Study 
for 
subjects 
with out
PD
≤28 days 
prior to 
apheresisIf 
perform -
edDay -5X,* -
4X, -3X 
(assessments 
may be 
conducted 
≤72 hours 
predose) bDay 1X
(Infusion)Day 
2XDay 
3X Day 
7X 
(±1 
day)Day 
10X 
(±1 
day)Day 
14X 
(±1 
day)Day 
21X 
(±2 
days)Day 
28X 
(±2 
days
)Day 
42X 
(±2 
days)Day 
56X 
(±2 
days)Day 
78X 
(±2 
days
)Day 
100X 
(±2 
days)Day 
184X
(±7 
days )
CyTOF/ 
PBMC/ 
Plasma 
(whole 
blood)X X X X X X X X X X Xe,f
MRD 
(aspirate)
(bone 
marrow)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Sample should be collected: 
 For all dosed subjects at Day 28X, and at approximately 6X, 12X, 18X, 24X months regardless of the status 
of disease measured in blood and urine
 For subjects with suspected CR at the time of CR and then yearly for subjects that remain on study up to 
disease progression.
Cytogeneti
cs (bone 
marrow)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])X
Replicatio
n 
Competent 
Lentivirus 
(RCL)
(whole 
blood)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Pre-dose At approximately 3X (Day 84) , 6X (Day 168), and 12X (Day 364) months (±1 month) ; then yearly (±3 months) 
until EOS, and then yearly (±3 months) forup to 15 years after cilta -cel infusion in a separate long -term follow -
up study. Yearly collection of RCL samples is not required if assess ments within the first year are negative. 
Additional samples may be collected triggered by events which may be relevant to RCL per clinical assessment.
Cytokine 
profilingg
(serum)X (prior to 
first dose of 
conditioning 
regimen 
[≤7days])Pre-dose,
2hrs Post 
(±10 
minutes)X X X X X X X X X X X
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 143
Status: Approved ,  Date: 15 June 2022Abbreviations: ADA=anti -drug antibody; BCMA=B -cell maturation antigen; CAR=chimeric antigen receptor; CR = complete response; CRS=cytokine release syndrome; 
CyTOF= cytometry by time of flight ; PD= progressive disease ; EOI=end of infusion; MRD=minimal residual disease; PBMC=peripheral blood mononuclear cell; PK=pharmacokinetic; 
sCR=stringent complete response
aFor subjects who discontinue the study before Day 100X , the Day 100X assessments should be performed if feasible.
bWindow for start of conditioning regimen: Day -7 to Day -5
cCollect additional samples when any of the following are suspected or reported: 1) CRS or CAR -T cell-related neurotoxicity (eg, ICANS) Grade ≥2 (at onset of the event, and 24 and 
72 hours after) or as clinically indicated; and 2) as indicated based on emerging data. 
dADA sample should be collected if a subject withdraws from the study after JNJ -68284528 administration but prior to disea se progression or study completion.
eSample should also be collected at suspected CR
fSample should be collected at 12 months, relative to Day 1X, for subjects that achieve CR/sCR and remain on study.
gCollect additional samples when any of the followin g are suspected or reported: 1) CRS or CAR -T cell-related neurotoxicity (eg, ICANS) (any grade) (at onset of the event, and then 
every 24 hours until CRS or ICANS event has stabilized or is resolving at which time additional collections should occur at 24, 48, and 72 hours ) or as clinically indicated; and 2) as 
indicated based on emerging data.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 144
Status: Approved ,  Date: 15 June 2022Attachment 10: Patient Reported Outcomes ( PRO) Measures
EORTC QLQ -C30

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 145
Status: Approved ,  Date: 15 June 2022

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 146
Status: Approved ,  Date: 15 June 2022Single Items from the EORTC QL Q MY20

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 147
Status: Approved ,  Date: 15 June 2022EQ-5D- 5L
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 148
Status: Approved ,  Date: 15 June 2022

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 149
Status: Approved ,  Date: 15 June 2022

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 150
Status: Approved ,  Date: 15 June 2022

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 151
Status: Approved ,  Date: 15 June 2022Patient Global I mpression of Severit y (PGIS)

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 152
Status: Approved ,  Date: 15 June 2022Patient Global I mpression of Change (PGIC)

JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 154
Status: Approved ,  Date: 15 June 2022Attachment 12: Immune Effector Cell -associated Encephalopathy (ICE) Tool
Immune Effector Cell -Associated Encephalopathy (ICE) Toola
Orientation : Orientation to year, month, city, hospital: 
4 points
Naming : Name 3 objects (eg, point to clock, pen, button): 
3 points
Following commands : (eg, Show me 2 fingers or Close your eyes and stick out your tongue): 
1 point
Writing : Ability to write a standard sentence (eg, Our national bird is the bald eagle): 
1 point
Attention : Count backwards from 100 by ten: 
1 point
a: ICE -Tool Scoring:
Score 10: No impairment
Score 7- 9: Grade 1 ICANS
Score 3- 6: Grade 2 ICANS
Score 0- 2: Grade 3 ICANS
Score 0 due to patient unarousable and unable to perform ICE assessment: Grade 4 ICANS
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 155
Status: Approved ,  Date: 15 June 2022Attachment 13: Immune Effector Cell -associated Neurotoxicity Syndrome (ICA NS) A SBMT 
Consensus Grading Systema,b
Neurotoxicity 
Dom ainGrade 1 Grade 2 Grade 3 Grade 4
ICE Score 7-9 3-6 0-2 0 (patient is 
unarousable and 
unable to perform 
ICE).
Depressed Level of 
ConsciousnessAwakens 
spontaneously.Awakens to 
voice.Awakens only to tactile 
stimulus.Patient is 
unarousable or
requires vigorous or
repetitive tactile 
stimuli
to arouse. Stupor or
coma.
Seizure N/A N/A Any clinical seizure,
focal or generalized, that
resolves rapidly; or
Non-convulsive
seizures on EEG that 
resolve with
intervention.Life-threatening
prolonged seizure 
(>5 min); or
Repetitive clinical 
or electrical seizures
without return to
baseline in between.
Motor Findings N/A N/A N/A Deep focal motor
weakness such as
hemiparesis or
paraparesis.
Raised 
Intracranial 
Pressure / 
Cerebral Ede maN/A N/A Focal/local edema on 
neuroimaging.Diffuse cerebral 
edema on 
neuroimaging; or
Decerebrate or
decorticate 
posturing; or
Cranial nerve VI 
palsy; or 
Papilledema; or
Cushing's triad.
a: Toxicity grading according to Lee et al 201 9
b: ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, 
raised ICP/cerebral edema) not attributable to any other cause .
Note: all other neurological adverse events (not associated with ICANS) shoul d continue to be graded w ith CTCAE 
Version 5.0 during both phases of the study
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 156
Status: Approved ,  Date: 15 June 2022Attachment 14: Anticipated A dverse Events
Anticipated Event
An anticipated event is an adverse event that commonly occurs independent of exposure to the drug under 
investigation.
For the purposes of this study the following serious adverse events will be considered anticipated events:
 Anaemia
 Bleeding
 Bone diseases
 Hypercalcaemia
 Hyperuricemia
 Infection
 Neutropenia
 Renal failure and insufficiency
 Thrombocytopenia
These anticipated events will be periodically analyzed in aggregate by the sponsor during study conduct.  
The sponsor will prepare a safety report in narrative format if the aggregate analysis indicates that the 
anticipated event occurs mo re frequently in the treatment group than in the general disease population and 
the sponsor concludes there is a reasonable possibility that the drug under investigation caused the 
anticipated event.
The plan for monitoring and analyzing the anticipated ev ents is specified in a separate Anticipated Events 
Safety Monitoring Plan. The assessment of causality will be made by the sponsor’s safety assessment 
committee.
The sponsor assumes responsibility for appropriate reporting of the listed anticipated events according to 
the requirements of the countries in which the studies are conducted.
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 157
Status: Approved ,  Date: 15 June 2022Attachment 15: Handwriting A dverse Event Toxicity Grading Criteria
Adverse Event Term Grade 1 Grade 2
Micrographia :
abnormally  small or 
cramped handwritingMildly  smaller letters 
or reduced spacing 
(eg,<50% decrease 
from baseline)Moderate to severel y 
smaller letters or reduced 
spacing (eg , >=50% 
decrease from baseline)
Dysgraphia:
illegible writing or 
writing that takes an 
unusually  long time or 
great effortMildly  slower 
writing, impaired 
straightness of line, 
difficulty  in 
completing task from 
baseline; most words 
are legibleModerate to severel y 
slower writing, impaired 
straightness of line, 
difficulty  in completing 
task from bas eline; most 
words are illegible
Agraphia:
pathologic loss of the 
ability  to writeAble to write part of 
a sentence (3 or more 
words); noted change 
from baselineAble to write just 1 to 2 
words, or unable to write 
any words; noted change 
from baseline
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 158
Status: Approved ,  Date: 15 June 2022Attachment 16: Anti-microbial Prophylaxis Recommendations
Subjects should receive antimicrobial prophylaxis as per recommendations below or per institutional 
standards.
Prophylaxis Therapy Start Stop 
Anti -Bacterial Fluoroquinolones (Levofloxacin - 500 
mg PO or IV daily , or equivalent )
Suggested Alternative for subjects 
with allergy to quinolones :
Cefpodoxime -  200 m g PO twice a 
dayAt neutropenia onset
(ANC < 500/μL)AtNeutropenia 
resol ution (for example, 
ANC ≥ 500/µL)
Anti -Fungal Fluconazole -400 mg daily
(or equivalent) 
Alternative s: Caspofungin or 
Micafungin
Prolonged neutropenia > 3 w eeks –
Consider switching to Posaconazole, 
oras per institutional guidelinesAtneutropenia onset 
(ANC < 500/μL)AtNeutropenia 
resol ution (for example, 
ANC ≥ 500/µL)
Anti -Viral Acyclovir –400 -800 mg PO tw ice a 
day2(dose to be adjusted as per 
institutional guidelines)
Alternative :
Valacyclovir -500 mg PO twice a dayDay 1 of infusion Suggested for at least 12 
months post infusion 
Pneumocystis
Pneumonia (PCP)Trim ethoprim -sulfamethoxazole –1 
DS tablet PO daily or 1 SS tablet PO 
daily
Alternatives :
Pentamidine ( as per institutional 
guidelines ), or
Dapsone –100 mg PO daily or 50 mg 
PO BID ,
or
Atovaquone –1500 PO dailyDay 1 of infusion Suggested duration: 6 
months OR until CD4 
count ≥ 200 cells/ µL, 
(whichever is longer)
Consider CMV serology at baseline, monitor with PCR testing as clinically indicated per institution al
guidance
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 159
Status: Approved ,  Date: 15 June 2022Attachment 17: COVID -19 Guidance on Study Conduct and Vaccine Timing
GUIDANCE ON STUDY CONDUCT DURING THE COVID-19 PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this cli nical study  due to, for example, self -isolation/quarantine by  participants and 
study -site personnel; travel restrictions/limited access to public places, including hospitals; study  
site personnel being reassigned to critical tasks. 
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgement of the 
investigator to protect the health and well -being of participants and site staff. 
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Participants will also be questioned regarding 
general health status to f ulfill any  physical examination requirement. 
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted via COVID -19 Appendix after consultation with the participant, investigator, and the 
sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study  interventions and withdrawal from the study should 
be documented with the prefix “COVID -19-related” in the case report form (CRF). 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance. 
If a participant has tested positive for COVID 19, the investigator should contact the sponsor’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
Testing for COVID -19 should be performed according to local guidance. If a participant has tested 
positive for COVID -19, the following should be reported in the EDC tool:
all cases of COVID -19, regardless of severity  or causalit y (including asymptomatic 
COVID -19) up to 1 year after cilta -cel infusion
all medications given to prevent (including vaccines) or treat COVID -19 up to 1 year after 
cilta-cel infusion
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 160
Status: Approved ,  Date: 15 June 2022GUIDANCE SPECIFIC TO THIS PROTOCOL:
These emergency provisions are meant to ensure subject safet y on stud y wh ile site capabilities are 
compromised by COVID-19 -related restrictions. As restrictions are lifted and the acute phase of 
the COVI D-19 pandemic resolves, sites should revert to original protocol conduct as soon as 
feasible.
Study Visits and Assessments
At the discretion of the investigator and with sponsor approval, study  visits may be performed 
remotely  via telemedicine technology  that connects study  subjects totheir research 
coordinators and investigators. Blood sample collection may be performed at the subject’s 
home by mobile study  personnel (ie, nurses and mobile phlebotomist). Home health nursing 
can either be centrally sourced via sponsor agreement with a vendor, or done via site contract 
with a visiting nurse service independent of the sponsor.
For subjects who are unable to come to the site for scheduled visits and/or if site capabilities 
are compromised b y COVID -19 related restrictions , contact (eg, tele phone, videoconference, 
or other channels) with the subject should be made in advance , to collect information on the 
subject’s current health status and any new or ongoing adverse events and concomitant 
medications. Normal study  procedures should be follow ed for the applicable visits as closely  
as possible even if lab assessments and physical exams are performed locally . Where local 
laboratories are used, it is important to ensure appropriate documentation of laboratory 
reference ranges. The remote contact with the subject (as allowable per local regulations) , the 
local laboratory  results, and the sponsor discussion should be documented in the subject 
source record. Similarl y, at a minimum, a comment must be entered in the Comments eCRF 
clearl y designating a s “COVID -19-related” and acknowledging the discussion between the 
investigator and the sponsor.
For subjects eligible to receive retreatment, original protocol conduct must be followed until 
Day 100. 
All deviations from protocol -required assessments shoul d be documented in detail within the 
subject’ s source record and should be clearly  designated as “COVID -19-related ”. It must be 
documented if a visit is conducted remotel y. Source documentation should detail how each 
assessment was collected (eg, remote vs . on-site, central vs. local laboratory, vital signs taken 
at home by  caretaker vs. delegated in- home nursing).
Consenting and re-consenting of subjects will be performed as applicable for the measures 
taken (including also remote consenting by phone or video consultation) and according to 
local guidance for informed consent applicable during the COVID- 19 pandemic.
The above measures are recommended for consideration on a temporary  basis during the 
COVID -19 pandemic to ensure that subject assessments contin ue as outlined in the protocol 
without imposing health risk to subjects, their families, and site staff. Every effort should be made 
to complete all protocol -required assessments. 
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 161
Status: Approved ,  Date: 15 June 2022GUIDANCE ON COVID- 19 VACCINE TIMING, AND COVID -19 PREVENTION AND 
TREATMENT FOR CILTA -CEL RECIPIENTS
It is recommended that participants receive prophy lactic COVID -19 vaccination when locally  
available, at the discretion of investigator judgement or institutional practice, and in compliance 
with the cilta-cel study  protocol and local labels for the vaccine.  Below is general guidance for 
consideration.
Many  vaccines against COVID -19 are being developed with different technologies and platforms 
and may have safet y and efficacy  profiles that are not fully  characterized even after preliminary  
health authority  approval. However, the benefit -risk ratio of receiving a COVID -19 vaccine among 
patients with multiple myeloma participating in cilta-cel studies is considered to be positive and 
should be considered for administration while in c ompliance with the cilta -cel study  protocol and 
when not otherwise contraindicated for use in the vaccine label.
Per protocol, live attenuated vaccines must be completed at least 6 weeks prior to lymphodepletion 
therap y or initiated at least 100 days after cilta-cel infusion. There are no specific timing 
restrictions for inactivated vaccines, which include vaccines which use alternative technology like 
mRNA or replication -incompetent viral vectors, per protocol. Enrollment into an interventional 
clinical trial for an experimental vaccine is prohibited during study . Any vaccination, including 
COVID -19 vaccinations, must be recorded on the Concomitant Medication page of the eCRF. 
No data is currently  available to suggest that COVID -19 vaccines pose specific or additional safety 
risk bey ond other vaccines for cancer patients undergoing treatment.  Theoreticall y, a diminished 
immune response may occur in immunocompromised patients, and therefore these patients may 
have reduced vaccine effectiveness.
While not sp ecificall y required per protocol, it is encouraged to complete the COVID -19 vaccine 
series at least 2 weeks prior to lymphodepletion, and to delay  vaccination for at least 3 months 
after cilta -cel infusion, to maximize immune response.
Several organization s and journals have published recommendations for COVID -19 vaccine 
administration in cancer patients, including:
European Societ y for Blood and Marrow Transplantation (EBMT)
https://www.ebmt.org/covid-19- and-bmt 
American Societ y for Transplantation and Cellular Therap y (ASTCT) 
https://www.hematology .org/covid -19/ash- astct-covid -19-vaccination -for-hct-and-car-t-cell-
recipients
National Comprehensive Cancer Network (NCCN) 
https://www.nccn.org/covid- 19/pdf/COVID -19_Vaccination_Guidance_V2.0.pdf
Centers for Disease Control and Prevention (CDC) 
https://www.cdc.gov/vaccines/covid- 19/info- by-product/clinical -considerations.html   
JNJ-68284528
Relapsed or Refractory Multiple Myeloma Clinical Protocol 68284528MMY2001 –Amendment 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 162
Status: Approved ,  Date: 15 June 2022Nature Reviews Clinical Oncology : COVID -19 vaccine guidance for patients with cancer 
participating in oncology  clinical trials. Desai A, Gainor JF, Hegde A, et al. (March 15, 2021). 
DOI:   10.1038/s41571- 021-00487 -z
 https://www.nature.com/articles/s41571 -021-00487 -z
Investigators should inform patients that emerging data from another cilta-cel study  show that 
patients receiving cilta-cel are possibly  at higher risk of severe/fatal outcomes from COVI D-19 
infection compared with patients receiving standard of care therapy (Section 6.3.6 ).
Based on guidance from the organizations listed above, the following measures should be 
implemented to minimize subjects’ risk of severe COVID- 19 infection: 
Subjects, particularl y those who are less than 6 to 9 months from cilta -cel infusion, should be 
reminded that the ongoing pandemic is still putting them at risk of contracting COVID -19. 
Investigators should ask subjects to continue to limit their risk of exposure to infected 
individuals as much as possible and strictly  adhere to prevention measures such as proper 
masking, hand h ygiene, social distancing, and avoiding travel and public transportation to the 
extent possible.
Investigators should discuss with subjects the importance of COVID -19 vaccines in the 
prevention of severe illness, hospitalization, and death from COVID -19. Subjects should 
assume that any vaccination administered prior to lymphodepletion and cilta-cel infusion no 
longer provides protection. For this reason, it is strongl y recommended that all subjects 
receive a full COVI D-19 vaccination series (eg, a primary  series of 3 vaccines and a 4th 
booster dose for mRNA vaccines; note: mRNA vaccines are recommended), no sooner than 
3 months after cilta-cel infusion, regardless of vaccination status prior to cilta-cel. In addition, 
if not alread y vaccinated, caregivers, family , and household contacts should be advised to 
receive COVID -19 vaccination as well.
Investigators should consider prophy laxis (eg, Evusheld, if available in the region) to reduce 
subjects’ risk of severe/fatal C OVID during the first 6 to 9 months after cilta -cel. It is critical 
that subjects understand that multiple myeloma patients (even those who have not received 
CAR -T therap y) may not seroconvert until after the 3rd vaccine dose and as a result they may 
remai n at a very high risk of severe COVID -19 for at least 2 to 3 months after starting 
vaccination2.
Investigators should instruct subjects to notify t hem or study site staff immediatel y if they are 
diagnosed with COVID 19, even if they are asymptomatic, so that appropriate treatment 
measures can be determined.
If available in the region, antivirals (eg, Paxlovid or other available agents) should be 
considered early after COVID -19 diagnosis. Subjects may remain asymptomatic or have 
minimal symptoms for a period of time prior to deteriorating. Investigators should make 
subjects aware that these drugs may potentially significantly  lower their risk of severe
COVID -19.
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 30 April 2020Janssen Research & Development *
Clinical Protocol
COVID -19 Appendix
Protocol Title
A Phase 1b -2, Open -Label Study of JNJ -68284528, a Chimeric Antigen Receptor T cell 
(CAR -T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory 
Multiple Myeloma
Protocol 68284528MMY2001; Phase 1b-2
JNJ-68284528
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics,
BV; Janssen- Cilag Internationa l NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland
UC; Janssen Biopharma Inc.;or Janssen Research & Development, LLC. The term “sponsor” is used
throughout the protocol to represent these various legal entities; the sponsor is identifi ed on the Contact
Information page that accompanies the protocol.
This study  will be conducted under U nited States (U S)sites of t his study  will be conducted under 
US Food & Drug Administration Investigational New Drug ( IND)regulations (21 CFR 
Part312). ]
Status: Approved   
Date: 30April 2020
Prepared by: Janssen Research & Development, LLC
EDMS number: EDMS- RIM-48939, 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF PROTOCOL
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipient
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or 
otherwise.
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-68284528 Clinical Protocol 68284528MMY2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: 30 April 2020COVID -19 APPENDIX
GUIDA NCE ON STUDY CONDUCT DURING THE COVID- 19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (C OVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  participants and 
study -site personnel; travel restrictions/limited access to public places, including hospitals; study  
site personnel being reassigned to critical tasks. 
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgement of the 
investigator to protect the health and well -being of participants and site staff. 
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Participan ts will also be questioned regarding 
general health status to fulfill any  physical examination requirement. 
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted via COVID -19 Appendix after consultation with the participant, investigator, and the 
sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study  interventions and withdrawal from the study  should 
be documented with the prefix “COVID -19-related” in the case report form (CRF). 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance. 
If a participant has tested positive for COVID 19, the investigator should contact the sponsor’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
COVID -19 Appendix
JNJ-68284528 Clinical Protocol 68284528MMY2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 30 April 2020GUIDANCE SPECIFIC TO THIS PROTOCOL:
These emergency provisions are meant to ensure subject safet y on stud y wh ile site capabilities are 
compromised by COVID-19 -related restrictions. As restrictions are lifted and the acute phase of 
the COVI D-19 pandemic resolves, sites should revert to original protocol conduct as soon as 
feasible.
Study Visits and Assessments
At the discretion of the investigator and with sponsor approval, study  visits may be performed 
remotely  via telemedicine technology  that connects study  subjects to their research 
coordinators and investigators. Blood sample collection may be performed at the subject’s 
home by mobile study  personnel (ie, nurses and mobile phlebotomist). Home health nursing 
can either be centrally sourced via sponsor agreement with a vendor, or done via site contract 
with a visiting nurse service independent of the sponsor.
For subjects who are unable to come to the site for scheduled visits and/or if site capabilities 
are compromised b y COVID -19 related restrictions , contact (eg, telephone, videoconference, 
or other channels) with the subject should be made in advance , to collec t information on the 
subject’s current health status and any new or ongoing adverse events and concomitant 
medications. Normal study  procedures should be followed for the applicable visits as closely  
as possible even if lab assessments and physical exams are performed locally . Where local 
laboratories are used, it is important to ensure appropriate documentation of laboratory 
reference ranges. The remote contact with the subject (as allowable per local regulations) , the 
local laboratory  results, and the sponsor discussion should be documented in the subject 
source record. Similarl y, at a minimum, a comment must be entered in the Comments eCRF 
clearl y designating as “COVID -19-related” and acknowledging the discussion between the 
investigator and the sponsor.
For subjects eligible to receive retreatment , original protocol conduct must be followed until 
Day 100. 
All deviations from protocol -required assessments should be documented in detail within the 
subject’ s source record and should be clearly  designated as“COVID -19-related ”. It must be 
documented if a visit is conducted remotel y. Source documentation should detail how each 
assessment was collected (eg, remote vs. on- site, central vs. local laboratory, vital signs taken 
at home by  caretaker vs. delegated in-home nursing).
Consenting and re-consenting of subjects will be performed as applicable for the measures 
taken (including also remote consenting by phone or video consultation) and according to 
local guidance for informed consent applicable during the C OVID -19 pandemic.
The above measures are recommended for consideration on a temporary  basis during the 
COVID -19 pandemic to ensure that subject assessments continue as outlined in the protocol 
without imposing health risk to subjects, their families, and site staff. Every effort should be made 
to complete all protocol -required assessments. 